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1.1 Bipolar Disorder
1.1.1 Clinical Aspects
For nearly 2,500 years, mood disorders have been described as 
very serious and invalidating disorders. Mood disorders cover a large 
group of psychiatric disorders characterized by pathological mood 
states, often accompanied by psychomotor and vegetative disturbances. 
Within the group of mood disorders two major groups can be divided; 
major depressive disorders (unipolar depression) and bipolar disorders 
(previously called manic-depressive disorder).
Regarding the historical concept of bipolar disorders, the following 
can be mentioned. As early as the 1st century AD, a Greek physician, 
Aretaeus of Cappadocia, described mania and melancholia as two 
different phenomenological states of the same disease1. A more modern 
concept of this disease as a single cyclical disorder was introduced by 
Emil Kraepelin2 in 1921 with the term manic depressive insanity. In the 
1960s, a few psychiatrists showed independently that there are various 
clinical characteristics that account for manic depressive disorder as a 
distinct mood disorder from unipolar depression3-5. Modern classification 
systems, such as ICD-106 (International Classification of Diseases) 
and DSM-IV7 (Diagnostic and Statistical Manual of Mental Disorders), 
describe bipolar disorder as an episodic, chronic illness, usually with full 
recovery between episodes. The diagnosis of bipolar disorder requires 
that a person has suffered of at least one episode of mania in their life 
with or without episodes of depression at other times. This requirement 
distinguishes bipolar disorder from unipolar depression, in which subjects 
suffer from at least one episode of depression without ever experiencing 
episodes of pathological elevated mood.
In DSM-IV7 bipolar disorder is subdivided in different subtypes, 
depending on it’s symptom profile. In subtype I, bipolar patients experience 
episodes of clear-cut mania, usually with psychotic symptoms. However, 
in subtype II, patients suffer from a disease course predominated by 
depressive episodes alternated with milder, short-lived periods of 
hypomania, rather than full-blown mania8. Some studies suggest that 
subtype II is more prevalent than subtype I9.
Clinically, major depression frequently arises from a low-grade 
depressive mood state, in which no vital symptoms are present and 
psychosocial functioning is not seriously disturbed. This is known 
as dysthymic disorder. When patients go through more than 2 years 
of numerous brief periods of hypomanic symptoms and low-grade 
depression in a biphasic alternating pattern, they are classified as having 
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a cyclothymic disorder. Patients with cyclothymic disorder have a high 
risk of eventually developing more severe forms of bipolar disorder. In the 
case of rapid cycling bipolar disorder, patients have gone through more 
than 4 mood episodes in the past year10. Finally, patients with bipolar 
features that do not meet criteria for the aforementioned categories are 
classified as Not Otherwise Specified (NOS).
It is difficult to estimate the incidence of bipolar disorder, because 
the disease generally becomes apparent only over a period of years and 
a reliable diagnosis can only be made later in life. The first episode is 
often a depressive phase, which causes a diagnosis of bipolar disorder 
to be overlooked11,12. Therefore, incidence statistics are usually based 
on retrospective data13. Figures on lifetime prevalences are probably 
underestimated due to an over-diagnosis of unipolar depression and an 
under-diagnosis of subtype II14. The Netherlands Mental Health Survey 
and Incidence Study (NEMESIS) calculated the lifetime prevalence of 
bipolar disorder in The Netherlands at 1.9%15. This is consistent with 
figures in other Western countries, ranging from .3-3.7%. The disease 
rate is equally distributed between men and women16. Another difficulty 
by estimating the prevalence figures is caused by the usage of different 
diagnostic instruments, study populations, and classification systems 
with subtle differences in illness characteristics. When the whole bipolar 
spectrum disorder (DSM-IV; including cyclothymic disorder) is included, 
prevalence rates of 3-7% are estimated, both in an extensive review17 
and nationally in the NEMESIS study18.
Bipolar disorder is associated with a high rate of morbidity and 
mortality19. Patients often have comorbid psychiatric conditions, 
such as panic disorders20, alcohol or substance abuse21,22, and eating 
disorders23. Moreover, somatic disorders, such as obesity24,25, diabetes 
mellitus26,27, hypothyroidism28,29, and multiple sclerosis30,31 are also more 
prevalent in patients with bipolar disorder compared to the general 
population. Unfortunately, next to the burden of the disease itself, this 
high prevalence of comorbidity is associated with a relatively low quality 
of life32,33. Along with mortality due to the somatic comorbidity, suicide 
plays an important role. Research reports on suicide estimate that 
8-18% of all bipolar patients die by suicide, whereas 17-24% attempt 
suicide34-36. All together, bipolar disorder is one of world’s top 10 most 
disabling conditions37, which results in a heavy burden for the patients 
themselves and for their social environment38-40. The impact for society is 
also considerable, due to health service utilizations and high costs41,42.
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1.1.2 Etiology
In parallel with other psychiatric diseases, the exact pathophysiology 
of bipolar disorder is not yet unraveled. There is sufficient evidence to 
claim that the etiology of bipolar disorder is multifactorial, but it would 
carry too far in the introduction of this thesis to go into detail on the 
potential mechanisms. In the following section, some important factors 
will briefly be listed.
First of all, genetic factors play an important role. The lifetime risk 
of developing bipolar disorder for relatives of bipolar patients ranges 
from 40-70% for a monozygotic co-twin and 5-10% for a first degree 
relative43-45. Although bipolar disorder tends to aggregate in families, the 
pattern of inheritance is not clear-cut and is characterized by a complex 
relationship between gene susceptibility and clinical phenotypes. The 
majority of linkage studies are rather confusing but some point to 
associations of genes on chromosome 18, 21, or 2246-48. However, no 
consistent or specific polymorphism has been identified thus far. The overall 
consensus is that bipolar disorder is a polygenetic disease. Innovative 
and promising methods, such as microarrays, could provide interesting 
approaches to try to answer questions with regard to RNA expression, 
the interphase between gene expression and protein production49,50.
Second, environmental factors are important, such as social 
environment, major life events, and stress16,51-53.
Third, there are numerous biological mechanisms that may play a 
role in the pathophysiology. In addition to disturbances in the immune 
and the endocrine system, which will be covered extensively further on 
in this thesis, metabolic disturbances (e.g., fatty acid metabolism) also 
appear to be important. One could even carry this back to aberrancies 
within different molecular mechanisms, such as signal transduction 
pathways53-55.
Finally, extensive studies have been performed on structural and 
functional abnormalities of the brain. Post mortem studies revealed, for 
example, abnormalities in frontal cortical interneurons56, in the degree of 
myelination57, and in neuronal size58. Magnetic resonance imaging (MRI) 
studies showed structural deficits in gray59-61 and white matter62,63, in 
the third and lateral ventricle, striatum, thalamus, amygdala, prefrontal 
cortex, cerebellum, and in the temporal lobe63-66. Magnetic resonance 
spectroscopy (MRS) visualizes functional abnormalities by using strong 
magnetic fields to measure and analyze the chemical composition of the 
brain. MRS-studies with bipolar patients gave indications for aberrancies in 
oxidative phosphorylation, phospholipid metabolism, choline metabolism, 
and second messenger systems65-67.
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1.1.3 Treatment
Either to recover from an acute episode or to maintain long-term 
stability, moodstabilizers are indicated. Lithium is the oldest and, 
according to various studies and meta-analyses, still the most effective 
mood stabilizer68,69. It even has anti-suicidal effects after long-term 
treatment70. Some anti-epileptics, such as valproate, carbamazepine, 
or lamotrigine, were found to have mood stabilizing activities as well71. 
Unfortunately, in many cases one or two moodstabilizers are not sufficient 
and therefore treatment of bipolar patients often entails relatively long-
term, complex medication regimens that combine mood stabilizers, 
antipsychotic agents, antidepressants, and other medications, such as 
benzodiazepines72-74. Lately, antipsychotic agents, such as quetiapine 
and olanzapine, were also found to have some mood stabilizing potency. 
Although the role of antidepressants in the treatment of bipolar disorder 
has been rather controversial due to the possible triggering of mania 
or circadian cycling, recent findings suggest an important role in the 
treatment approach71,75. Noncompliance to treatment can be a substantial 
problem in bipolar disorder76.
Next to the pharmacological treatment options, a range of psychosocial 
interventions, such as psycho-education or cognitive behavior therapy, 
appear to benefit patients with bipolar disorder77,78.
1.2 Immune System
1.2.1 Innate/Adaptive Immune System
The main function of the immune system is to provide an effective 
response against harmful pathogens. To establish this, the immune 
system must distinguish between potential pathogenic material, such as 
viruses or bacteria, and material originating from its own body. To provide 
an effective defense mechanism, which differentiates between “self” 
and “non-self”, a complex system is present with various components 
interacting with each other in a sequential and regulated manner.
The different cells of the immune system arise from pluripotent stem 
cells in the bone marrow and develop during the course of life by getting 
in touch with different self and non-self antigens mainly in the thymus, 
lymph nodes, and the periphery. Roughly, two systems can be defined, 
the innate and the adaptive immune system (Figure 1).
Innate Immune System: This is phylogenetically the oldest system. 
The first lines of defense are our natural barriers, such as the skin and 
General Introduction
15
mucous membranes. Other important players are soluble mediators and 
phagocytic cells, like monocytes, macrophages, and polymorphonuclear 
neutrophils. Examples of soluble agents, belonging to the innate immune 
system, are cytokines like interleukin-8 (IL-8) or pro-inflammatory 
cytokines (IL-1β, IL-6, TNFα), chemokines like MCP-1, and complement 
factors, all of which provide essential communication between the 
different immune cells. The innate immune system acts quite fast (i.e., 
within hours), but the response is antigen non-specific. If this system fails 
to eliminate the pathogen, it can activate the adaptive immune system. 
The main players in this process are the antigen-presenting cells (APC; 
e.g., the dendritic cell), which take up the pathogen and process it in 
various compartments of the cell. Afterwards, APC can present the antigen 
to the cells of the adaptive immune system in a proper way with the right 
receptor and supporting co-stimulatory molecules on the cell surface79.
Adaptive Immune System: This system acts more slowly than the 
innate immune system (i.e., after a few days), but the reaction is antigen-
specific and more effective in terms of elimination of the pathogen. Next 
to the specificity, it also provides a memory function after repeated 
exposure. Roughly, two types of adaptive immune reactions can be 
distinguished. The first is a cell-mediated immune reaction and the second 
is an antibody-mediated immune reaction, also called humoral immunity. 
T and B cells, respectively, perform the key roles in these forms of 
immune reactions, but many other cells and soluble pleiotrophic factors, 
like the cytokines IL-10 and IL-12, and chemokines, are essential as well.
T cells form a heterogeneous group of cells with different functions. 
Some T cells take care of the previously mentioned memory function 
(memory T cells). Others destroy host cells, which are infected with 
intracellular pathogens, like viruses (cytotoxic CD8+ T cells). The CD4+ 
T-helper 1 (Th1) cells interact with mononuclear cells to destroy 
intracellular pathogens, and the CD4+ T-helper 2 (Th2) cells interact with 
B cells and induce these cells to divide and differentiate into plasma cells. 
The balance of the cytokines produced by Th1 and Th2 cells determines 
the final outcome of the adaptive immune response (i.e., humoral or 
cellular; see also Figure 1).
B cells are genetically programmed to encode a surface receptor 
specific for a particular antigen. After encountering and recognizing such 
antigens, B cells differentiate into plasma cells. In this latter stage they 
produce large amounts of these receptor molecules in a soluble form, 
which are called antibodies. Antibodies specifically bind to the attacking 
antigens. In this way they, for instance, inactivate the antigens and 
provide extra signals for the innate immune system to attack these 
antigens by complement activation or by facilitated phagocytosis.
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Figure 1. The Innate and Adaptive Immune System.
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1.2.2 Autoimmunity
As mentioned before, one of the main functions of the immune 
system is to distinguish self and non-self. Generally this occurs by the 
induction of tolerance. Briefly, tolerance mechanisms cause a block in 
the development, growth, or differentiation of B and T cells that are 
autoreactive80. As a result, the remaining circulating lymphocytes react 
only with a wide pattern of foreign antigens.
Autoimmunity occurs as a result of the breakdown of tolerance 
mechanisms of autoreactive T and B cells, and the immune system starts 
to attack self-antigens. When parts of the body or specific organs are 
functionally damaged by these autoimmune mechanisms, a state of organ 
failure will eventually develop. One generally distinguishes organ specific 
autoimmune diseases, such as diabetes mellitus type I (confined to the 
beta cells in the pancreatic islets) or Hashimoto’s thyroiditis (confined 
to the thyrocytes in the thyroid), and systemic autoimmune diseases, 
such as rheumatoid arthritis or systemic lupus erythematosus (SLE), 
which show autoreactivity towards antigens in multiple organ systems. 
Autoimmune diseases are present in approximately 3% of the Caucasian 
population81. The pathogenesis of the different autoimmune diseases 
is not yet exactly unraveled. Table 1 indicates that auto-antibodies 
directed against cellular compartments, such as enzymes or proteins, 
can be used as markers for autoimmune diseases. In a small part of 
the general population auto-antibodies are also present without having 
any clinical concequences. However, the majority of these subjects show 
signs of an already started autoimmune process often accompanied by a 
mild inflammation of the target organ. The presence of auto-antibodies 
in these “healthy” subjects induces an increased risk for autoimmune 
disease development.
Figure 1. The Innate and Adaptive Immune System.
The main players in the innate immune system, the adaptive immune system, and the 
“interphase” between these two systems, as also described extensively in the text. 
Different systems will be activated, dependent on the type of pathogen encountered and 
the microenvironment.
IL, interleukin; TNF, tumor necrosis factor; IFN, interferon; APC, antigen presenting cell; 
DC, dendritic cell; Th, T helper cells; Ig, immuneglobulins.
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1.3 Hypothalamus Pituitary Adrenal Axis
1.3.1 HPA-axis in General
The hypothalamus pituitary adrenal (HPA)-axis is a neuroendocrine 
system with an essential function in the regulation of stress-related 
responses. The anatomical mediators comprise the hippocampus, the 
hypothalamus (i.e., hypothalamic paraventricular nucleus), the anterior 
pituitary gland, and the adrenal cortex. These brain components excrete 
hormones, like corticotrophin-releasing hormone (CRH), vasopressin 
(AVP), and adrenocorticotrophin hormone (ACTH) (depicted in Figure 2), 
which finally regulates the release of cortisol, a glucocorticoid (GC), from 
the adrenal cortex. The basal state and the normal circadian rhythm of 
the HPA-axis are regulated via the hippocampus. The release of ACTH and 
cortisol is pulsatile. ACTH and cortisol also take care of negative feedback 
in the system to maintain homeostasis of the HPA-axis and to control the 
sensitivity of the stress response. Exogenous GCs, like dexamethasone 
(DEX), sort effects comparable with endogenous cortisol82. Next to the 
Table 1. Auto-antibodies can be used as Markers for Autoimmune Diseases.
Target Organ Disease Associated with Abs against:
Thyroid Hashimoto’s disease TPO, Tg Organ specific 
autoimmune 
disease
Systemic 
autoimmune 
disease
Graves disease TSH-R, TPO
Stomach Pernicious anemia H+/K+ ATPase
Islets of Langerhans Diabetes mellitus type I GAD65, IA-2, IAA
Muscles Myasthenia gravis ACh-R
Liver Primary biliary cirrhosis Mitochondrium, actin
Autoimmune hepatitis Actin, SLA
Exocrine glands, 
e.g. salivary gland
Sjögren’s syndrome ANA (SS-A/Ro, SS-B/La)
Connective tissue, 
joints, blood vessels
Rheumatoid arthritis
Systemic lupus 
erythematosus
Fc part of IgM (RF), CCP
ANA (dsDNA, Sm)
Abs, antibodies; TPO, thyroid peroxidase; Tg, thyreoglobulin; TSH, thyroid stimulating 
hormone; H+/K+ ATPase, H+/K+ adenosine triphosphatase; GAD65, glutamic acid 
decarboxylase; IA-2, tyrosine phosphatase-like protein; IAA, Abs against insulin; 
AChR, acetylcholine receptor; SAL, soluble liver antigen; ANA, antinuclear antibody; 
SS-A/Ro and SS-B/La, antibodies directed against nuclear targets; Fc, constant region of 
a immunoglobulin; Ig, immunoglobulin; RF, rheumatoid factor; CCP, cyclic citrullinated 
peptide; dsDNA, double stranded deoxynucleotide acid; Sm, Smith antigen.
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effects on the metabolic status and neurodevelopment83, GCs are well 
known for their inhibitory effects on virtually every aspect of the immune 
response84-86.
1.3.2 HPA-axis Abnormalities in Mood Disorders
The HPA-axis as main regulator of the stress response has been a 
logical and major topic of interest in psychiatric research. Mood disorders 
have been the main subject of various HPA-axis related studies, although 
to a lesser extent also other disorders, such as schizophrenia87, anxiety 
disorders88, and eating disorders89 have been investigated.
The amount of cortisol can simply be determined in blood and saliva, 
both with comparable diurnal patterns. The highest cortisol excretion can 
be measured early in the morning90. Different tests have been developed 
to investigate the function of the HPA-axis and its feedback mechanisms 
in more detail. The most frequently used tests are the dexamethasone 
suppression test (DST)91 and the dexamethasone/corticotrophin-
releasing hormone (DEX/CRH) test92,93. An aberrant response after 
the administration of DEX is generally caused by a blunted feedback 
mechanism (i.e., less negative feedback of this synthetic corticosteroid 
in the HPA-axis). During the DST, DEX is administered at night. The 
next morning, ACTH and cortisol are measured. If ACTH and cortisol 
CNS
Hypothalamus (PVN)
Pituitary (APG)
Adrenal Cortex
Hippocampus
+/_
_
_
+
+ ACTH Cortisol
DEX
(synthetic GC)
CRH
AVP
Central
Control
CNS, central nervous system; +, positive feedback; -, negative feedback; CRH, 
corticotrophin releasing hormone; AVP, vasopressin; ACTH, adrenocorticotrophin hormone; 
GC, glucocorticoid.
Figure 2. Hypothalamus Pituitary Adrenal Axis.
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levels remain high, compared to the healthy response, this is caused by 
reduced cortisol suppression (feedback resistance). It is important to 
mention that DEX cannot easily pass the blood-brain barrier and thereby 
will not influence the hypothalamus. For this reason, the DST mainly 
measures the feedback route via the pituitary. On the contrary, the 
DEX/CRH test has been suggested as measuring more closely the actual 
HPA-axis activity92,93. During this test, DEX is administered at 11 PM 
(increasing a feedback loop via the pituitary) and subsequently CRH is 
administered the next day at 3 PM (giving the pituitary directly an extra 
impulse). When the feedback mechanism is disturbed, as is the case 
in mood disorders, peripheral measured ACTH and cortisol levels after 
these administrations are higher compared with healthy individuals.
The majority of studies on HPA-axis disturbances in mood disorders 
focus on unipolar depression, although bipolar disorder has also been 
studied. Endogenous hypercortisolemia was described in 25-30% of 
unipolar depressed patients90,94-97, although these prevalence figures 
have also been disputed98-100. CRH levels are also increased101,102. With 
regard to ACTH levels, data are more inconsistent. Specifically, some 
investigators report increased ACTH levels97,103, whereas others indicate 
normal to low levels96,104,105. Although the DST was initially considered a 
diagnostic tool specific to melancholic or endogenous depression91,106-109, 
a disturbed test could also be found more generally in various sets of 
depressed patients94,110-116. In more recent papers on HPA-axis alterations 
a disturbed DEX/CRH test is taken by some investigators as a state marker 
of unipolar depression117,118 and is suggested to be an easily accessible 
tool for monitoring and estimating the treatment response119,120, the 
relapse risk90,121, and the number of depressive episodes122. In contrast, 
suicidal behavior is associated with a less abnormal DEX/CRH test123. 
Others, however, consider a disturbed DEX/CRH test as a trait marker 
and found that these HPA-axis disturbances are already present in very 
young unipolar patients124,125 and even in healthy family members at risk 
for developing mood disorders126. However, a recent study revealed that 
most disturbances in the HPA-axis only develop after the onset of the 
disease127. Presently, the discussion whether a disturbed DEX/CRH test 
is rather a state or a trait marker is still going on.
When we focus more specifically on the bipolar mood disorder, some 
publications suggest an even more profound dysregulated HPA-axis 
compared to its unipolar counterpart128,129. The basal cortisol levels, the 
DST, and the DEX/CRH test are abnormal in bipolar disorder109,130. Although 
some suggest that this HPA-axis dysfunction is a potential trait marker in 
bipolar disorder130,131, others describe a state dependent effect either for 
mania114,132, depression109, or rapid cycling133. Clinically sufficient lithium 
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prophylaxis in some studies did not automatically prevent intermittent 
HPA dysregulation134,135, whereas in another it did136.
Intriguingly, steroid treatment can induce mood disorders with clinical 
features, such as manic episodes, psychosis, and recurrence137-139. 
On the other hand, patients with Cushing’s disease and comorbid 
depressive symptoms experience antidepressive effects after using anti-
glucocorticoid treatment140.
The common mechanism for these HPA-axis disturbances in mood 
disorders is thought to be a decreased sensitivity for GCs in the GC 
sensitive areas in structures, such as the brain, which could explain the 
absence of Cushing-like features in patients with mood disorders in the 
presence of their elevated levels of cortisol126. Whether this is due to a 
decreased number of GC-receptors141-144, polymorphisms at the receptor 
level145-149, environmental factors149-151, a disturbance in the centrally 
regulated set point152,153, or other factors has not yet been resolved. 
Holsboer, one of the most important pioneers in this research area, 
hypothesized that an impaired GR signaling could be a key pathogenetic 
factor in depression, which is summarized in his “cortisol resistance 
hypothesis of depression”154.
Both the DEX and the DEX/CRH test use peripherally produced 
hormones in the blood or saliva as their readout. However, GC also 
have effects on immune cells. Therefore, the different immune cells and 
their function could also act as a potent readout system and are easily 
accessible for in vitro tests. A meta-analysis from 2001155 concluded that 
many of these immune assays are disturbed in mood disorders.
All these findings on HPA-axis disturbances in mood disorders have 
opened new avenues for potential new strategies with regard to the 
treatment of mood disorders and the development of animal models. 
With regard to new treatment modalities, usage of CRH-R antagonists is a 
promising approach. As GC receptor function is impaired in many patients 
with mood disorders, the central secretion of CRH is enhanced. CRH has 
all sorts of effects on mood regulation and anxiety. The disturbances in 
the HPA-axis, disturbed feedback mechanism and hypercortisolism, can 
be amplified with a CRH-R antagonist and thereby “reset” this disrupted 
set point. Although this treatment strategy is still under investigation 
in animal models156, at least one clinical trial157 has also showed 
beneficial effects. One can also influence the HPA-axis at other levels. 
GR antagonists158 and steroid-synthesis inhibitors like metyrapone 140,159 
also showed potentially beneficially effects for therapeutic purposes.
Regarding the development of animal models for mood disorders 
with the current knowledge on HPA-axis disturbances, transgenic mice 
overexpressing the GC receptor in their forebrain show an increased 
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emotional lability160. Long term exposure of exogenous administered 
corticosterone in rats results in a behavioral pattern comparable to 
depression. A decreased sensitivity at the receptor level in this rat model 
also resembles the findings in mood disorders161. Even in established 
stress models for mood disorders, such as the social disruption model, 
disturbances in the HPA-axis can be found162.
In conclusion, in mood disorders abnormalities in the HPA-axis have 
been found, such as hypercortisolism, a disturbed DST and DEX/CRH 
test. Taken together, the aberrancies point in the direction of a decreased 
sensitivity for GCs. However the exact mechanism behind this alteration 
in sensitivity has not been resolved yet. Nevertheless, it opens new 
venues for treatment strategies and animal models for mood disorders.
1.4 Immune Abnormalities in Bipolar Disorder
1.4.1 Immune System and Psychiatric Disorders
There is also accumulating evidence that immune mechanisms 
play an important role in the pathophysiology of psychiatric disorders. 
Already in the late 1920s, the infectious theory was posed for some of 
the psychotic disorders163 and the possibility of a pathophysiological role 
of the immune system for psychiatric disorders has been considered ever 
since. In the research field of immunopsychiatry two psychiatric disorders 
(i.e., major depression and schizophrenia) have in particular been the 
focus of attention. The consensus, recently reviewed for both major 
depression155,164-166 and schizophrenia167-170, is that different components 
of the immune system are in an activated state. But also other psychiatric 
disorders, such as autism170,171, obsessive-compulsive disorder172, and 
anxiety disorder170,173, show aberrancies in immune function.
For this thesis we have concentrated on the immunopsychiatric findings 
in bipolar disorder, because within the continuum of mood disorders, 
bipolar disorder has up till now received less attention than unipolar 
depression174.
1.4.2 Monocyte-/Macrophage-derived Cytokines in 
Bipolar Disorder
Cytokines contribute to the biology of depression, as evidenced in 
several studies. The leading part is for pro-inflammatory cytokines, 
which are mainly produced by monocytes or macrophages. Important 
General Introduction
23
evidence for this statement can be found in the finding that an increased 
production of pro-inflammatory cytokines generally results in mild mood 
disturbances, next to the co-existence of fever. These cytokine-induced 
mood alterations are called “sickness behavior” and resemble several 
symptoms of depression, such as low mood, anhedonia, anorexia, and 
decreased physical and social activity86,175. The role of cytokines in this 
“sickness behavior” is demonstrated in various animal models176-178, 
but also in humans by mimicking an inflammatory response via a low 
doselipopolisaccharide (LPS; endotoxin) injection 179 or a Salmonella typhi 
vaccination180. Even in patients spontaneously infected with common 
pathogens, like Epstein Barr Virus, the severity of sickness behavior is 
positively correlated with pro-inflammatory cytokine levels181.
A large number of publications report an increased production 
of pro-inflammatory cytokines (i.e., IL-1β, IL-6, or TNFα) in different 
populations of depressed patients182-196, although not all do so197-201. The 
involvement of cytokines is further substantiated by reports showing 
increased cytokine-inducible plasma levels of acute phase proteins, like 
C-reactive protein or haptoglobin184,187,202-205.
This body of knowledge on pro-inflammatory cytokines in mood 
disorders resulted in 1991 in “the macrophage theory of depression”, 
which proposes that an excessive secretion of monocyte/macrophage 
cytokines can be held responsible for symptoms of depression206. Many 
other researchers in the field adopted this hypothesis. Although adjusted 
in various ways, the main point that cytokines play a pivotal role in the 
development of mood symptoms is consistent in these reviews165,207-212.
Several research groups tried to extrapolate the macrophage theory of 
depression to bipolar disorder and measured pro-inflammatory cytokines 
and other soluble immune factors in the serum of different groups of 
bipolar patients. Table 2 shows an overview of these cytokine related 
studies specific to bipolar disorder. Besides monocyte-/macrophage-
derived pro-inflammatory cytokines, also soluble shed-of receptors (e.g., 
sIL-6R) and acute phase proteins (e.g., Hp, CRP) have been measured 
in bipolar patients. Reviewing the literature on monocyte-/macrophage- 
derived cytokines and acute phase proteins, as summarized in 
Table 2, a plethora of results has been obtained. With regard to the pro-
inflammatory cytokines, increased serum levels has been associated with 
mania213, but others have not been able to confirm this association198,215. 
Conflicting results have also been found regarding acute phase 
proteins203,204. These conflicting results are most likely caused not only by 
differences in methodological approaches and sample sizes, but also by 
the heterogeneity of the subject groups and differences in confounding 
factors, such as age and gender differences198.
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1.4.3 Lymphocytes in Bipolar Disorder
In the following paragraph the association between of T cells, 
B cells, their products (such as cytokines and shed-of receptors), and 
mood disorders will be discussed. Regarding this topic far more studies 
have been performed with unipolar depressed patients than with bipolar 
patients, identical to the previously mentioned studies on monocyte-/ 
macrophage-derived cytokine production. Since both mood disorders 
show a clear overlap in their symptomatology and perhaps even in 
their pathological background, it is likely that the findings in unipolar 
depression are also important for bipolar disorder. To our knowledge, two 
meta-analyses reviewed the reports on depression and immunity155,164. 
Both reported, quite consistently, the following alterations in the 
measurements on lymphocytes: a moderate decrease in lymphocyte 
mitogen-induced proliferative responses, an overall leukocytosis, and 
alterations in numbers of several white blood cell populations, like 
relative neutrophilia, lymphopenia, and a marginal increase of CD4/CD8 
ratio. With regard to natural killer (NK) cells, they reported a decreased 
NK cell activity. However, the degree of heterogeneity between the 
individual study results still raises questions about their robustness. Age 
was in one meta-analysis determined to have clear effect on the immune 
parameters164, but not in the other one155.
In the previous paragraph the concept of “sickness behaviour” induced 
by monocyte-/macrophage-derived cytokines was described. There is 
also proof that interferon-alpha (IFNα) is involved in mood regulation, 
as evidenced in the treatment of hepatitis C patients with IFNα. This 
immunotherapy is complicated by high rates of depression (33-41%)217,218. 
This serious side effect can even lead to suicidal ideation219 and can be 
reversed by antidepressive treatment or stopping the IFN treatment220.
Table 3 shows a summary of studies on lymphocyte-derived immune 
parameters in bipolar disorder. The majority of the studies differed in 
the investigated immune parameters and the results are quite variable. 
Accordingly, it is difficult to draw a general conclusion. A fairly consistent 
finding is the increase of sIL-2R, a marker for T-cell activation213,221,222, 
though one study could not replicate this finding in euthymic bipolar 
patients223. The raised sIL-2R level points to an association of bipolar 
disorder with an activated T-cell system, but more and controlled studies 
have to be performed to confirm such activation of the T-cell system. 
T helper(Th)1-derived (e.g., IFNγ, IL-2), and Th2-derived (e.g., IL-4, 
IL-10) cytokines have also been measured in bipolar patients. Again 
conflicting results have been found regarding cytokines influencing 
T-cell mediated immunity215,216,224-226. Additionally, the reported decrease 
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Table 3. Studies of Lymphocytes in Bipolar Disorder
Reference Subjects Immune
Parameters
Results (focussed on BD)
Lymphocyte Subsets
Darko et al 
1988228
Bipolar depression
Unipolar depression
Healthy controls
Lymphocyte subsets BD: no aberrations
UP: lymphopenia, 
neutrophilia
Kronfol 
and House 
1988229 
Bipolar mania
Schizophrenia
Healthy controls
Lymphocyte subsets BD, SCH: no aberrations in 
cell numbers and subsets
Rapaport 
1994223
Bipolar disorder 
(euth)
Healthy controls 
Lymphocyte subsets BD: no aberrations in cell 
numbers
No effect of Lithium 
treatment
Breunis et al 
2003222
Bipolar disorder 
(manic/depressed/ 
euthymic)
Healthy controls
Lymphocyte subsets BD (all moods): activated 
T cells and B cells
Functional Tests
Albrecht et 
al 1985230
Bipolar depression
Unipolar depression
Healthy controls
Mitogen-induced 
lymphocyte 
blastogenesis
BD: no aberrations in
blastogenesis/CMI
Kronfol 
and House 
1988229
Bipolar mania
Schizophrenia
Healthy controls
Mitogen-induced 
lymphocyte proliferation 
BD (mania):
↓ lymphoproliferation
Tsai et al 
1999221 
Bipolar mania 
(during acute 
episode and after 
remission) 
Healthy controls
Mitogen induced 
lymphocyte proliferation 
BD (acute mania):
↑ lymphoproliferation
Barsi et al 
1989231
Bipolar mania
Major depression 
Healthy controls
Ab-dependent 
cytotoxicity against red 
blood cells
BD (mania): ↓ cytotoxicity
Sourlingas 
et al 1998232
Bipolar disorder 
(manic/depressed/ 
euthymic)
Healthy controls
Lymphocyte cell 
cyclerelated properties: 
histone synthesis rate
BD (euthymic), HC: 
lymphocytes are in resting 
phase
BD (manic/depressed): 
↑ cycling lymphocytes 
(activated)
Sourlingas 
et al 2003233
Bipolar disorder 
Schizophrenia 
Healthy controls
Lymphocyte cell 
cyclerelated properties, 
e.g. histone synthesis 
rate, cellular protein, 
and DNA synthesis
BD and SCH: lymphocytes 
are in activated state, 
instead of a resting phase
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T-cell Activation (sIL-2R)
Rapaport 
1994223
Bipolar disorder
(euthymic)
Healthy controls
Plasma sIL-2R BD (euthymic): 
no aberrations
No effect of Lithium treatment
Tsai et al 
1999221
Bipolar mania
Healthy controls 
Plasma sIL-2R BD (acute mania): ↑ sIL-2R
After remission; ↓ sIL-2R
Breunis 
et al 2003222
Bipolar disorder
(manic/depressed/ 
euthymic)
Healthy controls
Plasma sIL-2R BD (all): ↑ sIL-2R (trait)
Maes et al 
1995213
Bipolar mania
Schizophrenia 
Healthy controls
Plasma sIL-2R BD/ SCH (psychosis): ↑ sIL-2R
BD (mania): ↑ sIL-2R
Treatment (Valproate): 
no effect
Haack et al 
1999198
Bipolar disorder
Schizophrenia 
Major depression  
Healthy controls
Plasma sIL-2R BD: no aberrations in sIL-2R
No aberrations in other 
patient groups compared 
to HC
Rapaport 
et al 1999214
Rapid cycling (BD)
Healthy controls 
Plasma sIL-2R RC (at baseline): ↑ sIL-2R
Li treatment in RC: ↓ sIL-2R
Li treatment in HC: ↑ sIL-2R
T-cell-derived Cytokines
Rapaport et 
al 1999214
Rapid cycling (BD)
Healthy controls 
Th1: IL-2, IFNγ (plasma)
Th2: IL-10, IL-4 (plasma)
BD (RC): ud
BD (RC): ud
Kim et al 
2002224
Bipolar disorder 
Schizophrenia 
Major depression 
Healthy controls
Th1: IL-12 (plasma) BD, SCH: no IL-12 difference
but MD: ↑ IL-12
In all groups: treatment ↓
IL-12
Su et al 
2002225
Bipolar mania
Healthy controls 
Th1: IFNγ
Th2: IL-10 
(PHA-stim PBMC 
cultures)
BD (mania and remission): 
↓ IFNγ, no IL-10 aberrations
Boufidou et 
al 2004215
Bipolar disorder 
Healthy controls
Th1: IL-2, IFNα 
Th2: IL-10
(PBMC ELISPOT/ plasma)
BD (Li treated): ↓ IL-2, 
IL-10, IFNα (ELISPOT)
Plasma cytokines: ud
Kim et al 
2004226
Bipolar mania
Healthy controls
IFNγ, IL-4, and TGFβ
(resp Th1, 2, 3, plasma)
BD (mania): ↑ IFNγ, ↑ IL-4, 
TGFβ
Treatment: ↑ TGFβ
Liu et al 
2004216 
Bipolar mania
Healthy controls
Th1: IFNγ, IL-2
Th2: IL-4, IL-10 (plasma)
BD (mania): ↓ IFNγ, no 
aberration of IL-2, 4, or 10
CMI, cell mediated immunity; BD, bipolar disorder; UP, unipolar depression; SCH, 
schizophrenia; HC, healthy control subjects; RC, rapid cycling; IL, interleukin; sIL-2R, soluble 
interleukin-2 receptor; PHA, phytohemagglitinin; TGF, transforming growth factor; Th, 
T helper cytokine (subtypes 1, 2, and 3: Th1: IL-12, IFNγ, IL-2, Th2: IL-4, IL-10, Th3: TGFβ).
Table 3. Studies of Lymphocytes in Bipolar Disorder (continued).
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in NK cell activity in major depression, could not be confirmed in bipolar 
disorder227.
1.4.4 Autoimmune Disorders and Mood Disorders
The prevalence of mood disturbances in different autoimmune diseases 
has been the topic of many reports. SLE is probably the first autoimmune 
disease in which a connection with psychiatry has been found234. One of 
the reasons is that psychosis is one of the diagnostic criteria of SLE, but 
other psychiatric problems, such as mood symptoms, have also been 
reported in SLE235. The prevalence of psychiatric disorders in SLE varies 
from 40-80%236-238.
Also other autoimmune diseases are accompanied by mood 
disturbances. In patients suffering from thyroiditis, mood symptoms 
can parallel the hypo- and hyperthyroid episodes239,240. For Sjögren’s 
syndrome241,242, rheumatoid arthritis238, and diabetes mellitus243 the 
same association with mood disturbances has been suggested. Although 
Kessing244 proposed that the association is merely caused by the chronicity 
of the autoimmune diseases, others provided evidence that the mood 
symptoms are not only a response to coping with a chronic illness, but 
seem to occur more frequently than would be expected245,246.
Previously in this chapter, auto-antibodies were portrayed as good 
markers for autoimmune diseases. In the remaining part of this chapter, 
the literature on the prevalence of auto-antibodies (Abs) in patients with 
mood disorders will be reviewed to provide additional evidence that the 
co-occurence of mood disorders and some of the autoimmune diseases 
is more than just a coincidence.
Endocrine Autoimmunity: Various papers report thyroid problems 
in mood disorders, usually (sub clinical) hypothyroidism29,247-249, but 
one disputed this finding250. Treatment with thyroid hormone, like 
levothyroxine, is able to ameliorate mood symptoms in some depressed 
patients249,251. The oldest Ab-studies in mood disorders focus on anti-
microsomal and anti-thyroglobulin Abs (Tg-Abs). Anti-thyroid peroxidase 
Abs (TPO-Abs) replace anti-microsomal Abs in the more recent studies, 
since it is known from the early 1980’s onwards, that the major antigen 
in the thyroid microsomal fraction is TPO252.
A variety of studies using unipolar depressed patients found an 
increased prevalence of the various anti-thyroid Abs, such as microsomal-
Abs253-258, Tg-Abs253,256-258, and TPO-Abs248,259 in the serum of patients. 
Nevertheless, some studies did not report this increased prevalence 
in unipolar depression compared to healthy control groups100,260-262. 
The percentage of Abs-positive patients ranged from 8-20%, but the 
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experimental setup varied between the different studies.
Although Haggerty and others suggest an even higher prevalence of 
Abs against the thyroid in bipolar disorder compared to the unipolar 
population261,263, the overall figures of antibody-prevalences against the 
thyroid are comparable to it’s unipolar equivalent. Again Abs against 
microsomes258,261,263-266, Tg258,261,263,265,266, and TPO28,267 have been found 
increased, but controversies have also been reported262,268. Some studies 
suggested that the presence of autoAbs against the thyroid was associated 
with a rapid cycling pattern267 or mainly present in bipolar patients 
suffering from a depressive mood episode263, but a recent study from 
our group could not confirm such state-specificity28. Another interesting 
topic in bipolar disorder is treatment with lithium. One of the side effects 
of lithium treatment is hypothyroidism258,269, but the exact mechanism 
is not known yet. Some studies indicate that lithium influences265, 
increases264,270,271, or induces268 Abs against the thyroid, suggesting that 
these thyrotoxic effects could partly be due to autoimmune effects. Others 
dispute these findings by providing evidence that the increased level of 
Abs against the thyroid is unrelated to the usage of lithium28,261,263,272.
Other organs, regularly affected in endocrine autoimmunity, are 
less well studied in mood disorders. Although increased prevalence 
figures on diabetes mellitus in patients with bipolar disorder have 
been reported26,33,273, these studies hardly distinguish between type I 
(where the damage to the pancreas is autoimmune induced) and type II 
diabetes (characterized by insulin resistancy). Data on autoAbs against 
the pancreas in patients with mood disorders are lacking.
Systemic Autoimmunity: Antinuclear Abs (ANA) represent a 
group of auto-antibodies directed against nuclear antigens. As an 
example, Abs against double stranded DNA are a specific subgroup 
of ANA and can be used as marker for SLE. There is a strong relation 
between some of these systemic autoimmune diseases and psychiatry, 
mentioned previously in this chapter. Various investigators describe 
an increased ANA positivity (11-39%) in a broad group of psychiatric 
patients compared to the healthy population (3-16%)274-277. An increased 
ANA prevalence was also found for both bipolar and unipolar patients, 
suffering from depressive symptoms278,279. Maes and his group280 even 
found 72% of major depressed patients to be positive for ANA. However, 
it should be noted that the different detection methods between the 
various papers are not identical. The inconsistency in methods could 
explain why results vary so much, even resulting in negative findings 
compared to other patient groups258,262,281 or compared to healthy control 
subjects262,282,283. Furthermore, some types of medication, such as statins, 
antihypertensives284, as well as lithium285, are known to be able to induce 
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the production of ANA. Because the different types of ANA target different 
antigens (e.g., double stranded DNA [dsDNA]) or ribonuclear proteins 
(RNP), some studies tried to link ANA positivity to a specific ANA in mood 
disorder. These studies were not able to associate mood disorders with 
a higher seroprevalence of a specific ANA, such as Abs against dsDNA 
or one of the ENA254,262,277,283. With regard to rheumatoid factor (RF), no 
association with mood disorders has been found254,277.
Antibodies against Brain: A logical organ in the search of auto-
antibodies in psychiatric diseases is the brain. The initial studies in 
this field used indirect immunofluorescence employing patient serum 
and brain slides. A positive staining pattern was taken as evidence for 
anticerebral Abs in schizophrenic patients286-288. In these studies, patterns 
differed between the various slides and outcomes were difficult to repeat. 
Hence, unequivocal conclusions could not been drawn. Later studies 
noted increased antibody levels to specific antigens present in nervous 
tissue, such as somatostatin289, gangliosides290, and neurotransmitter 
receptors291 in serum of patients with mood disorders. Taken together, 
data are too limited to make a statement on the role of Abs against 
nervous tissue in mood disorders.
In conclusion, literature data on the prevalence of auto-antibodies in 
mood disorders are difficult to evaluate, due to large variations between 
the various reports. The variations in outcomes are probably due to the 
large variability in methodology, sample size, different inclusion criteria 
for patients, and co-variables. Nevertheless, the association between 
mood disorders and the presence of auto-antibodies is quite striking and 
it seems unlikely that it is just a co-incidence of separate events.
1.4.5 Concept of Neuro-Immuno-Endocrinology
In this first chapter different “regulating” systems, i.e. immune, 
endocrine, and nervous systems are mentioned extensively. Nowadays it 
is widely accepted that interactions between the immune, endocrine, and 
central nervous system have critical importance in the understanding of 
many psychiatric disorders, especially mood disorders292. Accumulating 
evidence, as mentioned in the previous paragraphs and reviewed 
repeatedly86,293-295, has indicated the existence of bidirectional 
communication pathways between the nervous, the endocrine, and the 
immune system. Evidence for these interactions arises from a number 
of experimental observations, such as the behavioral conditioning 
of immune responses (i.e. sickness behavior) or the effect of GCs on 
the immune system and behavior (i.e. anxiety). Main facilitators of 
this communication are soluble factors such as cytokines (e.g., IL-1β, 
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IL-6, TNFα), hormones (e.g., cortisol, TSH), and neurotransmitters 
(e.g., dopamine, norepinephrine). An overview of this concept of neuro-
immuno-endocrinology is depicted in Figure 3. The importance of this 
concept in future research in mood disorders is significant and has to be 
taken into consideration during the interpretation of findings.
1.5 Lithium-induced Effects on the Immune
  System
Lithium is one of the most potent mood stabilizers. The mood 
stabilizing effect of this seemingly simple molecule was first reported 
in 1949296 and the drug subsequently came into general use297. After 
various clinical trials, lithium remains in general the golden standard for 
long-term treatment of bipolar disorder68,298,299.
Nevertheless, the precise working mechanism has not been elucidated. 
Different mechanisms probably underlie the therapeutic effects of this 
potent monovalent cation. First, lithium modulates the balance of various 
neurotransmitters300, like dopamine301,302 or serotonin303-305. Second, 
various key components of signal transduction pathways are influenced 
by lithium, as has been frequently reviewed306-311. These molecular 
mechanisms comprise the GSK3β/Wnt signaling pathway312-314 and 
Figure 3. Neuro-Immuno-Endocrinology.
DOPA, dopamine; NE, norepinephrin; ACTH, adrenocorticotrophin hormone; TSH, thyroid 
stimulating hormone.
Immune System
Endocrine System
Central Nervous System
cortisol
thyroid hormone
cytokine
neurotransmitters
(e.g. DOPA, NE), cytokines
cortisol
thyroid hormone
ACTH, TSH
Sickness Behavior:
mood alterations, sleep and
eat disturbances, anhedonia
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G protein-coupled pathways315-318.
Furthermore, lithium has -interestingly in the scope of this thesis- 
various effects on different parts of the immune system. Treating patients 
or healthy control subjects with lithium resulted quite consistently in 
a decrease in the plasma levels of acute phase proteins203,204,319. With 
regard to pro-inflammatory cytokines less consistent results have been 
reported, ranging from no effect204, to an increase320,321, or a decrease 
of production215. In this last study on a decrease of pro-inflammatory 
cytokines by Boufidou and others, the decrease in the production of 
IL-6, a pro-inflammatory cytokine, was paralleled by a decrease of IL-10, 
an anti-inflammatory cytokine. This suggests that the balance between 
pro- and anti-inflammatory cytokines remained the same, although 
the number of cytokine producing cells was decreased. Lithium did not 
influence the overall antibody production by B cells322. In contrast, the 
effect of lithium on the T cell activation marker, sIL-2R, was seemingly 
dependent on the group of individuals under investigation; whereas 
lithium treatment raised sIL-2R levels in healthy control subjects214,323, 
it reduced these levels in bipolar patients214. Regarding other immune 
parameters, lithium treatment increased the white blood cell count324,325 
and the number of granulocytes326. More functionally, the natural killer 
cell activity is decreased by lithium327.
To explore in more detail the lithium-induced effects on the immune 
function, several groups performed in vitro experiments with the drug. 
Some generalizations with regard to these in vitro effects of lithium can 
be drawn. In vitro addition resulted in an increase of immunoglobulins, 
mainly of IgG328,329. A few studies hypothesized that lithium sorts anti-
inflammatory effects due to the increase of IL-10330-332. However, levels 
of pro-inflammatory cytokines are, at the same time, increased330,333,334. 
This finding is not consistent in all reports and for all pro-inflammatory 
cytokines215,330,331. In vitro addition of lithium also stimulates other 
indices of immune function, like the proliferation of lymphocytes in 
response to mitogens and the phagocytic capacity of macrophages335-339. 
It is not easy to translate the in vitro data to in vivo relevant effects, 
also because in vitro and in vivo data regarding lithium-induced effects 
are often in contrast. One disadvantage in interpreting the literature in 
this respect is that the methodology differs quite consistently between 
the various reports in read-out systems, lithium concentration, or the 
effects of acute versus chronic exposure to lithium. However, concerning 
immunological relevant side effects of lithium, it’s antiviral capacity is 
mentioned consistently320. A few case studies reported a remission of 
recurrent herpes virus infection in patients taking lithium for treatment 
of their mood disorder340-342. In vitro studies found the same inhibition of 
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viral replication, uniquely for DNA viruses343. Unfortunately, lithium did 
not inhibit the viral titers of HIV344.
The immune modulating effect of psychotropic agents is not 
confined to lithium alone. Antidepressants of several classes345-347 and 
antipsychotics348 also exert effects on the immune system, although 
results of studies to date are rather inconclusive. It is beyond the scope 
of this thesis to discuss this here in detail.
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2.1 Stanley Medical Research Institute
The Stanley Medical Research Institute was founded in 1994 as 
the Stanley Foundation Bipolar Network (SFBN; this abbreviation is 
used throughout the thesis), to address many of the neglected areas 
of research in bipolar disorder as was emphasized in the National 
Institute of Mental Health (NIMH) Bipolar Disorder Workshop in 1989 
and 19941,2. The Stanley Medical Research Institute is a multi-center 
research program and consisted in origin of four sites in the United States 
(Los Angeles, Dallas, Cincinnati, and Bethesda), two in Germany (Freiburg 
and Munich), and one in The Netherlands (Utrecht). The methodology of 
inclusion and follow up is uniform between the different centers.
All the included outpatients with bipolar disorder (type I, II or NOS) 
were diagnosed by the Structured Clinical Interview for DSM-IV Axis I 
(SCID)3 and a detailed illness history was assessed. During the monthly 
follow-up visits, a research clinician assessed cross sectional ratings for 
mania (Young Mania Rating Scale4), depression (Inventory of Depressive 
Symptoms5), and global illness severity (Clinical Global Impressions 
Scale modified for bipolar disorder6). The patients completed daily ratings 
of the severity of mania or depression and of the degree of functional 
impairment to gain a better insight into this heterogeneous bipolar 
population (NIMH-Life Chart Method)7-10.
The main goal of the SFBN was to explore the different and novel 
treatment methods in bipolar disorder with clinical trials (open-label 
or blinded) and naturalistic case series. Furthermore, the SFBN aimed 
to define clinical parameters and longitudinal illness patterns, and to 
perform neurobiological studies in order to get new insight into the 
pathogenetic mechanisms of bipolar disorder. The studies described in 
this thesis were performed to gain more insight into the immune system of 
patients with bipolar disorder. The longitudinal methodology of the SFBN 
with its naturalistic setup allows a reliable association of the immune-
parameter outcomes and the different co-variables. For the majority of 
these studies, we collected blood only from the SFBN-site in Utrecht 
because transportation of tubes from the United States with heparinized 
blood or with isolated PBMC would influence the immune cells too much. 
Blood was collected at 3 time points in Utrecht, in 1996, 1998, and 1999 
from 81 patients in total. Patient material from the bleeding in 1996 and 
1998 were used for previous projects.
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2.2 Previous Immunological Studies in the 
 SFBN
Kupka and others published the first immune paper on the SFBN 
sample. For this project, the prevalences of thyroperoxidase antibodies 
(TPO-Abs) and thyroid failure in outpatients with bipolar disorder were 
assessed and compared to a healthy control population and psychiatric 
inpatients of any diagnosis. The TPO-Abs were about three times more 
prevalent in patients with bipolar disorder (28%) than in the two control 
groups (3-18%). The presence of TPO-Abs in bipolar patients was 
associated with thyroid failure, but not with age, gender, mood state, 
rapid cycling, or lithium exposure. Thyroid failure was present in 17% of 
patients with bipolar disorder and more prevalent in women11.
The second immune paper published previous to my PhD investigation, 
focused on cell mediated immunity in the same bipolar population, using 
fluorescence activated cell scanning (FACS) analysis of peripheral blood 
lymphocytes and enzyme linked immunosorbent assay (ELISA) of the 
serum to measure serum soluble IL-2 receptor (sIL-2R; a T-cell activation 
marker). Significantly higher numbers of circulating B cells, activated 
T cells, and raised sIL-2R levels were found in the patients with bipolar 
disorder when compared with healthy controls. Manic patients showed 
significantly higher levels of sIL-2R in comparison with depressed patients12.
 
2.3 Present Research Questions
As described in the previous paragraphs, mood disorders most likely 
are accompanied by alterations in the immune and endocrine system. 
The majority of immune studies dealt with depressed patients. Patients 
with bipolar disorder are clearly underexposed in this respect.
The SFBN provides a group of clinically well-defined bipolar patients 
in a naturalistic setting. Two previous studies with bipolar patients from 
this SFBN cohort already dealt with aberrancies in the immune system. 
In the present studies we elaborated on these findings11,12 and approached 
the following questions:
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1. What is the capacity of monocytes of bipolar patients to produce IL-1β 
and IL-6 compared to healthy controls?
 We investigated whether the “macrophage theory of depression”13 
is also applicable for bipolar patients. We therefore measured the 
capacity of monocytes to produce IL-1β and IL-6 in bipolar patients 
and healthy controls.
2. What is the role of these pro-inflammatory cytokines in lithium-
induced psoriasis?
 
 In this study we investigated the level of pro-inflammatory cytokines 
produced by monocytes in “lithium-induced” psoriasis. Lithium-
induced psoriasis is a serious side effect of lithium14. We contrasted 
our findings to the production levels of monocytes of patients with 
“regular” psoriasis. It is well described that pro-inflammatory cytokines 
play an important role in the pathophysiology of psoriasis15,16.
3. What is the ability of monocytes to differentiate into dendritic cells 
(DC) and how does the phenotype and functionality of the monocyte 
derived-DC of bipolar patients relate to those of healthy controls?
 Dendritic cells are aberrant in animal models for endocrine 
autoimmunity, such as in non-obese diabetic (NOD) mice17 and 
biobreeding diabetic prone (BB-DP) rats18. Restoration of the DC 
function prevents autoimmunity19. Since a clear association was found 
between thyroid autoimmunity and bipolar disorder, we investigated 
if disturbances in monocyte-derived DC are also present in bipolar 
patients.
4. Are T cells of bipolar patients resistant to steroids?
 Since we found in a previous study a higher percentage of CD25+ 
activated T cells in the peripheral blood of bipolar patients, we 
investigated whether this activation might possibly be explained by 
steroid-resistancy20 and studied the in vitro dexamethasone-induced 
suppressive effects on the CD25 expression of T cells of bipolar 
patients and healthy controls.
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5. Is the prevalence of increased endocrine auto-antibodies restricted 
to antibodies against the thyroid, or are antibodies against other 
endocrine organs, such as the pancreas and the parietal cells of the 
stomach also increased?
 Since we found in a previous study an increased prevalence of TPO-
Abs in bipolar patients, we also determined auto-antibodies associated 
with other organspecific autoimmune diseases.
6. Is the increased seroprevalence of auto-antibodies restricted to 
organspecific autoimmune diseases or is there also an association 
with antibodies associated with systemic autoimmune diseases, such 
as antinuclear antibodies?
 Antinuclear antibodies (ANA) are associated with various systemic 
autoimmune diseases, such as systemic lupus erythematosus (SLE) 
and Sjögren’s syndrome. We first screened for a broad range of ANA 
and subsequently determined the fine specificity of these ANA.
7. What is the role of lithium, either in vivo or in vitro, with regard to 
various immune measurements in bipolar disorder?
 Since lithium is frequently used in the treatment of bipolar patients 
and it is known for its immunomodulating capacity, we put emphasis 
on the role of lithium with regard to the immune measurements in 
virtually all of the above mentioned studies.
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Abstract
Aim
To study the ex vivo IL-1β and IL-6 production of monocytes of bipolar 
patients in the absence/presence of lithium.
Methods
Monocytes of outpatients with DSM-IV bipolar disorder (n=80, of 
whom 64 lithium treated) and of healthy controls (n=59) were cultured in 
vitro and exposed (24 hours) or not exposed to lipopolysaccharide (LPS) 
and/or graded concentrations of lithiumchloride (LiCl). The IL-1β and 
IL-6 production was assessed by ELISA (supernatants). 
Results
LPS-stimulated monocytes of non-lithium treated bipolar patients 
were characterized by an abnormal IL-1β/IL-6 production ratio, i.e. a low 
IL-1β and a high IL-6 production. Lithium treatment increased IL-1β and 
decreased IL-6 production and thus restored the aberrant ratio. In vitro 
exposure of monocytes to LiCl did not have the same effects as lithium 
treatment: the procedure decreased IL-1β production and had minimal 
effects on IL-6 production.
Conclusion
Blood monocytes have an altered pro-inflammatory status in bipolar 
disorder. Lithium treatment restores this altered status. Short-time in 
vitro exposure of monocytes to lithium has other effects than lithium 
treatment.
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Introduction
IL-1β and IL-6 are pro-inflammatory cytokines and important 
messenger molecules in the immune system, modulating T- and B-cell
function. Monocytes and macrophages are major sources of these 
pro-inflammatory cytokines1. Besides having these immune functions, 
IL-1β and IL-6 also influence the brain and the neuro-endocrine system2. 
IL-1β and IL-6 are present in the central nervous system, can be produced 
by astrocytes and microglial cells, and receptors for these pro-inflammatory 
cytokines have been found in brain tissue3,4. Pro-inflammatory cytokines 
produced in the periphery are also capable of exerting their effect in 
the central nervous system5,6. This probably proceeds via two different 
routes. The neural route is represented by primary afferent neurons and 
the humeral route involves diffusion of the cytokines from the blood 
to brain target areas mainly via the circumventricular organs and the 
choroid plexus5,7.
The effects of IL-1β and IL-6 on the central nervous system include an 
array of metabolic, endocrine and behavioral alterations, amongst which 
an activation of the hypothalamic-pituitary-adrenal (HPA) axis, thereby 
influencing the production of neurotransmitters such as norepinephrin 
(NE), tryptophan, dopamine (DA), and serotonin (5-hydroxytryptamine, 
5-HT)4,8,9.
In animal models behavioral changes, comparable to the symptoms of 
depressed patients and referred to as ‘‘sickness behavior”, can be induced 
by central or peripheral induction of pro-inflammatory cytokines, such as 
IL-1β and IL-64,5,10. In humans low dosages (i.v.) of endotoxin increase 
the level of these cytokines and induce depressive symptoms11.
IL-1β and IL-6 have extensively been studied in mood disorders, 
yet with a focus on (unipolar) major depressive disorder (MDD). With 
regard to the serum concentration of these cytokines, the majority of 
publications describe an increased level12-19, although this could not 
be confirmed in all studies20-22. In studies on the ex vivo production of 
IL-1β and IL-6 by leukocytes of MDD patients, a more diverse picture has 
emerged. The majority of studies show an increased production of either 
IL-1β or IL-623-28, but decreased29,30 and normal productions31 have been 
documented as well. Measurements of IL-1β and IL-6 in cerebrospinal 
fluid in MDD patients have made the picture even more complex, showing 
lower levels of IL-6 and higher levels of IL-1β32-34. However, this latter 
observation has been disputed as well35.
On the basis of a putatively raised production of pro-inflammatory 
cytokines in MDD the “macrophage theory of depression” was formulated, 
which proposes that an excessive secretion of pro-inflammatory 
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cytokines by monocytes/macrophages causes symptoms of depression. 
A presumed explanation is that these cytokines act as neuromodulators, 
becoming key factors in the mediation of the behavioral, neuroendocrine 
and neurochemical features of MDD5,36-38. Maes39,40 has tried to extend 
the theory of cytokines acting as neuromodulators to bipolar disorder 
(BD), but so far studies on IL-1β and IL-6 production in BD patients are 
scarce41,42.
The here-reported study involves a large group of well-defined 
outpatients with DSM-IV bipolar I and II disorder (n=80) and 
addresses the question whether the capacity of monocytes to produce 
pro-inflammatory cytokines is altered in BD. We therefore determined 
the production of IL-1β and IL-6 by monocytes of BD and compared this 
production to that of healthy control subjects (HC, n=59). Apart from 
studying the spontaneous IL-1β and IL-6 production by monocytes, we 
also studied the lipopolysaccharide (LPS)-induced production. The LPS-
stimulated production was studied because previous research suggests 
that disturbances in pro-inflammatory cytokine synthesis are studied 
best under dynamic conditions43,44.
Since decades lithium is known as an effective mood-stabilizing drug. 
Many consider it the drug of first choice in BD, particularly in long-term 
treatment45. The exact mode of action has not been elucidated yet, but 
it exerts complex effects on multiple biological systems such as signal 
transduction pathways. Reasonably it has multiple actions critical for its 
ultimate therapeutic effect46,47. Since lithium has also been recognized 
as an immune modulating drug, it is possible that some of its effects 
on affective disorders are mediated via altering the pro-inflammatory 
cytokine production48,49. We therefore additionally investigated the effect 
of lithium treatment on monocyte IL-1β and IL-6 production by comparing 
data in lithium users (n=64) versus non-users of lithium (n=16) and by 
studying the in vitro effects of lithium exposure to monocytes by adding 
lithium chloride to the monocyte culture systems.
Materials and Methods
Patients and Healthy Control Subjects
Patients: Heparinized blood was obtained from outpatients with 
DSM-IV bipolar I and II disorder (n=80) participating in the Stanley 
Foundation Bipolar Network (SFBN), a multi-center research program 
described elsewhere in detail50,51. For the here-described experiments 
all patients were recruited from the SFBN-site in The Netherlands. The 
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Institutional Review Board (IRB) of the University Medical Center Utrecht 
had approved the study protocol and written informed consent was 
obtained from all patients.
A DSM-IV52 diagnosis of bipolar disorder was made by means of the 
Structured Clinical Interview for DSM-IV Axis I (SCID)53. A detailed illness 
history, including past and present medication, was assessed at entry 
into the Network. Blood for the present study was drawn during one of 
Table 1. Clinical and Demographic Characteristics.  
Bipolar 
Patients
Healthy Control 
Subjects
Group size 80 59
Age (years)1 44 (21-60) 38 (22-58)
Gender Male 40 (50.0%) 26 (44.1%)
Female 40 (50.0%) 33 (55.9%)
Psychotropic medication Carbamazepin 19 (23.8%)
Valproate 28 (35.0%)
Thyrax 17 (21.3%)
Antidepressives 13 (16.3%)
Antipsychotics 19 (23.8%)
Benzodiazepins 20 (25.0%)
Duration of treatment (years)1 13.5 (1-35)
Lithium users 64 (80.0%)
Li titer in serum (mM)2    .76 ± .17
Cumulative period of Li treatment (months)1 74 (6-305)
Patients without current Li 16 (20.0%)
Period without Li (months)1 39 (6-118)
Current mood state Euthymic 50 (62.5%)
Depressed 15 (18.8%)
Manic 11 (13.8%)
Cycling   4 (5.0%)
Diagnosis (DSM-IV) Bipolar I disorder 61 (76.3%)
Bipolar II disorder 19 (23.8%)
Duration of illness (years)1 19.4 (2-42)
1 mean (range)
2 mean ± SD
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the monthly follow-up visits, when a research clinician also assessed 
the current mood state, i.e. euthymic, depressed, (hypo) manic or 
cycling, by means of a detailed interview including the Young Mania 
Rating Scale54, the Inventory of Depressive Symptoms55 and the Clinical 
Global Impressions Scale – Bipolar Version56. Clinical characteristics of 
the patients are shown in Table 1. Patients were included as “not using 
lithium” (nonLi-BD) when they had not used lithium for at least 6 months. 
The lithium users were on lithium for at least 6 months (Li-BD).
Blood was collected in sodium-heparin tubes (Becton and Dickenson, 
Franklin Lakes, New Jersey, USA), since lithium-anticoagulant for the 
collection of blood has been found to influence the in vitro cytokine 
production57. Blood was drawn in the morning and transported by courier 
to the laboratory in Rotterdam, lasting an acceptable 8-10 hours before 
further processing. If the samples are stored overnight, mainly the 
monocytes (needed for the production of pro-inflammatory cytokines) 
start to phagocytose the erythrocytes and become activated and less 
viable, as determined by trypan blue staining (unpublished results). As 
long as blood is collected into endotoxin-free anticoagulant, the cytokine 
measurements are relatively stable and reflect the in vivo status57,58.
Healthy Control Subjects: Blood was collected from two healthy 
control groups:
1. Healthy blood bank donors (n=10). Blood was drawn and buffy  
 coats were immediately prepared according to the standard
  protocols of the blood bank. Mononuclear blood cells were
  isolated from the buffy coats and subsequently frozen and stored 
 within 2 hours. Monocytes prepared from these cell suspensions
 were used in a series of lithiumchloride (LiCl) dose–response
  experiments.
2. Healthy laboratory and hospital staff members of the 
  Erasmus MC (The Netherlands) (n=59). Blood collections were
  performed on the same days as those of the patients, using the same 
 procedures. All healthy control subjects (HC) gave written
   information about medication use and medical history and informed 
 consent was obtained. The HC subjects needed to be both mentally 
 and physically well and the exclusion criteria for this HC group were: 
 any immune disorder, serious medical illness, recent infections, 
 fever, any life-time major psychiatric disorder (including psychosis,
  mood disorders, anxiety disorders, or substance abuse disorders)
  or usage of any psychotropic or other medication (apart from 
 anti-conceptive hormonal therapy).
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Isolation of Mononuclear Cells
Monocyte-lymphocyte suspensions were prepared from heparinized 
blood via Ficoll (Pharmacia, Uppsala, Sweden; density 1.077 g/ml) 
gradient centrifugation. Firstly PBS (Bio Whittaker Europe, Verviers, 
Belgium) containing .1% BSA (Bayer, Kankakee, USA) (PBS/.1% BSA) 
was added to the heparinized blood sample in a dilution of 1:1. These 
diluted cells were distributed on Ficoll gradient and centrifuged for 15 min 
at 1000g. After this centrifugation, peripheral blood mononuclear cells 
(PBMC; i.e. lymphocytes and monocytes) were collected from the interface 
and washed with PBS/.1% BSA (centrifugation for 10 min at 760g). 
The PBMC were thereafter re-suspended in RPMI 1640 with 25mM HEPES 
and L-glutamine (Bio Whittaker Europe, Verviers, Belgium), additionally 
containing 10% inactive FCS (Bio Whittaker Europe, Verviers, Belgium; 
FCSi), penicillin/streptomycin (Bio Whittaker Europe, Verviers, Belgium;
 P/S) (P 100 U/ml, S 100 mg/ml) and extra ultraglutamine (Bio Whittaker 
Europe, Verviers, Belgium, 2mM; UG) (hereafter referred to as RPMI+).
Samples were frozen in 10% dimethylsulfoxide (DMSO) and stored in 
liquid nitrogen. This enabled us to test patient and control monocytes in 
the same series of experiments at appropriate times.
Cytokine Production by Monocytes
The frozen and stored PBMC suspensions were quickly thawed and directly 
diluted in RPMI+ to wash out the DMSO. The viability of the population was 
determined via trypan-blue exclusion staining. All populations contained 
at least 90% viable cells according to this staining. To separate monocytes 
from lymphocytes, PBMC suspensions were distributed on a Percoll gradient 
(Pharmacia; density 1.063 g/ml). Cells were thereafter centrifuged at 400g 
for 40 minutes. Monocytes were collected from the interface and the purity 
of the population was determined via a non-specific esterase staining. All 
populations contained at least 80% non-specific esterase positive cells.
The monocytes were placed in 24-wells flat-bottom plates (NUNC 
MaxiSorpTM, Roskilde, Denmark) at a concentration of 5.105 cells/ml and 
cultured for 24 hours in RPMI+. The following factors were either added or 
not to the monocyte cultures:
• Lipopolysaccharide (LPS) of E. Coli (Difco Laboratories, Detroit,
  Michigan, USA) in a sub-optimal concentration of 1 μg/ml.
• Lithiumchloride (Sigma, Munich, Germany; LiCl) in concentrations
 of .2, 1.0, 2.0, or 5.0 mM.
The cells were cultured at 37°C in 5% CO2. After 24 hours cells were spun 
down at 250g for 1 minute, supernatants were harvested and stored at 
minus 20°C until they were assayed for the concentration of IL-1β and IL-6.
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Measurements of IL-1β and IL-6
Pro-inflammatory cytokine levels in supernatants of the monocyte 
cultures were measured via an IL-1β and IL-6 specific enzyme-linked 
immunosorbent assay (ELISA). A 96-well ELISA plate (NUNC, Roskilde, 
Denmark) was coated overnight at 4°C with a diluted monoclonal 
capture antibody specific for human IL-1β or IL-6 (Biosource Europe S.A., 
Nivelles, Belgium). After a blocking step with a PBS/.5% BSA solution, the 
supernatants (if required diluted to a measurable solution), a negative 
control-culture fluid sample (RPMI+), and standard solutions of IL-1β 
or IL-6 were aliquoted in duplicate in the wells. IL-1β or IL-6 detection 
antibodies (Biosource Europe S.A., Nivelles, Belgium) were thereafter 
added to the wells and plates were incubated for two hours. After washing, 
a Streptavidine-poly-HRP solution (horse-raddish peroxidase) was added 
to enhance the reaction, followed by incubation for 30 minutes and a 
second wash step. All incubations took place under continuous shaking.
Subsequently TMB substrate (KPL, Gaithersburg, Maryland, USA) was 
added and the reaction was developed in dark until the colour of the 
standard solution started to turn blue in the lower concentrations of the 
standard solution (5-10 min). The reaction was stopped with 1M H3PO4.
Absorbance at 450-650 nm was measured with an Easia reader 
(Medgenix Diagnostics, Brussels, Belgium). Using the standard titration 
curve, concentrations of IL-1β or IL-6 in unknown samples were calculated 
based on their optical density values (4-parameter fit). The inter-assay 
variation was less than 10%.
Statistical Analysis
Statistical analysis was performed using the SPSS 11.0 package 
for Windows (SPSS, Chicago, Illinois, USA). Data were tested for 
their parametric distribution using the Kolmogorov-Smirnov test. 
Since the cytokine expression profiles did not show a parametric 
distribution, we decided to use non-parametric tests. We compared 
the different groups using a Kruskal-Wallis test, followed by a 
Mann-Whitney U test to determine differences between two groups. 
To analyze the in vitro data of LiCl we performed paired statistical analysis 
(0 vs. 1mM and 0 vs. 5mM LiCl) using the Wilcoxon signed-rank test. 
Correlations of the cytokine expression with different clinical parameters 
were examined using Spearman’s rho test. Level of significance was set 
at the critical value of p=.05 (2 tailed).
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Results
LPS-stimulated Monocytes of BD show an Imbalance in 
the Production of Pro-inflammatory Cytokines in Favor 
of IL-6: Lithium Treatment restores this Imbalance
Table 2 shows that the production of IL-1β and IL-6 was, as expected, 
considerably higher if monocytes had been stimulated with LPS as 
compared to the spontaneous in vitro cytokine production. The table 
also indicates that monocytes of bipolar patients not being treated 
with lithium (nonLi-BD) show a trend for a reduced production of 
IL-1β and an enhanced production of IL-6, particularly under conditions 
of LPS stimulation (yet values did not reach statistical significance 
when compared to HC; Table 2). However expressed as IL-1β/IL-6 ratio 
(Figure 1), values did reach statistical significance, illustrating an 
imbalance in the production of IL-1β and IL-6 by monocytes of bipolar 
patients in favor of IL-6 and at the expense of IL-1β. 
HC nonLi-BD Li-BD HC nonLi-BD
spontaneous LPS-induced
Li-BD
0
0.1
0.2
0.3
0.4
0.5
0.6
IL
-1
�/
IL
-6
 ra
tio
�
�
�
n.s.
�
�
Data represent the production ratio IL-1β/IL-6. Means and SEM are given. Light bars 
represent spontaneous ex vivo production of monocytes, dark bars represent dynamic 
LPS stimulated conditions. In both conditions Kruskal-Wallis test p value <.01.
* Represents p value <.05 using Mann-Whitney U test
Figure 1. Effect of Lithium Treatment on the IL-1β/IL-6 Production Ratio.
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When patients were treated with lithium (Li-BD), monocytes showed 
an enhanced IL-1β production as compared to that of monocytes of 
nonLi-BD (Table 2) and a reduced IL-6 production, but the latter only 
under LPS-stimulated conditions. Lithium treatment thus results in a 
normalization of the IL-1β/IL-6 ratio, which became comparable to 
the ratio found in the HC both under LPS-stimulated and spontaneous 
conditions (Figure 1).
Table 3 shows the correlation between the IL-1β and the IL-6 
production by patient monocytes and various clinical characteristics of 
the patients. We were not able to find statistically significant correlations 
neither between the studied cytokines separately (both spontaneous and 
LPS-stimulated) on the one hand and age, gender, duration of illness, 
psychotropic medication used (apart from lithium, see before), duration 
of lithium treatment, or diagnosis on the other hand, nor between these 
clinical parameters and the IL-1β/IL-6 ratio (data not shown). As weight 
can also be a confounder, we also checked for a possible association 
between body mass index (BMI) and the cytokine production. We only 
had the BMI data of 61 bipolar patients (no data on healthy controls, 
19 missing values). The mean BMI was 25.2 ± 4.2 (Li-BD: 24.9 ± 3.3, 
nonLi-BD: 26.2 ± 6.6) and no significant associations with the cytokine 
production were found (Table 3). Regarding the psychopathological state 
of the patients, we could not find differences between the euthymic 
patients and the patients with mood symptoms, either depressed, manic, 
or cycling (Table 3). We also could not find a difference between the 
individual mood symptoms, which points more in the direction of a trait 
effect. This applied to both the entire dataset and the nonLi-BD and 
Li-BD subgroups of patients.
In vitro LPS-stimulated Monocytes reduce their IL-1β 
Production when exposed to LiCl.
In a first series of experiments we tested monocytes that had been 
isolated from frozen mononuclear cell suspensions prepared from buffy 
coats of healthy blood bank donors and performed a dose response study 
with different dosages of LiCl (0, .2, 1.0, 2.0 and 5.0 mM), searching for 
an effect on the in vitro production of IL-1β and IL-6. While the relatively 
low spontaneous production of IL-1β and IL-6 was not influenced by 
the addition of LiCl, the LPS-induced cytokine production was. The in 
vitro addition of LiCl dose-dependently down regulated IL-1β production, 
reaching statistical significance at 5.0 mM. It did not influence the IL-6 
production by LPS-stimulated monocytes (Figure 2). It must be noted 
here that after 24 hours of culture all samples showed a viability of >90% 
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Data represent the effects of graded concentrations of lithium chloride (LiCl) on the 
production of IL-1β (a) and IL-6 (b) of monocytes of healthy blood bank donors. Means and 
SEM are given. Open triangles represent spontaneous ex vivo production of monocytes, 
black squares represent dynamic LPS-stimulated conditions.
*  Represents p values <.05 using Wilcoxon signed-rank test (LiCl concentration vs. no
  LiCl)
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Figure 2.  Effects of Graded Concentrations of Lithium Chloride on the Production
  of IL-1β and IL-6 from Monocytes of Healthy Blood Bank Donors.
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Data represent the change in IL-1β (a) or IL-6 (b) production of monocytes in healthy 
controls (HC), bipolar patients without lithium treatment (nonLi-BD), and with lithium 
treatment (Li-BD), due to in vitro lithium chloride (LiCl) addition in dynamic, LPS-stimulated 
conditions. Mean fold changes (compared to the condition without LiCl) and SEM are given. 
Black bars represent the condition without LiCl, the gray bars represent the change after 
1mM (dark) or 5mM (light) LiCl relative to the condition without LiCl (fold change).
* Represents p values <.05 using Wilcoxon signed-rank test (LiCl concentration vs. no
  LiCl)
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Figure 3.  Effects of Lithium Chloride on the IL-1β and IL-6 Production on Monocytes 
 of Different Subject Groups.
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by trypan blue exclusion testing (data not shown), also in the highest 
concentration of 5mM LiCl. LiCl also did not affect the cell yield after 
culture. Both observations exclude a toxic effect of LiCl on monocytes 
even in the 5mM dose.
In a second series of experiments we used the monocytes of our 
actual patient populations, i.e. nonLi-BD (n=8) and Li-BD (n=8) patients 
and of the HC sampled at the same time as the patients (n=27). We used 
LiCl concentrations of 1mM, correlating with physiologic serum levels, 
and 5mM on the basis of the above described dose response experiment. 
First, we were able to confirm in this second set of experiments that 
LiCl did not affect the low spontaneous production of IL-1β and IL-6 
(data not shown). Second, LiCl down regulated the production of IL-1β 
of LPS-stimulated monocytes of all groups, as in our first series of in 
vitro experiments. Third, in this second series LiCl stimulated the IL-6 
production by HC monocytes to some extent (in contrast to the first series 
of experiments), but it did not affect the IL-6 production by monocytes of 
nonLi-BD and Li-BD patients (Figure 3).
Discussion
In our study on a large sample of 80 well-characterized bipolar 
patients, we were not able to find statistically significant increases 
in the IL-1β and/or IL-6 production by monocytes of bipolar patients. 
Therefore, we cannot support the concept that a high IL-1β and/or 
IL-6 production is an important (and perhaps even prime) abnormality 
in major affective disorders as postulated in the “macrophage theory of 
depression”5,36-38. However, we found that LPS-stimulated monocytes of 
bipolar patients had an aberrant pro-inflammatory status, i.e. the cells 
showed a relative high ex vivo production of IL-6 in comparison to a 
low production of IL-1β when compared to LPS-stimulated monocytes 
of healthy control subjects. Thus, our data do point in the direction of 
the existence of monocyte/macrophage aberrancies in bipolar disorder 
and more specifically of an imbalance in pro-inflammatory cytokine 
production under LPS-stimulated conditions. Our data also show that 
lithium treatment corrected this imbalance.
With regard to the validity of our data it must firstly be noted that the 
pro-inflammatory cytokine production from monocytes is sensitive to 
a number of confounding factors, such as age and gender20. We tested 
for these factors both across the entire data set and within the separate 
subgroups, but were neither able to find male-female differences nor 
associations between age and cytokine production profile. In addition, 
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there were no indications for a state dependent effect regarding the 
IL-1β and IL-6 production. 
A major limitation of our study is its naturalistic set-up. Because 
of this naturalistic set-up, the majority of patients used various 
psychiatric co-medications (Table 1). Although we found lithium to be a 
prominent determinant in the IL-1β and IL-6 production by monocytes 
(see results), we could not find an effect of other medications in our 
sample. Nevertheless, such other medications are known to have immune 
modulating effects59 and the considerable variability of the various 
(co-)medications in our patient group may have influenced our results. 
To answer the question, whether these various medications have an 
effect on the cytokine production, a longitudinal approach changing one 
such medication while keeping the others stable, would have been a 
better option, but again the naturalistic set-up of our study precluded 
such approach. 
In addition smoking may have had an effect on the cytokine production 
in our patients. In contrast to our healthy control subjects, the majority 
of the bipolar patients were smokers, but details on smoking behavior of 
individual patients are lacking.
Moreover, psychological stress (both acute and chronic) can affect 
the immune system. A recent meta-analysis showed that stressors 
have an up-regulating effect of IL-1β and IL-660. Unfortunately, no data 
were available on recent or more chronic stressful events in our cohort, 
so we could not correct for this potential confounding factor. Although 
none of the healthy control subjects suffered from a clear psychiatric 
or somatic disorder or used medication, we cannot rule out a low level 
of depressive symptoms in our HC subjects. We did not verify this by 
performing (semi-)structured psychiatric interviews. Finally, weight can 
also be a confounding factor61. Although the bipolar patients were slightly 
overweighed, we could not find any significant association between the 
BMI and the cytokine levels. No data were available on the BMI of our 
healthy controls. 
What might be the relevance of the here found imbalance in IL-1β 
and IL-6 production of LPS-stimulated monocytes of non-lithium treated 
bipolar patients? IL-1β and IL-6 are both considered as pro-inflammatory 
cytokines playing a similar role in the acute phase response and the innate 
immune response, but IL-6 has an additional role in B cell stimulation62. 
In previous studies we found an increase in circulating B cells and a higher 
prevalence of auto-antibodies63-65 in bipolar patients and it is tempting to 
speculate that such B cell/auto-antibody predominance is related to the 
here-described preferential production of IL-6 by bipolar monocytes.
With regard to the brain activities of IL-1β and IL-6, it is known that both 
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cytokines induce various neurotransmitter activities, yet their individual 
effects vary: Both stimulate the production of serotonin (5-HT)8, but 
only IL-1β (not IL-6) stimulates the production of norepinephrin8,66. 
This implicates that the here reported imbalance in IL-1β and IL-6 
production by monocytes under dynamic conditions (f.i. during infections) 
may also lead to imbalances in the neurotransmitter make-up in the brain, 
which in our opinion needs further exploration. A possible explanation for 
our finding that the individual cytokines did not show clear significant 
differences, but the IL-1β/IL-6 ratio did, is that primarily the interplay 
between the cytokines causes effects on the different systems, such 
as auto-antibody production or neurotransmitter balance instead of the 
individual cytokines.
One can hypothesize that the here reported results may be caused 
by counter-regulatory mechanisms within the serum influencing the 
monocytes. However, we could not find any proof for this assumption. 
During the first set of experiments we also measured the serum levels of 
IL-1β and IL-6 in a limited set of patients (n=39; with the same ELISA kits 
as described in the result section). In line with the findings of Boufidou et 
al67, we could hardly detect any cytokine levels in the serum. Concerning 
IL-1β only one patient had a cytokine level just above the detection 
limit (10 pg/ml). As to IL-6, only in 7 patients cytokine levels above the 
detection levels were measured (mean 1.7 ± 4.3 pg/ml). 
How do our data of IL-1β and IL-6 production by monocytes of bipolar 
patients and the effect of lithium treatment compare to those previously 
reported in the literature? Although there are several conflicting reports on 
the ex vivo production of IL-1β and IL-6 by circulating leukocytes of major 
depressed patients (see introduction), reports on the ex vivo production 
of these cytokines by leukocytes of non-lithium treated bipolar patients 
are scarce. There is one recent study67 which investigates, as we do, the 
ex vivo production of IL-6 by immune cells in lithium treated and non-
treated bipolar patients (IL-1β was not studied). In accord with our study, 
lithium treatment decreased the IL-6 production by stimulated immune 
cells. In contrast to the scarcity of studies on the ex vivo production 
of pro-inflammatory cytokines by immune cells, there is a reasonable 
number of reports on the serum level of cytokines in non-lithium treated 
bipolar patients. In particular the serum level of IL-6 has been studied 
and compared to that of healthy control subjects. IL-6 serum levels were 
undetectable67,68 or not altered20,39. With regard to IL-6 in serum, it must 
be noted that this cytokine is not only derived from immune cells but 
also from thyroid cells69, hence parallels between these serum studies 
and the here-described ex vivo production by monocytes/macrophages 
are difficult to draw. Interestingly lithium treatment increased serum 
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levels of IL-620,49,70 and IL-1β49. 
Unexpectedly we found that the in vitro exposure of monocytes to 
lithium had another effect than lithium treatment: while lithium treatment 
raised the IL-1β production of ex vivo cultured monocytes and lowered 
their IL-6 production, LiCl added in vitro dose-dependently reduced the 
capacity of LPS-stimulated monocytes to produce IL-1β. There is only one 
report, that -similar to this report- compares the in vivo treatment effects 
of lithium with the in vitro effects of the drug on the function of immune 
cells in the same patients and controls67. In that study lithium treatment 
and in vitro lithium exposure also had different effects: while lithium in 
vitro lacked any effects on the number of circulating cytokine secreting 
cells, lithium treatment of patients reduced the number of IL-2, IL-6, 
IL-10 an IFNγ secreting cells. These differences between lithium treatment 
and in vitro lithium exposure might be explained by the difference in 
concentration and duration to which the immune cells are exposed to 
lithium in the treatment as compared to the in vitro situation. However, 
also indirect effects of lithium treatment on the immune system may play 
a role in the treatment situation, such as effects exerted via the neuro-
endocrine system. Obviously such indirect effects are lacking in the in 
vitro LiCl exposure situation. In this regard it is worth noticing that in 
our study the 1mM in vitro concentration (an effective serum level) had 
only minimal effects on the monocyte/macrophage pro-inflammatory 
cytokine production in the (be it short) in vitro exposure experiments 
(see results).
How do our data on the effects of in vitro lithium exposure on IL-1β 
and IL-6 production by monocytes in general relate to the effects of 
lithium exposure reported in the literature? There are many reports on 
the effects of in vitro lithium exposure on the cytokine production by 
immune cells, but these reports differ widely in experimental conditions, 
such as the actual cytokines under study, the studied immune cell 
populations, the state of stimulation of the immune cells, the readout 
systems and the concentration, duration and in vitro or in vivo character 
of lithium exposure67,71-74. The group of Kleinerman was the only group 
to determine the effect of LiCl on spontaneous IL-1β production. In line 
with our results, LiCl did not affect the spontaneous IL-1β production71. 
The effect of in vitro LiCl on IL-6 production is studied into more extent. 
Although two groups reported that the spontaneous IL-6 production was 
not influenced by LiCl67,73, Arena et al reported an increased production72. 
Regarding the mitogen-stimulated IL-6 production, LiCl decreased the 
IL-6 production in one study74 but LiCl did not affect it in two other 
studies67,73. The different reaction profile of IL-6 production of monocytes 
of bipolar patients and healthy control subjects, as found in our study 
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(respectively no difference after in vitro LiCl addition versus an increased 
production) was not found by others67,72. It is clear that a consistent 
picture has not been generated on the in vitro effects of lithium regarding 
IL-1β and IL-6 production.
In conclusion our study shows that monocytes of bipolar patients 
have an imbalance in their IL-1β/IL-6 production, which is corrected 
by lithium treatment. In vitro, lithium also had an effect on the 
IL-1β/IL-6 production ratio of monocytes, but different from that 
observed by lithium treatment. Our data do support the view expressed 
in the “macrophage theory of depression” that monocytes/macrophages 
have an altered status in affective disorders, but doubt the idea that a 
simple rise in the production of the pro-inflammatory cytokines IL-1β and 
IL-6 by monocytes/macrophages would be responsible for the changes 
in mood.
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Letter to the Editor:
Lithium is known as an effective mood-stabilizing drug1 with immune 
regulatory properties2. A well-known side effect of lithium treatment is 
the exacerbation of psoriasis3. Psoriasis is a mostly localized, chronic 
inflammatory skin disease, characterized by a strong increase in the 
proliferation of keratinocytes and an accumulation of T cells, monocytes, 
and monocyte-derived cells4. Pro-inflammatory cytokines such as IFN-γ, 
IL-1β, and TNFα, are thought to activate these inflammatory cells5. The 
pro-inflammatory cytokine network is not only disturbed in the immune 
and epithelial cells in the psoriatic lesion, but also in the circulating 
monocytes of the patients6.
We investigated the basal and lipopolysaccharide (LPS, 1 μg/ml culture 
fluid) stimulated production of IL-1β, TNFα, and IL-6 by density gradient-
purified peripheral blood monocytes of 27 healthy control subjects (HC: 
eight male/19 female, mean age 33.6 ± 8.5), 16 patients with a “regular” 
psoriasis (Reg-Psor: 10 male/six female, mean age 45.8 ± 16.1; all 
active lesions: body surface area 11.6%, no systemic medication), 
and six outpatients with DSM-IV bipolar disorder with lithium-induced 
psoriasis (Li-Psor BD: four male/two female, mean age 52.7 ± 8.5, all 
active lesions: body surface area 4.3%, only psychotropic medication, 
2 euthymic/4 symptomatic) in the absence or presence of 1 and 5 mM 
lithium chloride (LiCl) with previously described methods7.
Figure 1 shows the IL-1β, TNFα, and IL-6 production of the blood 
Means and SEM are given. Black squares represent healthy control subjects (HC), open 
triangles represent bipolar patients with lithium-induced psoriasis (Li-Psor BPD), and 
open circles represent patients with a regular psoriasis.
#  represent p values < .05 between the groups (Kruskal-Wallis test)
*  represent p values < .05 comparing the cytokine production with LiCl added (1 or 5mM)
    versus 0mM (Wilcoxon signed-rank test)
Figure 1. Pro-inflammatory Cytokine Production after Lithium and/or LPS-
 addition.
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monocytes of Reg-Psor, Li-Psor BD, and HC. Blood monocytes of Reg-
Psor showed an enhanced production of the pro-inflammatory cytokines 
when compared with the values found in HC, particularly under non-LPS 
stimulated conditions. However, the production profiles of the cytokines 
of Li-Psor BD were in the same range as the HC, in sharp contrast to 
the high production range of Reg-Psor. When LiCl was added in vitro to 
LPS-stimulated monocytes, the production of IL-1β and TNFα of HC and 
Li-Psor BD was significantly down regulated, particularly in the case of 
Li-Psor BD having a significant decline at 1mM. This contrasted again 
to monocytes of Reg-Psor, where LiCl lacked a statistically significant 
dampening effect on the production of the pro-inflammatory cytokines. 
Further analysis did not show an association between the cytokine 
production and age or gender.
Our observation on the discrepancy between the pro-inflammatory 
cytokine production of monocytes of Reg-Psor and Li-Psor BD indicates 
that the pathogenesis of Li-induced psoriasis must be different from 
regular psoriasis. An excessive production of pro-inflammatory cytokines 
–as described for regular psoriasis8- is less likely to be an important 
pathogenic factor in lithium-induced psoriasis. Interestingly direct 
stimulating effects of lithium have been found on the proliferation of 
keratinocytes in in-vitro-cultured normal human skin explants9, pointing 
to a non-immunological effect of the drug in its potency to elicit the 
psoriatic skin condition. Perhaps our observation of monocytes of patients 
at risk for a lithium-induced psoriasis being ultra-sensitive to the effects 
of lithium might also be extrapolated to their keratinocytes, which may 
be ultrasensitive and respond with an excessive proliferation to lithium 
exposure.
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Abstract
Background
Dendritic cells (DC) are key regulators of the immune system, which 
is compromised in patients with bipolar disorder.
Aim
To study monocyte-derived DC in bipolar disorder.
Methods
Monocytes purified from blood collected of DSM-IV bipolar disorder 
outpatients (n=53, 12 without lithium treatment) and healthy individuals 
(n=34) were differentiated into DC via standard granulocyte-macrophage 
colony-stimulating factor/interleukin-4 culture (with/without 1, 5, and 
10 mM LiCl). DC were analyzed for DC-specific and functional markers 
and for T-cell stimulatory potency. 
Results
Monocytes of bipolar patients showed a mild hampering in their 
differentiation into fully active DC, showing a weak residual expression 
of the monocyte marker CD14 and a relatively low potency to stimulate 
autologous T cells. Lithium treatment abolished this mild defect and 
monocyte-derived DC of treated bipolar patients showed signs of 
activation (i.e., an up regulated potency to stimulate autologous T cells 
and a higher expression of the DC-specific marker CD1a). This activated 
phenotype contrasted with the suppressed phenotype of monocyte-
derived DC exposed to lithium in vitro (10 mM) during culture.
Conclusion
Dendritic cells show mild aberrancies in bipolar disorder that are fully 
restored to even activation after in vivo lithium treatment.
Chapter 4.1
96
Introduction
We previously reported a raised prevalence of autoimmune thyroiditis, 
defined as a raised level of thyroperoxidase-antibodies (TPO-Abs), in 
bipolar patients1. In a consecutive study on the same cohort not only 
thyroid autoimmune reactivity but also autoimmune reactivity to 
pancreatic islets (GAD65-Abs) and to gastric mucosa (H+/K+ ATPase-
Abs) were more prevalent in bipolar disorder2. The raised prevalence of 
TPO-Abs, GAD65-Abs, and H+/K+ ATPase-Abs was not associated with 
the current use of lithium.
To investigate whether a higher prevalence of autoimmunity in 
bipolar disorder (BD) was associated with a generalized activation of the 
T-cell system, we extended our studies and measured levels of serum-
interleukin-2 receptor (sIL-2R) and numbers of activated T cells in the 
circulation of BD patients3. The T-cell system was found activated, as 
evidenced by a higher serum level of sIL-2Rand raised numbers of CD3+ 
CD25+ cells, in both symptomatic and euthymic patients; however, manic 
patients showed the highest state of T-cell activation. As with the auto-
Abs, the T-cell activation was not associated with the use of lithium.
The stimulation of antigen-specific T cells and the production of 
antibodies, including that of TPO-Abs, GAD65-Abs, and H+/K+ ATPase-
Abs, are under the control of dendritic cells (DC), a specialized group of 
immune cells. The DC are antigen-presenting cells (APC) par excellence 
and the only cells capable of stimulating naïve T cells and initiating an 
effective immune response towards foreign antigens4-6. Besides that, 
DC are also involved in preventing autoimmune responses by inducing 
tolerance to auto-antigens. To exert these functions, DC express major 
histocompatibility complex (MHC)-class II molecules and the 
so-called co-stimulatory molecules (CD80, CD86, and CD40) on their 
cell membrane to be able to strongly stimulate (auto-)antigen-specific 
T-helper and regulatory cells6,7. One of the main precursors of DC is the 
blood monocyte6,8.
Our observation of an aberrant T-cell activation and a higher prevalence 
of thyroid, islet, and gastric-Abs in BD patients led to the hypothesis that 
DC might also be aberrant in these patients. To our knowledge, studies on 
the function of DC in bipolar disorder have not been performed. Therefore, 
we induced purified peripheral blood monocytes of 53 BD patients to 
differentiate into DC with a 6-day-culture of cells in the presence of the 
differentiating cytokines granulocyte-macrophage colony-stimulating 
factor (GM-CSF) and IL-4. The DC character of the cells was verified by 
the expression level of the DC-specific type II lectin DC-SIGN, of the 
DC-specific lipid antigen-presenting molecule CD1a, and of CD83 on the 
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cultured cells. The functional activity of the cells was determined by 
the capability of the generated DC to stimulate T cells to proliferate in 
mixed lymphocyte reactions (MLR). We also measured the expression 
levels of MHC-class II, CD80, CD86, CD40, and of molecules involved in 
APC/T-cell interactions (i.e., of the integrins CD11b, CD18, CD29, CD54). 
We investigated these functional and phenotypic DC parameters in BD 
patients with current lithium treatment and without lithium treatment 
separately, since this drug is known to be immune modulatory9,10. 
Outcomes were compared to those obtained using cells of healthy control 
subjects (n=34). We also investigated whether in vitro co-culture with 
lithium influenced the capacity of monocytes to differentiate into DC.
Materials and Methods 
Patients and Healthy Control Subjects
Patients: Heparinized blood was obtained from outpatients with 
DSM-IV bipolar I and II disorder (n=53) participating in the Stanley 
Foundation Bipolar Network (SFBN), a multi-center research program 
described elsewhere in detail11,12. For these experiments, all patients 
were recruited from SFBN sites in The Netherlands. The Institutional 
Review Board of the University Center Utrecht had approved the study 
protocol and written informed consent was obtained from all patients. 
A DSM-IV13 diagnosis of bipolar disorder was made by means of 
the Structured Clinical Interview for DSM-IV Axis I, Patient Edition 
(SCID-I/P) Research Vision14. A detailed illness history, including past 
and present medication, was assessed at entry into the Network. Blood 
for the present study was drawn during one of the monthly follow-up 
visits, when a research clinician also determined present mood (i.e., 
euthymic, depressed, [hypo-] manic or cycling) by means of a detailed 
interview including the Young Mania Rating Scale15, Inventory of 
Depressive Symptoms16, and Clinical Global Impressions Scale – Bipolar 
Version17. Patient clinical characteristics are shown in Table 1. Patients 
were included as “not using lithium” (nonLi-BD) when they were either 
lithium naive or did not use lithium for at least 12 months. The lithium 
users had effective lithium treatment for at least 6 months (Li-BD). It 
must be noted that Li-BD had comparable profiles of other psychotropic 
medication as the nonLi-BD.
Blood was collected in sodium-heparin tubes (Becton and Dickenson), 
since lithium-anticoagulant for the collection of blood has been found 
to influence the in vitro cytokine production18. Blood was drawn in the 
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Table 1. Clinical and Demographic Characteristics. 
Bipolar 
Patients
Healthy Control 
Subjects
Group size Total 53 34
1st Series 14 11
2nd Series 15 9
3rd Series 8 8
4th Series 16 6
Age (years)1 45 (22-62) 38 (23-62)
Gender Male 25 (47%) 12 (35%)
Female 28 (53%) 22 (65%)
Psychotropic medication Carbamazepin 35 (66%)
Valproate 16 (30%)
Thyrax 10 (19%)
Antidepressives 14 (26%)
Antipsychotics 9 (17%)
Benzodiazepins 18 (34%)
Duration of treatment (years)1 14 (1-36)
Lithium users 41 (77%)
Li titer in serum (mM)2     .78 ± .17
            Cumulative period of Li treatment (months)1 76 (6-203)
Patients never used Li (naïve) 6 (11%)
Patients without current Li but with Li in past 6 (11%)
Period without Li (months)1 43 (12-114)
Current mood state Euthymic 31 (58%)
Depressed 12 (23%)
Manic 8 (15%)
Cycling 2 (4%)
Duration of illness (years)1 21 (3-42)
Hematological 
parameters
Hb2,3     8.7 ±   .8
Leucocytes2,4     6.9 ± 1.4
ESR2,5     5.8 ± 2.8
1 mean (range)
2 mean ± SD
3 reference values: 7.4 – 9.6 mM
4 reference values: 4.0 – 10.0*109/l
5 reference values <10mm/hour
Li, lithium; Hb, hemoglobin; ESR, erythrocyte sedimentation rate.
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morning and transported by courier to the laboratory in Rotterdam, 
lasting an acceptable 8-10 hours before further processing.
Healthy Control Subjects: Blood was collected from healthy 
laboratory and hospital staff members of the Erasmus MC (The 
Netherlands) (n=34) on the same days and at the same time points as 
the patients with the same procedures. All healthy controls (HC) gave 
written information about medication use and medical history. Informed 
consent was obtained. The exclusion criteria for this HC group were: 
any immune disorder, serious medical illness, recent infections, fever, 
psychiatric disorder, or use of any psychotropic or other medication 
(apart from anti-conceptive hormonal therapy). 
Generation of DC
Peripheral blood mononuclear cells (PBMC; i.e., the lymphocytes 
and monocytes) were prepared from the heparinized blood via Ficoll 
(Pharmacia, Uppsala, Sweden) gradient centrifugation as has been 
described in detail before19. The PBMC were thereafter re-suspended in 
RPMI 1640 with 25 mM HEPES and L-glutamine (Bio Whittaker Europe, 
Verviers, Belgium), additionally containing 10% inactive fetal calf serum 
(Bio Whittaker Europe, Verviers, Belgium; FCSi), penicillin (100 U/ml)/
streptomycin (100 µg/ml; Bio Whittaker Europe, Verviers, Belgium; P/S),
and extra ultraglutamine (Bio Whittaker Europe, Verviers, Belgium, 
2mM; UG) (RPMI+). Samples were frozen in 10% dimethylsulfoxide 
and stored in liquid nitrogen. This enabled us to test patient and 
control monocytes in the same series of experiments at appropriate 
times. The frozen PBMC were quickly thawed and washed twice 
in RPMI+ (trypan blue exclusion: >85% viable cells). To separate 
monocytes from lymphocytes, Percoll (density 1.063 g/ml; Pharmacia) 
density gradient centrifugation (for 40 min, 400g) was used.
Monocytes were cultured in 4 series (see Results) at a concentration 
of .5x106 cells/ml on 24-well culture plates (Falcon) under plastic-
adherent conditions in RPMI+ in the presence of GM-CSF 800 U/.5x106 
cells/ml (series 1+2: Pepro Tech, Rockyhill, New Jersey, USA; series 3+4: 
Biosource, London, England) and IL-4 1000 U/.5x106 cells/ml (series 
1+2: Biosource, London, England; series 3+4: Pepro Tech, Rockyhill, 
New Jersey, USA). In series 2-4 we added lithium chloride (LiCl) to the 
culture plates (1, 5, and 10 mM). Cells were thereafter incubated at 37°C, 
5% CO2
 and 95% humidity. On day three, the culture fluid was refreshed 
with complete RPMI+, containing cytokines (and, where appropriate 
LiCl). After six days, DC were collected by re-suspending and washing 
the wells thoroughly with cold phosphate buffered saline (PBS) pH 7.4 
(Bio Whittaker Europe, Verviers, Belgium) containing 3 mM ethylene 
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diamine tetra-acetic acid (Sigma-Aldrich, Steinheim, Switzerland). This 
culture method is well established8.
T-cell Isolation
The pellet of the Percoll gradient was washed twice with PBS containing 
.1% bovine serum albumine (Bayer, Kankakee, Illinois, USA) (PBS/.1% 
BSA) and the cells were incubated with anti-CD3 microbeads (20µl/107 
cells: Miltenyi Biotec, Bergisch Gladbach, Germany) for 20 minutes at 
4°C. A magnetic cell sorting system (autoMACS, Miltenyi Biotec) was used 
for the selection of CD3 positive T cells (positive selection). We isolated 
T cells from BD and HC to use in the autologous Mixed Lymphocyte 
Reaction (MLR) and from a cohort of HC to use in allogeneic MLR.
Fluorescence-activated Cell Sorting Analysis of DC
For analysis of marker expression by flowcytometry, all cell 
populations were stained by incubating for 10 minutes in the dark at 
room temperature with mouse anti-human FITC (fluorescein)- or PE 
(phycoerythrin)-conjugated monoclonal antibodies (mAbs), and washed 
afterwards. The following mAbs were used for flowcytometry: anti-IgG1 
FITC (B&D), anti-IgG1 PE (B&D), anti-CD14 PE (Beckman Coulter [BC], 
Hialeah, Florida, USA), anti-DC-SIGN FITC (R&D systems, Minneapolis, 
Minnesota, USA), anti-CD83 PE (B&D), anti-HLA-DR FITC (B&D), anti-
CD1a PE (BC), anti-CD80 PE (B&D), anti-CD86 FITC (Pharmingen, San 
Diego, California, USA), anti-CD40 FITC (Serotec, Oxford, England), 
anti-CD11b PE (B&D), anti-CD18 FITC (B&D), anti-CD29 FITC (BC), and 
anti-CD54 PE (B&D) (Table 2).
Immediately after staining, cells were subjected to fluorescence-
activated cell sorting (FACS) on a FACScan flowcytometer (B&D). During 
the FACS measurement and analysis of the data, the researcher was 
blind to the identity (patient/control subject) of the sample. Debris and 
dead cells were gated out in the samples on the basis of their light 
scatter properties. The DC population was gated out by means of cell size 
(forward scatter) and irregular shape (side scatter). Because monocyte-
derived cells often have a considerable amount of auto-fluorescence 
(granular aspects and lysosomes/vesicles) we used FACS instrument 
settings to correct for auto-fluorescence. As a positive control, we used 
beads with a standardized known fluorescence intensity (Spherotech, 
Libertyville, Illinois, USA) and expressed data as fluorescence 
intensities relative to the intensity of the beads (with excel-software 
by Spherotech). As a negative control, we determined the fluorescence 
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intensity of the negative control antibodies IgG1-FITC or IgG1-PE. For 
analysis of the data, we used CellQuestPro software (B&D Pharmingen, 
Alphen aan de Rijn, The Netherlands). Data are generally expressed 
as mean fluorescence intensity (MFI). Our measuring method and the 
development of monocytes to DC is illustrated in Figure 1. Here, we 
show the CD14/DC-SIGN profile of monocytes and monocyte-derived 
DC; monocytes are CD14 high and DC-SIGN low (Figure 1A), monocyte-
derived DC are CD14 low, DC-SIGN high (Figure 1B).
Table 2.  Characterization of the Phenotype of the Monocyte-derived DC via CD
 Marker Determination.
CD Marker Cell Specificity Functions/Remarks
Monocyte/DC Marker Molecules
CD14 monocytes Receptor for LPS
DC-SIGN dendritic cells DC-specific type II lectin: capturing carbohydrate-
bearing antigens
CD83 dendritic cells Cell surface glycoprotein, member of Ig superfamily, 
DC maturation marker
Antigen Presenting Molecules
HLA-DR APC MHC-class II molecule presenting peptide antigens
CD1a APC MHC-class I like molecule presenting lipid antigens
Co-stimulatory Molecules
CD80 APC Ligand for CD28 and CTLA-4
CD86 APC Ligand for CD28 and CTLA-4
CD40 APC Ligand for CD154
DC-/T-cell Adhesion Molecules/Integrins
CD11b No specificity Forms Mac-1 together with CD18, ligand for ICAM-1
CD18 No specificity Integrin β2 subunit associates with CD11a, b, c and d
CD29 No specificity Integrin β2 subunit associates with CD49 in VLA 
integrins
CD54 No specificity Intracellular adhesion molecule binds CD11a and Mac-1
Clusters of differentiation (CD) markers used in flow cytometric staining and their 
characteristics. 
DC, dendritic cell; LPS, lipopolysaccharide; APC, antigen presenting cell; MHC, major 
histocompatibility complex; Ig, immuneglobulin; CTLA, cytotoxic T-lymphocyte associated 
antigen; ICAM, intercellular adhesion molecule; VLA, very late antigen. 
Modified from Immunobiology, fifth edition, C.A. Janeway, et al.
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Mixed Lymphocyte Reaction
Autologous and allogeneic MLR were performed to measure the 
accessory capability of the DC. For these MLR, DC were irradiated 
with 20 Gy and placed in flat-bottom 96-wells-plates (NUNC, Roskilde, 
Denmark) in RPMI containing UG, P/S, and A+-serum. We added 100 µl DC 
suspension with concentrations of 3x105, 1.5x105, .75x105 cells/ml and 
an equal volume of autologous or allogeneic T cells (1.5x106 cells/ml) to 
the wells, resulting in a total volume of 200 µl/well. As positive control, 
T cells were stimulated with the T-cell mitogen phytohaemagglutinin (PHA, 
20 ng/ml, Sigma). As negative control, T cells were left unstimulated. 
Proliferation was determined after 16 hours of 3H-thymidine addition 
(.5 µCi/well) on day 5. Cells were harvested on filter papers, and 
radioactivity was counted in a liquid scintillation analyzer (Microbeta; 
Wallac, Turun, Finland). The values are the mean of triplicates.
Auto-antibody and sIL-2R Determinations
The levels of TPO-Abs, GAD65-Abs, and H+/K+-ATP-Abs have been 
measured in the same cohort and described previously1,2. The sIL-2R 
levels have also been measured previously3.
Statistical Analysis
Statistical analysis was performed with the SPSS 11.0 package for 
Windows (SPSS, Chicago, Illinois, USA). Data were tested for their 
parametric distribution with the Kolmogorov-Smirnov test. Because 
this test showed a nonparametric distribution for the investigated data, 
Figure 1. FACS Analysis of Monocytes and Dendritic Cells. 
Monocytes (A: relatively small and regular shape) and dendritic cells (B: relatively large with 
irregular shape) were gated out on the basis of forward (size, FSC) and side scatter (shape, 
SSC). The CD14 (PE) and DC-SIGN (FITC) expression of the gated population is presented 
as both percentages of positive/negative cells and histograms showing the fluorescence 
intensity. The gray lines represent the isotype/negative control (IgG-FITC/-PE),
the black lines represent the CD14 or DC-SIGN expression of the gated population (healthy 
control subject). Due to instrument settings (see text) relatively low fluorescence intensities 
are reached. As positive controls we used 8 graded peaks generated with commercially 
available beads with a predetermined/fixed fluorescence intensity. The values of minimum, 
medium and maximum peaks (peak 1,5,8) were with regard to FITC labeling 1, 20, and 
388, and with regard to PE labeling 1, 29, and 744 (data not included in the Figures), hence 
the marker expression on the cells were all within the positive control range.
Monocyte-derived DC in Bipolar Disorder
103
100100
101
101
102
102
103
103
104
104
100 101 102 103 104 100 101 102 103 104
6.5 %
81.2 %
0.2 %
12.1 %
DC-SIGN
C
D
14
100100
101
101
102
102
103
103
104
104
2.5 %
1.0 %
92.3 %
4.2 %
100 101 102 103 104 100 101 102 103 104
DC-SIGNgated
 monocytes
fluorescence
intensity
% cells
CD14
C
D
14
ev
en
ts
DC-SIGN
ev
en
ts
CD14
ev
en
ts
DC-SIGN
ev
en
ts
forward scatter
si
de
 s
ca
tte
r
forward scatter
si
de
 s
ca
tte
r
gated DC
fluorescence
intensity
% cells
A Monocyte population
B Dendritic Cell  population
Figure 1. FACS Analysis of Monocytes and Dendritic Cells. 
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including marker expression and MLR, we decided to use nonparametric 
tests to analyze differences between groups. To analyze FACS and MLR 
data, statistical significance between the various groups was determined 
with a Kruskal-Wallis test, followed by a Mann-Whitney U test to 
determine differences between two groups. To analyze the in vitro data 
of LiCl (series 2-4) we performed paired statistical analysis (0 vs. 1 mM, 
0 vs. 5 mM, and 0 vs. 10 mM LiCl) with the Wilcoxon signed-ranks test. 
Correlations of the various laboratory parameters with different clinical 
parameters were examined with Spearman’s rho test. All data were 
tested for two-tailed significance. P values below .05 were considered to 
be statistically significant.
Results
Treatment with Lithium stimulates the Generation of 
Fully Active Dendritic Cells from Monocytes of Bipolar 
Patients
We carried out four separate series of culture experiments over time 
(first: January-February 2002; second: April-May 2002; third: September-
December 2003; fourth: October-December 2004) to obtain monocyte-
derived DC. These series of cultures differed regarding the FCS badges 
and the supplier of the cytokines used (see previous). In each series, 
cells were obtained with a clear phenotype of monocyte-derived DC 
when starting from monocytes of healthy control subjects (see Table 3)
 (i.e., cells with a very low CD14 expression, a positive expression for the 
DC-specific markers DC-SIGN, CD1a and also CD83, a positive expression 
of the T-cell stimulatory molecules MHC-class-II, CD86, CD40 and CD80 
and a high expression of the integrins CD11b, CD18 and CD54). The 
range of expression levels of these various markers, however, clearly 
differed between the four series. This observation is congruent with our 
experience of a considerable inter-series variation in DC phenotype, 
depending on culture conditions, like FCS and cytokine-supplier (data 
not shown). Therefore, we decided to use a calculated normalizing factor 
to be able to compare data from the four series. We took the mean 
fluorescence intensity of a given marker obtained in the HC group of 
that series as 100% and calculated every single patient measurement 
relative to this 100% HC value. 
Table 3 shows the data of this analysis and gives the expression levels 
of the various membrane markers on monocyte-derived DC of nonLi-BD 
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Table 3. Phenotype of Monocyte-derived Dendritic Cell of Healthy Control 
 Subjects and Bipolar Patients with and without Lithium Treatment. 
                Healthy Control 
                Subjects (HC)
                         Bipolar Patients (BD)
nonLi-BD Li-BD
MFI ± SE Relative 
change versus 
HC (± SE)
vs. HC2 Relative 
change versus 
HC (± SE)
vs. HC2 vs. 
nonLi-
BD2
Monocyte/DC molecules
CD141 10.5 ± 9.3 123% ± 15 p<.05 63% ± 11 p<.05 p<.05
DC-SIGN 199.2 ± 111.7 76% ± 11 ns 111% ± 11 ns ns
CD83 39.62 ± 14.4 114% ± 19 ns 103% ± 17 ns ns
APC molecules
HLA-DR 286.4 ± 177.2 101% ± 20 ns 85% ± 7 ns ns
CD1a1 95.25 ± 58.94 83% ± 21 ns 200% ± 28 p<.05 p<.05
Co-stimulatory molecules
CD80 47.8 ± 19.3 98% ± 12 ns 106% ± 13 ns ns
CD86 155.0 ± 61.1 84% ± 13 ns 106% ± 11 ns ns
CD40 337.1 ± 129.4 92% ± 10 ns 112% ± 13 ns ns
Adhesion molecules/
Integrins
CD11b 735.9 ± 179.0 84% ± 12 ns 107% ± 9 ns ns
CD18 140.8 ± 50.2 92% ± 13 ns 103% ± 10 ns ns
CD29 38.26 ± 12.78 91% ± 15 ns 109% ± 11 ns ns
CD54 394.6 ± 99.9 93% ± 16 ns 120% ± 10 ns ns
1 statistical significant difference (p<.01) within the group with Kruskal-Wallis test 
2 represent statistical analysis between 2 groups with Mann-Whitney U test 
Mean Fluorescence Intensity (MFI) of the monocyte-derived dendritic cells of healthy 
control subjects for the different markers, expressed as medians of the 4 different series 
of experiments (First column). The negative control antibody reaches a MFI of 7.0 (median 
for FITC) and 13.5 (median for PE). The positive controls are the 8 graded peaks generated 
with commercially available beads with a predetermined/fixed fluorescence intensity (see 
Material and Methods and legend of Figure 1). The median values of the different markers, 
shown in the table are higher than the negative control value and all within the range of 
the positive control beads. Fluorescence intensities for the DC of bipolar patients (without 
lithium treatment [nonLi-BD] and with [Li-BD]) are expressed as percentages relative to 
the healthy control value (set as 100%) obtained in the same series of experiments (see 
also text).
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and Li-BD relative (in percentages) to the expression level of the marker 
found on HC DC of that series. 
With regard to the nonLi-BD, the expression levels of the various 
markers were practically identical to the monocyte-derived DC populations 
of HC, albeit the monocyte specific marker CD14 was slightly higher 
on nonLi-BD DC (see Table 3 and Figure 2a; giving a representative 
example). The presence of this residual monocyte molecule on nonLi-BD 
DC indicated to us that a full transition of monocytes into DC had most 
likely not completely taken place.
To determine the functional capacity of such not-fully developed DC of 
BD patients, we performed an MLR with 3H-thymidine incorporation into 
autologous and allogeneic T cells as a readout system to test the capacity 
of the DC, being excellent APC, to stimulate such T cells to proliferate. The 
autologous T-cell stimulation by APC is generally regarded as reflecting a 
T-cell reaction towards auto-antigens presented by the APC20,21, whereas 
the allogeneic T-cell stimulation represents the reaction towards foreign 
antigens (i.e., mismatched transplantation) on the APC. First of all, it 
should be noticed (and relevant for the outcomes of the autologous MLR) 
that the T cells of the BD patients and HC did not show the same intrinsic 
proliferation capacity when stimulated with the mitogen PHA (Figure 3). 
The T cells of nonLi-BD showed an intrinsically enhanced proliferation, 
whereas those of Li-BD had a proliferation capacity comparable to that 
of HC. Such an intrinsic activation of the T-cell system in BD patients has 
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Representative examples of the actual fluorescence intensity of CD14 (A) and CD1a (B) on 
monocyte-derived dendritic cells (DC). The thin black lines represent a healthy control 
sample (HC), the thick black lines represent a bipolar patient sample without lithium 
therapy (nonLi-BD), and the gray lines represent a bipolar patient sample with lithium 
therapy (Li-BD). 
Figure 2. Fluorescence Intensity of CD14 and CD1a on DC.
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been noticed by others and us previously3,22-24. With regard to the actual 
stimulation by DC, autologous T cells were less stimulated to proliferate by 
their DC in the nonLi-BD, despite the intrinsically higher T-cell proliferation 
capacity of such T cells (however, not statistically significantly different 
from HC). This tendency for a reduced stimulatory capacity of DC of 
nonLi-BD for autologous T cells is in accord with the mild differentiation 
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Autologous mixed lymphocyte reaction (MLR) of monocyte-derived dendritic cells (DC) 
of bipolar patients versus healthy control subjects (HC), representing the capacity of 
monocyte-derived DC to stimulate T cells to incorporate 3H-thymidine, given as counts 
per minute (cpm). Open circles represent T-cell stimulatory capacity of DC of HC, filled 
squares that of bipolar patients without lithium treatment (nonLi-BD), and open squares 
that of patients with lithium treatment (Li-BD). The figure shows T-cell proliferation 
without any stimulus or DC added (negative control sample), with the addition of only 
phytohaemagglutinin (PHA: positive control sample), T-cell proliferation with autologous 
DC, and with allogeneic DC. Data are expressed as mean values ± SEM and various ratios 
of DC versus T cells are shown. 
* p<.05 using Kruskal-Wallis test, # p<.05 of Li-BD versus nonLi-BD users using 
Mann-Whitney U test, ## p<.05 of Li-BD versus nonLi-BD and HC using Mann-Whitney U 
test.
Figure 3. Autologous MLR of Monocyte-derived DC.
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defect of DC noticed in the marker analysis previously mentioned (increased 
CD14). The T-cell stimulation capacity of the DC was much higher for 
allogeneic T cells, not disturbed, and equal to that of HC DC (Figure 3). 
When evaluating the expression level of the marker molecules on 
the monocyte-derived DC of Li-BD, it seemed that the expression 
level of the monocyte marker CD14 was now absent and that of the 
DC-specific marker CD1a significantly higher as compared with DC of HC 
and nonLi-BD (Table 3, Figure 2B). This indicated that there are signs of 
an enhanced differentiation of prototypic DC from monocytes in Li-BD. 
It must be noted, however, that the expression levels of HLA-DR, the 
tested co-stimulatory molecules, and integrins were the same as those 
of DC of HC and nonLi-BD. In accord with the view of an improved DC 
differentiation from monocytes of lithium-using BD patients, the DC of 
Li-BD also showed a statistically higher capability to stimulate autologous 
T cells as compared with the DC of nonLi-BD and HC. The allogeneic 
T-cell stimulation capacity of the monocyte-derived DC of Li-BD was, 
however, equal to that of nonLi-BD and HC (Figure 3).
It is also relevant to note that the DC yields harvested after culture for 
both BD groups (Li-BD: 7.2x105 ± 3.6x105, nonLi-BD: 7.4x105 ± 3.2x105) 
were comparable to yields in HC (9.1x105 ± 4.9x105) (p=.23).
Collectively our data indicate that the DC of nonLi-BD are mildly 
defective, leading to a relatively low autologous MLR (despite the higher 
intrinsic proliferative capability of T cells of nonLi-BD) and that, in lithium 
using patients, the DC are actually activated, leading to a stronger 
proliferation of their own T cells in an autologous MLR (overcoming the 
intrinsically lower T-cell stimulation of DC of Li-BD). 
Because we found effects of the use of lithium on DC development, 
we correlated the expression of CD14 and CD1a with the duration of 
lithium treatment. A significant negative correlation was found for CD14 
expression (r=-.43, p<.05), meaning that the longer patients were 
treated with lithium, the lower CD14 was expressed on the monocyte-
derived DC; CD1a expression was not correlated to the duration of 
lithium treatment (r=-.11). With regard to a possible effect of the other 
psychotropic medication on in vitro DC differentiation from monocytes, we 
were unable to find statistically significant associations (data not shown). 
We were also not able to find any statistically significant correlation 
between the differentiation of monocyte-derived DC and mood state 
(either between the four mood states or between symptomatic and 
euthymic BD patients), duration of illness (CD14: r=-.26, CD1a: 
r=.08), age (CD14: r=-.30, CD1a: r=.07), and gender (CD1a male: 
1.8 ± .32 versus female: 1.6 ± .34). This was the case both in the entire 
dataset and within the different subgroups. We also tested the possible 
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associations with the other phenotypic markers, but again without 
significant correlations (data not shown).
With regard to a possible correlation between the DC phenotype 
and other markers of immune activation in the patients, we were again 
unable to find a correlation with either sIL-2Rlevel (CD14: r=.15, CD1a: 
r=.04) or auto-antibodies against the thyroid (TPO-Abs) (CD14: 
r=.04, CD1a: r=.11). With regard to GAD65-Abs and H+/K+ ATPase-Abs, 
numbers in this sample of antibody-positive patients were too low to 
draw valid conclusions.
In Vitro Exposure to LiCl hampers the Generation of 
Fully Functional Dendritic Cells from Monocytes
On the basis of a limited dose-response study on the effects of various 
dosages of LiCl (.2 mM, 1.0 mM, 2.0 mM, 5.0 mM, 10.0 mM) on the in 
vitro generation of DC from monocytes of six HC, we decided to culture 
the monocytes of the BD patients and HC in 0, 1, 5, and 10 mM LiCl. The 
1 mM was chosen because it equals the therapeutic levels reached in 
serum; 5 and 10 mM were chosen because these concentrations showed 
clear effects in our limited dose-response study.
Lithium chloride did not affect the viability of the generated DC and 
after 6 days of culture, trypan blue staining showed a viability of >90% 
in all cases, including in the highest concentration of 10 mM LiCl; LiCl also 
did not affect the cell yield after culture. This observation excluded a toxic 
effect of LiCl on the cells, even in the high dose of 10 mM (data not shown).
Lithium chloride exposure in vitro led to a relatively diverse picture, 
regarding the up or down regulation of the various markers and functional 
molecules on the monocyte-derived DC related to the dose of LiCl used 
(Figure 4). Nevertheless, generalizations can be made; the low 1 mM 
dose of LiCl only had very limited effects, whereas the higher dosages of 
5 and 10 mM had clear effects. Such clear effects were, in particular: a 
dose-dependent down regulation of the DC-specific marker DC-SIGN and 
also of CD1a, and a slight up regulation of CD14 on the DC, indicating 
that the generation of prototypic DC from monocytes was hampered, 
owing to in vitro LiCl exposure. The antigen-presenting molecule HLA-DR 
and the co-stimulatory molecule CD86 were, however, up regulated on 
these LiCl-exposed monocyte-derived DC, whereas the co-stimulatory 
molecule CD40 was down regulated. This indicates a complex and 
different effect on molecules that are normally regulated in a coordinated 
fashion. Lithium chloride in vitro also affected the integrin expression on 
the monocyte-derived DC in a complex manner: CD54 and CD29 were up 
regulated, whereas CD11b and CD18 were in general down regulated.
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Figure 4. In Vitro Effect of Lithium Chloride on Monocyte-derived DC.
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With regard to the functionality of the monocyte-derived DC generated 
in the presence of LiCl, we used again the 3H-thymidine incorporation of 
T cells in an autologous MLR as a read-out system for the T-cell stimulatory 
capacity of the DC, but only with 1 and 10 mM LiCl. Figure 5 shows that 
monocyte-derived DC, cultured in the presence of 1 mM LiCl were not 
affected, but that 10 mM LiCl resulted in a reduced potency of monocyte-
derived DC to stimulate the proliferation of T cells. These findings are 
generally in accord with the marker profiles of the DC as described 
previously, showing a hampering of the generation of prototypic DC due 
to an in vitro exposure of lithium.
Figure 4. In Vitro Effect of Lithium Chloride on Monocyte-derived DC.
In vitro effect of lithium chloride (LiCl) on monocyte-derived dendritic cells of healthy 
controls (HC: white bars), bipolar patients without lithium (nonLi-BD: black bars) and 
with lithium treatment (Li-BD: gray bars) from series 2-4. Data are expressed as the mean 
fold change (compared to the 0 mM LiCl condition) ± SEM of the fluorescence intensity, 
corrected with pre-labeled beads (CFI). The phenotypic membrane markers are (in order of 
appearance): monocyte-DC markers (CD14, DC-sign, CD83), antigen presenting molecules 
(HLA-DR, CD1a), and co-stimulatory molecules (CD80, CD86, CD40), and integrins (CD11b, 
CD18, CD29, CD54). 
* p<.05 of the LiCl versus the non-LiCl condition using Wilcoxon signed-rank test
Li-BDHC non Li-BD
�
� �
�
�
�
1:40 1:20 1:10 1:51:40 1:20 1:10 1:51:40 1:20 1:10 1:5
0
20
40
60
DC : T cell ratio
T 
ce
ll 
pr
ol
ife
ra
tio
n 
x1
03
 c
pm
)
0 mM LiCl
1 mM LiCl
10 mM LiCl
The in vitro lithium chloride (LiCl)-induced effects on autologous mixed lymphocyte reaction 
(MLR) of monocyte-derived dendritic cells (DC) of bipolar patients and healthy control 
subjects (HC). MLR (see also Figure 3) represents the capacity of monocyte-derived DC 
to stimulate T cells after in vitro LiCl exposure measured by their proliferation in counts 
per minute (cpm). Circles represent condition without LiCl, squares represent condition 
with 1 mM LiCl, and triangles represent condition with 10 mM LiCl. Data are expressed as 
mean values ± SEM.
* p<.05 of the 10 mM versus the 0 mM LiCl condition using Wilcoxon signed-rank test
Figure 5. In Vitro Effect of LiCl on Autologous MLR.
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Discussion
Reported signs of an aroused immune system in BD patients comprise 
a rise in serum levels of acute phase proteins9,25, a higher prevalence of 
thyroid, gastric, and islet antibodies1,2, an enhanced activity and level 
of B cells3, an activated T-cell system3,23,24, and an altered cytokine 
production22,26,27. There are, however, also reports that refute such 
activation28-30. It is also not clear whether the immune aberrancies are 
linked to the mood state of the patients, genetically determined, or due 
to environmentally determined influences such as the use of lithium, 
which is known to be an immune modulating drug.
We report here that DC cultured from monocytes of nonLi-BD show 
a mild hampering in the differentiation into fully active DC: the cells 
showed an increased residual expression of the monocyte marker CD14 
after one week culture in GM-CSF and IL-4 and had a relatively low 
capability to stimulate T cells in autologous MLR. 
Lithium treatment of BD resulted in a complete restoration of this 
mildly hampered in vitro differentiation defect and, in fact, the treatment 
activated monocyte-derived DC: the cells possessed an enhanced 
capability to stimulate autologous T cells, had an up regulated expression 
of the DC-specific marker CD1a, and completely lost the weak residual 
expression of the monocyte marker CD14, the loss of which was correlated 
with the duration of lithium treatment.
With regard to the validity of our data, it must be noted that monocyte 
function is sensitive to age and gender31 and these variables might, 
indeed, have affected the DC generation from monocytes. We tested 
for these variables, however, and were neither able to find male-female 
differences nor associations between age and the different characteristics 
of monocyte-derived DC. A clear limitation of our study is its naturalistic 
set up and, hence, the majority of patients used various psychiatric 
medications (Table 1). Although we found lithium to be a prominent 
determinant in the DC generation, we could not find an effect of the other 
medications in this sample. Literature suggests a potential immune-
modulating role for such other non-lithium medications32; however, the 
variability of these medications in our patient group was enormous, 
and numbers of patients per therapeutic group small. This might have 
influenced power to detect correlations. 
Can we relate the findings on a mild DC differentiation defect in 
nonLi-BD reported here to the previously reported tendency of the 
patients to develop islet, thyroid, and gastric autoimmunity?
Similar mild differentiation defects (i.e., a 20-30% reduced CD1a 
expression and a 50-70% reduced T-cell stimulatory capacity) have been 
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found in patients with recent onset type I diabetes and their first-degree 
relatives33. It is also known, from studies in animal models of type I 
diabetes and thyroiditis (i.e., studies in the NOD mouse34 and in the 
BB-DP rat35), that mild inborn defects in the differentiation and function 
of DC lead to autoimmune reactivity. Restoration of such defective DC 
function leads to a prevention of autoimmune disease36. This has been 
taken as evidence that an optimal function of DC is not only required for 
an appropriate defense against foreign invaders but also for an avoidance 
of autoreactivity by an appropriate stimulation of T-regulatory cells35. 
Lithium treatment did restore the mildly defective DC differentiation and 
autologous T-cell stimulation in BD patients. Hence, it might be worthwhile 
to study the autoimmune preventive aspects of lithium treatment.
One can only speculate whether the here-reported data on monocyte-
derived DC are of relevance for the psychiatric phenotype. There exists a 
theory that the macrophage system is intrinsically activated in patients 
with mood disorders. The corner stone of this theory is the assumption 
of an intrinsically enhanced production of pro-inflammatory cytokines 
by activated macrophages in these patients and that such enhanced 
production is thought to lead to a “sickness behavior”, reminiscent of 
many mood symptoms known of depressed patients37. It might be that the 
here-described mild defect in the differentiation of DC from monocytes of 
nonLi-BD is due to a preferential tendency of the monocytes to develop 
into active macrophage-like cells. A similar imbalance, a defective DC 
development in favor of the macrophages, has been found in the NOD 
mouse model for autoimmune thyroiditis and insulitis38. Interestingly, 
NOD mice also show behavioral and hormonal abnormalities, such as 
a high locomotor activity in open field tests and an intrinsically high 
corticosterone response to repeated constraint stress, which have been 
taken as evidence for an altered emotional behavior of the mice39,40.
With regard to the previously posed question of whether the here-
described DC aberrancies might be of relevance for the psychiatric 
phenotype, it is also worth noting that DC and brain microglia are 
strongly related41,42. It has been reported that parenchymal microglia 
are noncommitted myeloid progenitors and that the cells can be skewed 
towards a DC-like profile in response to the lineage growth factor GM-
CSF43-45. Are the defective differentiation profiles of DC from circulating 
monocytes found here perhaps reflected in an abnormal differentiation 
and function of microglia in bipolar brains? There is little information on 
microglia/DC/macrophages in postmortem brains of BD patients. Bayer et 
al46 reported on an activation of frontal cortex and hippocampal microglia 
in one of six patients with mood disorders, yet Hamidi et al47 were not 
able to confirm this observation and found a reduction in glial cells 
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(particularly of oligodendrocytes) in amygdala of BD patients not treated 
with lithium. Further research is indicated to study a possible relationship 
between monocyte-derived DC and microglia in BD patients.
We not only report here on the in vivo effects, but also on the in 
vitro effects of lithium on the differentiation of DC from monocytes. To 
our surprise, we found suppressive effects on DC generation of in vitro 
exposure to lithium, in contrast to the previously described stimulating 
effects on DC generation of lithium therapy in vivo. Lithium chloride 
(10 mM) in vitro clearly reduced the capacity of monocytes to differentiate 
into DC with a high potency to stimulate autologous T cells. It also resulted 
in a reduced differentiation of DC with a high expression of characteristic 
markers: the generated cells expressed lower levels of DC-SIGN and 
CD1a and higher levels of the residual monocyte marker CD14. This 
in vitro suppressive effect of lithium on DC differentiation can perhaps 
be explained by the previously found predominant production of Th2 
cytokines (like IL-10 and IL-4) by cultured monocytes and lymphocytes 
when exposed to lithium during culture48.
To our knowledge, there is only one report that –like we do- also 
compares the in vivo treatment effects with the in vitro effects of lithium 
on the function of immune cells in the same study49. Discrepant results 
were found in that report also: whereas lithium in vitro lacked any effects 
on the number of cytokine secreting cells, lithium treatment of patients 
reduced such numbers. These and our results might be explained by 
the difference in concentration and duration of lithium to which the 
immune cells are exposed in the in vivo and in vitro situation. The in 
vivo stimulatory effects found here are perhaps due to the fact that the 
leukocytes are exposed much longer to lithium in treatment conditions 
(months to years) than in the artificial in vitro situation (days). With 
regard to differences in concentration, it must be noted that we only 
clearly detected in vitro effects of LiCl with a 10 mM concentration; when 
we used in vitro 1 mM LiCl (high therapeutic serum level), only minimal 
effects on DC differentiation were found, although indirect effects of 
lithium might also play a role. Whereas the only variable in vitro was 
the exposure to lithium, in vivo lithium treatment must have had all 
sorts of effects on neuronal and other systems that, in turn, might have 
influenced the immune cells and their generation.
In conclusion, we found a mildly impaired differentiation of monocytes 
into fully active DC in BD patients. Lithium treatment resulted in a 
complete restoration of the impaired DC differentiation, and activated 
DC were obtained. In contrast, lithium in vitro had a suppressive effect 
on the generation of prototypic and fully active DC from monocytes.
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Abstract
Background
A relative resistance of immune cells to steroids has been established 
in patients with major depression. In this study we investigated the in 
vitro responsiveness of T cells to dexamethasone (DEX) of patients with 
bipolar disorder.
Methods
T cells of outpatients with DSM-IV bipolar disorder (BD: n=54) 
and of healthy control subjects (HC: n=29) were isolated, cultured, 
and stimulated with phytohaemagglutinin (PHA) for 72 hours. The 
suppressive effect of graded concentrations of DEX (5x10-9-10-5M) on 
PHA-induced CD25 (IL-2R) expression was measured by fluorescence-
activated cell sorting (FACS) analysis. Data were correlated to the T-cell 
activation status in the peripheral blood of the same patients and to their 
diagnosis, current mood state, ultradian cycling pattern, and current use 
of medication, including lithium.
Results
T cells of patients with BD were less sensitive to DEX induced 
suppressive effects as compared with T cells of HC. These data were 
particularly evident at 10-7M DEX (mean % suppression ± SEM BD: 
18.9% ± 3.5 versus HC: 35.8% ± 4.7, p=.001). We found no correlations 
of this relative in vitro DEX resistance of T cells neither with the previously 
mentioned clinical characteristics nor with the actual activation status of 
the T cells in the BD patients.
Conclusion
A relative T-cell resistance to steroids, as has been observed in major 
depression previously, may be a trait phenomenon of BD, independent 
of mood state.
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Introduction
Bipolar disorder (BD) is a severe and chronic mood disorder with 
a complex and an unraveled pathophysiology1. Several studies have 
reported on an activated immune system in BD (i.e., an activated T-cell 
system)2-4, raised numbers of B-cells2, an activated monocyte/macrophage 
system5-11, increased serum levels of acute phase proteins12,13, and a 
higher prevalence of thyroid, gastric, and islet auto-antibodies14-17. The 
outcomes of these studies have led to the hypothesis that immune 
activation forms part of the etiopathogenetic mechanism leading to BD. 
In addition, an activation of the immune system has been found in major 
depression (MD), another severe mood disorder with also depressive 
episodes but, unlike BD, without (hypo-)manic episodes18-20. However, it 
must be noted that not all reports describe an immune activation in BD 
and MD21-24.
Apart from an activated immune system, there is also clear evidence 
for a disturbed activity of the hypothalamus-pituitary-adrenal (HPA)-axis, 
both in BD25-27 and in MD28-30. First, cortisol levels are increased in both 
disorders28,30,31, which interestingly is not accompanied by obvious signs 
of Cushing’s Syndrome32. Second, the dexamethasone (DEX) suppression 
test29 and the DEX/corticotrophin releasing hormone (CRH) test27,33 are 
disturbed, indicating a relative steroid resistance. These findings led to 
the hypothesis that an impaired glucocorticoid (GC) receptor signaling 
may be one of the key factors in the pathogenesis of mood disorders34. 
It must, however, be noted that in other psychiatric conditions such as 
schizophrenia, this phenomenon of GC resistance is also present, yet 
less pronounced35.
Glucocorticoids (GCs) not only play an important role in the stress 
response36, but are also known for their inhibitory effects on the immune 
system37-39. Hence, it is a short step to the hypothesis that a relative 
steroid resistance is responsible for the immune activation in patients 
with mood disorders. The first publication showing an in vitro steroid 
resistance of immune cells in mood disorders was of Lowy et al40. 
These authors established that immune cells of nonsuppressors in the 
DEX-suppression test were also resistant to DEX in a mitogen-induced 
lymphocyte proliferation assay. Bauer et al41 confirmed these data later 
specifically for the MD group. Patients with MD also showed less effect 
of orally administered DEX compared to HC on peripheral immune cell 
redistribution, suggesting an in vivo resistance to at least some effects 
of steroids42. In accordance with the view that steroid resistance is linked 
to immune activation, plasma cortisol and soluble serum interleukin-2 
receptor (sIL-2R), a T-cell activation marker, were positively correlated 
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to each other in patients with MD43. Steroid resistance has also been 
found on the level of lymphocytes and macrophages in a mouse model 
for mood disorders44. Taken together, these findings point to a relative 
steroid resistance of immune cells in MD. However, such data are lacking 
for immune cells in BD.
We therefore decided to investigate to what extent T cells of patients 
with BD are sensitive to GCs. The phytohaemagglutinin (PHA) activated 
T-cell assay was used as a read-out system. T cells are easy to access and 
possess GR45,46 resulting in an exquisite sensitivity of the cells to GC both 
in vivo and in vitro47. The PHA-activated T-cell assay is therefore a well-
established model system to test for steroid resistance48. We measured 
as a sign of T-cell activation the PHA induced increase of CD25 (i.e., the 
IL-2R) on T cells. IL-2 is the growth factor for T cells and both IL-2 and its 
receptor are up regulated on activated T cells. We investigated whether 
the suppressive effect of graded concentrations of DEX on PHA-induced 
CD25 expression differed between T cells of bipolar patients (BD, n=54) 
and those of healthy control subjects (HC, n=29). We also questioned 
whether these in vitro DEX response data could be correlated to our 
previously described activated T-cell status in the peripheral blood of the 
same patients2 and to their clinical characteristics.
Materials and Methods
Patients and Healthy Control Subjects
Patients: Heparinized blood was obtained from outpatients with 
DSM-IV bipolar I and II disorder (n=54) participating in the Stanley 
Foundation Bipolar Network (SFBN), a multi-center research program 
described elsewhere in detail49,50. All patients were recruited from the 
SFBN-site in The Netherlands for the here-described experiments. The 
Institutional Review Board of the University Medical Center Utrecht had 
approved the study protocol and written informed consent was obtained 
from all patients.
A DSM-IV51 diagnosis of BD was made by means of the Structured 
Clinical Interview for DSM-IV Axis I (SCID)52. A detailed illness history, 
including past and present medication, was assessed at entry into the 
Network. Blood for the present study was drawn during one of the 
monthly follow-up visits, when a research clinician also assessed the 
current mood state (i.e., euthymic, depressed, (hypo)manic, or ultradian 
cycling) during the past week. This overall assessment of mood was 
based on a detailed interview49, including the Young Mania Rating Scale53, 
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the Inventory of Depressive Symptoms54, the Global Clinical Impressions 
Scale – Bipolar Version55, and the Life Chart Methodology56. 
Euthymia was defined as the absence of mood symptoms or functional 
impairment caused by mood symptoms for at least one week as indicated 
by an YMRS score of <8 and an IDS score of <14. The longitudinal 
Table 1. Clinical and Demographic Characteristics.  
Bipolar 
Patients
Healthy Control 
Subjects
Group size 54 29
Age (years)1 Male 32 (59.3%) 18  (62.1%)
Female 22 (40.7%) 11  (37.9%)
Gender 45 (21-60) 39  (22-54)
Duration of illness (years)1   22.2   (2-42)
Duration of treatment (years)1   14.8   (1-36)
Psychotropic medication Carbamazepin 10 (18.5%)
Valproate 20 (37.0%)
Thyrax 14 (25.9%)
Antidepressives 13 (24.1%)
Antipsychotics   7 (13.0%)
Benzodiazepins 15 (27.8%)
Lithium 49 (90.7%)
Li titer in serum (mM)2  .77 ± .03
Cumulative period of Li treatment (months)1 75 (6-292)
No current Lithium   5 (9.3%)
                     Period without Li (months)1   44.6  (6-118)
Current mood state Euthymic 29 (53.7%)
Depressed 15 (27.8%)
Manic   9 (16.7%)
Cycling   1  (1.9%)
Diagnosis (DSM-IV) Bipolar I disorder 39 (72.2%)
Bipolar II disorder 15 (27.8%)
Rapid cyclers (>4 episodes/year) 16 (29.6%)
1 mean (range)
2 mean ± SD
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methodology of the SFBN with daily self-ratings of mood and monthly 
follow-ups of each patient, allows a reliable association of the immune-
parameter-outcomes with mood states and illness course. During the 
visit when the blood was drawn, patients had no serious medical somatic 
illness or fever. Clinical characteristics of the patients are shown in Table 1.
Blood was drawn in sodium-heparin tubes (Becton and Dickinson, 
Franklin Lakes, New Jersey, USA) in the morning and transported by 
courier to the laboratory in Rotterdam, lasting an acceptable maximum 
of 8-10 hours before further processing.
Healthy Control Subjects: Blood collections were obtained from 
healthy laboratory and hospital staff members of the Erasmus MC 
(The Netherlands; n=29) on the same days as those of the patients, with 
the same procedures. All HC gave written information about medication 
use and medical history. Informed consent was obtained. The exclusion 
criteria for this HC group were: any immune disorder, serious medical 
illness, recent infections, fever, any life-time major psychiatric disorder 
(including psychosis, mood disorders, anxiety disorders, or substance 
abuse disorders) or usage of any psychotropic or other medication (apart 
from anti-conceptive hormonal therapy). 
T-cell Cultures
Peripheral blood mononuclear cells (PBMC) (i.e., the lymphocytes 
and monocytes) were prepared from the heparinized blood via Ficoll 
(Pharmacia, Uppsala, Sweden density 1.077 g/ml) gradient centrifugation. 
First, PBS (Bio Whittaker Europe, Verviers, Belgium) containing .1% BSA 
(Bayer, Kankakee, USA) (PBS/.1% BSA) was added to the heparinized 
blood sample in a dilution of 1:1. These diluted cells were distributed 
on the Ficoll gradient and centrifuged for 15 min at 1000 g. After 
centrifugation the PBMC were collected from the interface and washed 
with PBS/.1% BSA (centrifugation for 10 min at 760g). 
Peripheral blood mononuclear cells were thereafter re-suspended 
in RPMI 1640 with 25 mM Hepes and L-glutamine (medium liquid, 
named after Roswell Park Memorial Institute, Bio Whittaker Europe, 
Verviers, Belgium), additionally containing 10% inactive fetal calf serum 
(Bio Whittaker Europe, Verviers, Belgium; FCSi), penicillin (100 U/
ml)/streptomycin (100 µg/ml; Bio Whittaker Europe, Verviers, Belgium; 
P/S), and extra ultraglutamine (2 mM; Bio Whittaker Europe, Verviers, 
Belgium; UG) (RPMI+). Samples were frozen in 10% dimethylsulfoxide 
and stored in liquid nitrogen. This enabled us to test T cells of BD and HC 
in the same series of experiments at appropriate times.
The frozen and stored PBMC suspension was quickly thawed and 
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washed twice in RPMI+. Viability of the population was at least 85%, 
using trypan blue staining. Cells were thereafter incubated with anti-CD3 
microbeads (20 µl/107 cells; Miltenyi Biotec, Bergisch Gladbach, Germany) 
for 20 minutes at 4°C (according to the manufacturer’s protocols) and a 
magnetic cell sorting system (autoMACS; Miltenyi Biotec) was used for 
the selection of CD3-positive T cells.
The CD3-positive T-cell preparations were washed with PBS/0.1% BSA 
and contained at least 85% viable cells, measured by trypan blue staining. 
T cells were resuspended in RPMI+ (1.5x106 cells/ml), supplemented 
with A+ serum (Bloodbank, The Hague, The Netherlands) and distributed 
over a 96-wells-plate (NUNC, Roskilde, Denmark) with or without PHA 
(final concentration; 100 µg/ml), a polyclonal mitogen-stimulating 
T-cell proliferation in vitro. To assess in vitro steroid sensitivity, graded 
concentrations of DEX (final concentrations; 5x10-9-10-5M; 9α-fluoro-
16α-methylprednisolone; SIGMA) were added to the mitogen-driven 
lymphocyte cultures. Each well ended with an equal volume of 200 µl 
and was incubated for three days (72h) at 37°C, 5% CO2, and 95% 
humidity.
Fluorescence-activated Cell Sorting Analysis of T cells
Lymphocyte populations were incubated for 10 minutes in the dark 
at room temperature with mouse anti-human fluorescein (fluorescein 
isothiocyanate, FITC)- or phycoerythrin (PE)-conjugated monoclonal 
antibodies (mAbs; Becton Dickinson (B&D), San Jose, CA, USA), and 
washed afterwards. The following mAbs were used: anti-IgG1 FITC, 
anti-IgG1 PE (both used as isotype control), anti-CD25 FITC (i.e., IL-2R 
α−chain, a marker for activated T cells), and anti-CD3 PE (i.e., a molecule 
associated with T-cell antigen receptor, a general T-cell marker).
Immediately after staining, cells were subjected to fluorescence-
activated cell sorting FACS) on a FACS calibur (B&D). The researcher 
was blind for the identity (BD/HC) of the sample during the FACS 
measurement and analysis of the data. Debris and dead cells were gated 
out in the samples on the basis of their light scatter properties. We 
used FACS instrument settings to correct for auto-fluorescence and as 
a negative control we determined the fluorescence intensity IgG1-FITC 
or IgG1-PE, correcting for possible aspecific binding of these mAbs. The 
T-cell population was gated out by means of CD3 expression. For analysis 
of the T-cell activation we used CellQuestPro software (B&D Pharmingen, 
Alphen aan de  Rijn, The Netherlands). We expressed the CD25 expression 
level of the CD3-positive T cells as percentages of cells staining positive 
for this marker or as mean fluorescence intensity (MFI) (for analysis 
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which are stained with the isotype control IgG FITC/PE (a) or with CD25/CD3 (b) versus 
T cells cultured with PHA, which are stained with CD25/CD3 (c). The CD25 expression of 
the gated population is presented as both percentages of CD3/CD25 double positive cells 
(respectively .1% in Figure a, 6.2% in b, 84.4% in c) and histograms showing the mean 
fluorescence intensity (MFI) of the CD25 expression of the CD3-positive lymphocytes. For 
statistical analyses we used the MFI corrected for the aspecific binding of the corresponding 
isotype control (i.e., IgG FITC; gray histogram), which gives the following values: 5.7 
(9.6 - 3.9) in the T-cell culture without PHA (b) and 299.5 (303.4 - 3.9) in the T-cell culture 
with PHA (c).
Figure 1. Fluorescence-activated Cell Sorting (FACS) Analysis of T cells.
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methods see Figure 1). In the case of DEX-suppression we used the 
MFI and expressed the DEX-induced effects in each assay relative to the 
condition without DEX. Thus, these data are expressed as “% suppression”.
sIL-2R Determinations and T-cell Activation of Freshly 
Isolated Lymphocytes
The serum soluble IL-2 receptor levels (sIL-2R) and the number of 
circulating activated T cells (CD25-expressing CD3+ T cells) in the periphery 
have been measured in the same cohort and described previously2.
Statistical Analysis
Statistical analysis was performed with the SPSS 11.0 package for 
Windows (SPSS, Chicago, Illinois, USA). Data were tested for their 
parametric distribution with the Kolmogorov-Smirnov test. Because the 
majority of data showed a non-parametric distribution, we decided to 
use non-parametric tests. Statistical significance between groups was 
determined by a Mann-Whitney U test; if there were more than two groups, 
preceded by a Kruskal-Wallis test. To analyze the DEX-induced effects in 
the samples, we performed paired statistical analysis (e.g. no DEX versus 
10-6M DEX) with the Wilcoxon signed-rank test. Correlation coefficients of 
the T-cell activation with different clinical parameters were determined by 
the method of Spearman. All data were tested for two-tailed significance. 
P<.05 were considered to be statistically significant.
Results
CD25 Expression on Cultured T cells 
We previously reported on an increased level of serum sIL-2R and on 
a slightly higher percentage of activated (i.e., CD25-expressing) T cells 
in the circulating lymphocyte fraction of patients with BD as compared 
with those values in HC2. In this sample we were able to confirm these 
data, both with respect to the serum sIL-2R concentrations (mean ± 
SEM BD: 512.6 IU/ml ± 25.7 versus HC: 365.7 IU/ml ± 18.7, p<.001) 
and with respect to the percentage of CD25-expressing CD3+ T cells 
(BD (no. available = 44): 1.5% ± .1% versus HC (no. available = 25): 
1.1% ± .1%, p<.001).
After a 72-hours in vitro culture of the T-cell population, even in the 
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absence of PHA, T cells became slightly activated and percentages of 
CD25-expressing T cells rose to 3.5% ± 2.5% for HC and to 4.2% ± 3.3% 
for BD in these non-PHA cultured samples (difference not statistically 
significant; ns). This observation also means that culturing of the T cells 
for 3 days led to the disappearance of the ex vivo difference between 
T cells of bipolar patients (“activated”) in comparison to T cells of healthy 
controls. 
PHA addition to the in vitro T-cell cultures resulted in a significant 
increase of CD25 expression on the T cells in all cases. Percentages 
of CD25-expressing T cells rose further to 56.6% ± 18.1% for HC and 
to 51.2% ± 19.3% for BD (ns). When data were expressed as mean 
fluorescence intensities (MFI), the rise of CD25 on T cells due to PHA 
stimulation was also clear, yet again without statistical significant 
differences between HC and BD (Table 2). We concluded from this set of 
experiments that the potential of T cells of BD patients to be activated 
by PHA was comparable to that of T cells of HC.
It is of note that the in vitro PHA-induced CD25 expression on T cells 
of BD patients correlated neither to the sIL-2R level in serum (r=-.109) 
nor to the CD25 expression on CD3+ circulating T cells in freshly isolated 
blood (r=.033). We were also unable to find any difference with regard 
to the CD25 expression on in vitro-cultured T cells between various sub-
groups of BD patients. In particular, there was no effect detectable of 
a specific mood state, neither comparing the 4 different mood states 
nor comparing euthymic versus symptomatic patients (Table 2, first and 
second column). Clinical parameters such as duration of illness (r=-.115, 
p=.408) or duration of lithium treatment (r=.088, p=.554) also did not 
correlate with the CD25 expression on cultured T cells. The demographic 
parameters age (r=-.029, p=.798) and gender (mean ± SEM male: 
328.6 ± 28.3 versus female: 349.4 ± 27.8) did not have any effect on 
the outcome either, which was also the case in the HC group.
Effects of Dexamethasone Addition to Cultured T cells 
on CD25 Expression
Dexamethasone dose-dependently suppressed CD25 up regulation 
induced by PHA (Figure 2). The kinetics of the DEX induced immune 
suppressive effects (i.e., the shape of the curve and the maximum 
effect) were comparable to earlier studies using T cells of healthy control 
subjects to record effects of DEX48. 
In the BD group DEX induced less-pronounced suppressive effects 
as compared with the HC group (Figure 2). This resulted in a statistical 
significant smaller suppressive effect of DEX in the lower concentration 
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range (5x10-9 through 1x10-7M, with the exception of the 1x10-8M 
concentration, reaching marginal significance of p=.07) in the BD group 
as compared with HC, indicating a relative resistance of T cells of BD 
patients to the immune suppressive effects of DEX.
We checked for possible associations between the relative DEX 
resistance of T cells of BD patients and various clinical parameters. We 
focused on the effects of 10-7M DEX, because this is the DEX concentration 
with the clearest and most significant difference between the BD and the 
HC group (Figure 2). As shown in Table 2 none of the sub-groups of 
patients differed significantly in DEX responsiveness. With regard to age 
(r=-.048, p=.668), duration of illness (r=-.123, p=.374), or duration 
of lithium treatment (r=.033, p=.822) associations could not be found. 
The DEX induced effects on male (23.0 ± 4.1) and female samples 
(26.7 ± 4.2) were comparable. The same is true for the other DEX 
concentrations (data not shown). We also could not find any association 
between the percentage suppression at 10-7M by DEX and the serum sIL-
Dexamethasone (DEX) suppression test using T cells after 72 hours of culture with 
phytohaemagglutinin (PHA) and graded concentrations of DEX. Data are expressed as “% 
suppression”, which means that the DEX-induced effects on CD25 expression in each assay 
are expressed relative to the CD25 expression in the condition without DEX. Open squares 
represent the healthy control samples (HC), the open circles represent that of the bipolar 
patients (BD), and data are expressed as mean ± standard error of mean (SEM). 
* p<.01 Mann-Whitney U test
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Figure 2. Dexamethasone Suppression Test with a PHA Activated T-cell Assay.
Chapter 5.1
134
2R level (r=-.226) in the patients or between this suppression and the 
CD25 expression on the circulating CD3+ T cells in freshly isolated blood 
of the same samples (r=-.133). 
Discussion
In this study we found – with an in vitro assay – that T cells of patients 
with BD are less sensitive to DEX induced suppressive effects as compared 
to T cells of HC. This DEX resistance of T cells of BD patients was only 
noted at the relative low in vitro concentration range of 5x10-9M to 
10-7M DEX, which indicates that T cells of BD patients are characterized 
by a relative, but not an absolute, DEX resistance, which disappears 
when high concentrations of DEX are used. It is of note that the relatively 
low concentrations of 5x10-9M to 10-7M DEX are more physiologically 
relevant57. Previously, Modell et al58 reported a shift of the DEX dose-
response curve in depressed patients similar to the shift found by us, 
be it that these investigators studied DEX resistance in vivo comparing 
depressed patients with healthy control subjects in the DEX/CRH test 
using different DEX dosages (.75, 1.5, 3.0 mg). 
In this study we also found that the relative resistance of T cells 
in BD patients was independent of the current mood state and several 
other clinical parameters, such as ultradian cycling pattern or duration of 
illness, suggesting that the DEX resistance may be a trait rather than a 
state phenomenon. This in vitro finding is also in line with earlier in vivo 
studies concerning a state-independency of a GC resistance of the HPA-
axis in BD patients27. 
With regard to possible confounding factors, like age and gender, 
we did not find associations with the outcomes of the relative DEX 
resistance of the T cells. This is in accord with previous findings on a 
lack of association between age or gender and steroid resistance31,59-61. 
Despite this, various other confounding factors and limitations have to 
be taken into account regarding our current study.
First, the naturalistic set-up of this study caused a considerable 
diversity of currently used psychotropic medication, and groups of 
separate specified treatments were too small to evaluate their effects on 
the relative DEX resistance of the T cells. Despite this, we did analyze 
the possible effects of lithium treatment on the DEX resistance of 
T cells of bipolar patients, because this drug is in particular known for 
its immune modulating effect62,63. There are data on the in vivo effects 
of lithium treatment on the deregulation of the HPA-axis. Two studies 
found that lithium treatment resulted in a normalization of the abnormal 
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DEX responsiveness of patients with a mood disorder41,64. It must be 
noted, however, that one of these authors61 reported in an earlier 
study that sufficient lithium prophylaxis did not automatically prevent 
the deregulation of the HPA axis. Bschor et al65 even reported that the 
overstimulation of the HPA axis in depressed patients worsened after 
lithium augmentation independent from the clinical responsiveness of 
lithium. Taken together the clinical in vivo studies are thus not consistent 
on either a positive or negative effect of lithium treatment on the 
deregulation of the HPA axis and it must be noted that the greater part 
of these surveys do not study single treatment effects, which makes 
it hard to draw firm conclusions. In the here-reported study, we were 
unable to find an effect of lithium treatment on the DEX responsiveness 
of T cells, but –as is stated before- the sub-group of non-lithium treated 
BD patients is too small (n=5) to reach a definite conclusion and more 
than one medication was used in the patients. We also did not study 
effects of lithium medication on DEX responsiveness of T cells in healthy 
control subjects, further highlighting the notion that our findings on a 
lack of effect of lithium on the DEX responsiveness of T cells should be 
taken with caution. 
A second important limitation of our study is that plasma cortisol levels 
of the tested subjects were not available, nor did we perform DEX/CRH-
tests. Consequently, associations between in vivo and in vitro effects of 
DEX could not be calculated. Some previous studies indicated a positive 
correlation between in vivo and in vitro DEX effects57,60, whereas others 
disputed such a link66,67. 
Previous reports on DEX induced effects on immune parameters in 
mood disorders solely focused on MD and/or therapy resistant depressed 
patients. The majority of these studies, which dealt with the in vitro 
effects of DEX, used mitogen (PHA)-induced lymphocyte proliferation 
assays. Already in 1988, DEX has been shown to decrease the 
proliferation of lymphocytes also in psychiatric patients, but with a relative 
resistance to DEX in the MD group when relatively low concentrations 
of the compound were used57. Later studies found comparable effects, 
both in MD patients41,68 and in healthy subjects suffering from chronic 
stress69. None of the studies used CD25 expression as their readout 
system. One study checked the production of IL-2 in the supernatant 
of the lymphocyte cultures, which is the ligand for CD25. In accord 
with the previous studies DEX decreased the IL-2 production, but less 
pronounced in patients with MD compared to HC, again suggesting 
relative steroid resistance41. Regarding the in vivo effects of DEX on the 
immune system after administering the drug orally, DEX decreased the 
lymphocyte number and changed the expression of adhesion molecules 
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more prominently in healthy control subjects as compared with MD 
patients42,66. Taken together, there is thus ample evidence that immune 
cells of major depressed patients are relatively resistant to DEX. Our 
data show that T cells of patients with BD share this resistance with the 
immune cells of patients with MD.
What can be the mechanism underlying this relative DEX resistance 
in MD and BD? First, polymorphisms of the glucocorticoid receptor (GR) 
gene are able to cause a relative GC resistance. Several GR gene variants 
and single nucleotide polymorphisms (SNPs) have been coupled to GC 
responsiveness in the general population70,71 but also specifically to patients 
with cortisol resistance72. Suggestive genetic associations related to the 
GR have been postulated in patients with mood disorders73,74. However, 
mutations in or polymorphisms of the glucocorticoid receptor alpha and 
beta isoforms could not be detected in PBMC of BD patients75. 
Second, stressful events or exogenous administration of DEX during 
fetal and early life are able to influence the structure and physiology 
of the brain and the stress axis in animal models76,77 resulting in an 
altered set point of the adult HPA axis and an altered GR expression on 
adult cells. With regard to lymphocytes of MD patients, a decrease of the 
number of receptors was positively correlated with the inhibitory effect 
on mitogen-induced lymphocyte proliferation78. More is known about 
the GR and MR density in various brain areas of patients with mood 
disorders. Although a review states that there is only little evidence that 
such density is decreased in patients with MD79, more recent papers did 
show a decrease in the receptor expression for both BD and MD59,80,81.
Perturbations in the pro-inflammatory cytokine milieu, might also be 
involved in the relative resistance of bipolar T cells to DEX. Cytokines, 
such as interleukin-1β (IL-1β), IL-6, and TNFα sort their effects via various 
intracellular routes, which counteract the transcriptional pathways 
or antagonize the immune suppressive effects of GCs upon immune 
cells82-84. Because Moutsatsou et al75 were unable to find GR mutations/
polymorphisms in PBMC of BD patients, these authors (and others) 
suggested that the altered responsiveness of immune cells to GCs are 
caused by, for example, the raised level of pro-inflammatory cytokines 
in mood disorders20. 
Taken together, it thus remains unclear from these literature data 
whether the alterations in the GC system of bipolar patients (also found 
here) are simply a result of a “chronic stress environment” or are closely 
related to inborn neurobiological underpinnings of BD. In this context it is 
important to know, whether or not the here-found DEX resistance remains 
detectable in cell lines prepared from the T cells of the bipolar patients. 
B lymphoblastic cell lines of, in particular, major depressed patients 
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show an increase of cytosolic glucocorticoid receptors and a enhanced 
decrease of such receptors in response to DEX when compared to the 
values found in B lymphoblastic cell lines of healthy controls even after 
12 weeks of culture of the cells85. This suggests trait-like characteristics 
of the abnormal DEX response in immune cells of patients with affective 
disorders. Similar trait-like characteristics have been found regarding 
altered beta-adrenergic receptor sensitivity, altered G protein-mediated 
cAMP signaling and altered Ca2+ homeostasis in B lymphoblastic cell 
lines of bipolar I patients86,87. These observations indeed urge for further 
studies in T lymphoblastic cellines of bipolar patients. 
Our study also shows that the higher activation status of the circulating 
T cells in BD patients over that of circulating T cells in HC2 does not remain 
after culturing the cells for 3 days. The expression of CD25 on T cells 
of HC and BD patients rose due to the culture conditions, but became 
mutually equal. In accord with this observation, Bauer et al41 found the 
in vitro IL-2 production in supernatants of lymphocytes of HC and MD 
patients to be equal. Hence the activation of T cells found in freshly 
isolated lymphocyte preparations of BD patients is most likely due to a 
factor operative in the patients in vivo (perhaps the pro-inflammatory 
cytokine milieu eluded to earlier). Interestingly, a positive correlation 
between the serum level of sIL-2R and the plasma cortisol level has been 
found in MD43.
In conclusion, this study found a relative glucocorticoid resistance in 
T cells of patients with bipolar disorder, as has been observed previously 
in major depression. This relative glucocorticoid resistance of T cell may 
be a trait phenomenon of BD since it was found independent of mood 
state and other clinical characteristics of the patients.
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Abstract
Background
In a previous study, we reported an increased prevalence of 
thyroperoxidase antibodies (TPO-Abs) in patients with bipolar disorder. 
Here, we report the prevalence of other organ-specific auto-antibodies: 
H+/K+ adenosine triphosphatase antibodies (H+/K+ ATPase-Abs), glutamic 
acid decarboxylase-65 (GAD65-Abs) and GAD-67 (GAD67-Abs).
Methods
H+/K+ ATPase-Abs, GAD65-Abs and GAD67-Abs were determined 
(via a commercially available enzyme linked immunosorbent assay for 
H+/K+ ATPase-Abs, and standardized radio immuno-assays for GAD65- 
and GAD67-Abs) in the sera of 239 patients with DSM-IV bipolar disorder, 
in 74 patients with DSM-IV schizophrenia and in 220 healthy control 
subjects.
Results
The positivity prevalences for H+/K+ ATPase-Abs and GAD65-Abs 
(but not that of GAD67-Abs) were raised in bipolar patients compared 
with those in healthy control subjects (11.7% vs. 6.1% and 11.3% vs. 
2.6% respectively; p<.05). Schizophrenia patients did not show such 
statistically higher prevalence. The elevated prevalence of H+/K+ ATPase-
Abs and GAD65-Abs in bipolar disorder was associated with neither rapid 
cycling nor the use of lithium. Interestingly, the presence of GAD65-
Abs (and not that of TPO-Abs and H+/K+ ATPase-Abs) tended to be 
associated with the activity of bipolar disorder. The level of TPO-Abs was 
negatively correlated with the serum level of sIL-2R, a measure of T-cell 
activation. 
Conclusion
Bipolar disorder is associated with organ-specific autoimmunity to the 
antigens TPO, H+/K+ ATPase and GAD65. 
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Introduction
Bipolar disorder is a severe, recurrent illness with a complex genetic, 
biological, and psychosocial etiology. There is increasing evidence that 
the immune system, in close interaction with the central nervous system 
and the endocrine system, plays a role in its pathophysiology. There 
is ample evidence to suggest that acute episodes of bipolar disorder 
(BD) are accompanied by an acute phase response and an activation 
of cell-mediated immune reactions, including an activation of the 
T cell system as evidenced by elevated levels of soluble IL-2 receptor 
(sIL-2R) in the serum of the patients1-7. An increased prevalence of 
thyroid auto-antibodies, that is of thyroid peroxidase auto-antibodies 
(TPO-Abs), in BD has been shown as well, and this higher prevalence of 
thyroid antibodies was associated with a higher prevalence of clinically 
overt thyroid failure (hypothyroidism) due to autoimmune thyroiditis8.
Autoimmune thyroiditis represents an organ-specific or endocrine 
autoimmune disease. In organ-specific autoimmunity, more than one 
organ is often affected. The most frequent co-occurrences are between 
autoimmune thyroiditis and type I diabetes and between autoimmune 
thyroiditis and autoimmune atrophic gastritis9,10. These syndromes are 
referred to as autoimmune polyendocrine syndrome (APS) type 3a and 
3b, respectively.
Autoimmune atrophic gastritis is characterized by an increased 
prevalence of antibodies to gastric parietal cells11. These auto-antibodies 
recognize gastric H+/K+ adenosine triphosphatase (H+/K+ ATPase), a highly 
specialized proton pump located in the unique intracellular membranes 
of gastric parietal cell membranes. The presence of these H+/K+ ATPase 
auto-antibodies (H+/K+ ATPase-Abs) provides a convenient diagnostic 
probe for chronic autoimmune (type A) atrophic gastritis11.
Type I diabetes has several serological markers. The most frequently 
used markers are auto-antibodies against the 65-kDalton (65kD) isoform 
of glutamic acid decarboxylase (GAD65-Abs), which are positive in 
approximately 80% of recent-onset cases12. Two forms of GAD occur in 
mammalian tissues: a 65kD form and a 67kD form. GAD65 and GAD67 
are enzymes that catalyze the reaction of L-glutamate to γ-aminobutyric 
acid (GABA), a major inhibitory neurotransmitter in the central nervous 
system. GAD65 and GAD67 are both highly expressed in the brain, but 
the two forms appear to be differentially expressed in pancreatic islets. 
In human islets, GAD65 is abundant, but GAD67 can barely be detected 
(or cannot be detected at all) using various detection methods13-16.
Because of the high prevalence of autoimmune thyroiditis in bipolar 
patients and the known association of autoimmune thyroiditis with 
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autoimmune atrophic gastritis, type I diabetes, or both, we investigated 
the presence of auto-antibodies to H+/K+ ATPase and GAD65 in the sera of 
a group of well-characterized bipolar patients (n=239). The same blood 
samples had been used in previous studies conducted by our group on 
the prevalence of TPO-Abs and the level of sIL-2R in bipolar patients1,8.
As control subjects, we used a group of well-characterized 
schizophrenia patients (n=74) and a group of healthy individuals 
(n=220). Apart from auto-antibodies to H+/K+ ATPase and GAD65, we 
also determined antibodies to gastric parietal cells using the classical 
indirect immunofluorescence (IIF) assay and antibodies to GAD67 as a 
possible sign of autoimmunity against “brain” GAD.
We report a higher prevalence of auto-antibodies to H+/K+ ATPase 
and to GAD65 (but not to GAD67) in BD compared with healthy control 
subjects. The schizophrenia patients did not show statistically higher 
prevalences of these organ-specific auto-antibodies.
Materials and Methods
Patients and Healthy Control Subjects
Patients: The subjects were 239 outpatients with bipolar I, II or not 
otherwise specified (NOS) disorder from the Stanley Foundation Bipolar 
Network (SFBN), a multi-center longitudinal treatment research program 
performed in the United States and The Netherlands described in detail 
elsewhere17,18. A DSM-IV19 diagnosis of bipolar disorder was made by 
means of the Structured Clinical Interview for DSM-IV Axis I, Patient 
Edition (SCID-I/P) Research Version20. A detailed illness history, including 
age of onset, previous illness course, medical history, and past and 
present medication, was assessed at entry into the Network. Blood for 
the present study was drawn during one of the monthly follow-up visits, 
when a research clinician also determined the present mood by means 
of a detailed interview including the Young Mania Rating Scale21, the 
Inventory of Depressive Symptoms22 and the Clinical Global Impressions 
Scale – Bipolar Version23. Based on the retrospective and prospective 
Life Chart Methodology24 patients were defined as rapid cyclers (DSM-IV: 
four or more episodes of mania/hypomania, depression, or both in the 
previous year) or nonrapid cyclers.
Subjects were 122 (51%) women and 117 (49%) men, mean age 45 
(range 23-83) years. At the time of blood collection, 124 (52%) were 
euthymic, 84 (35%) depressed, and 31 (13%) manic or hypomanic, 
all meeting syndromal DSM-IV criteria; 103 (43%) had a rapid-cycling 
Chapter 6.1
150
course. Medication use was as follows: 84% used or had used lithium, 
43% used or had used carbamazepine, 70% used or had used valproate, 
42% used or had used antidepressants, and 19% used or had used 
antipsychotics.
Healthy Control Subjects: Healthy control subjects were recruited 
from three groups of healthy individuals (the staff of the Altrecht Institute 
for Mental Health Care, Utrecht; Department of immunology, Erasmus MC,
Rotterdam, The Netherlands; Department of Medicine, University of 
Washington Medical Center, Seattle, USA), representing 129 Dutch and 
91 U.S. control subjects. All 220 healthy subjects gave written information 
about medication use and medical history. All were free of any psychiatric 
or medical illness and none used any psychotropic or other medication 
(apart from anticonceptive hormonal therapy). Control subjects were 
145 (66%) women and 75 (34%) men, mean age 32 (range 18-59) 
years. The racial composition of both the patient group and the control 
group was comparable, being mainly of Caucasian origin.
A second control group consisted of 74 inpatients and outpatients with 
a DSM-IV diagnosis of schizophrenia19, made by means of the Structured 
Clinical Interview for DSM-IV Axis I, Patient Edition (SCID-I/P) Research 
Vision20. A research clinician assessed current and past medication use 
at the time of blood sampling. Subjects were 16 (22%) women and 
58 (78%) men, mean age 41 (range 19-61) years.
Blood was drawn and serum collected, which was stored immediately 
at –20 °C. All samples were sent frozen to the Department of Immunology 
of the Erasmus MC and stored there, enabling us to test patient and 
control material in the same series of experiments at appropriate times. 
The average duration of storage before testing was the same for the 
patient and control groups (i.e., about 3 to 4 years). It is our experience 
that titers of auto-antibodies do not change during such storage time 
when sera are not thawed and frozen several times during storage, which 
was not the case in this study. Blood samples had been used before in 
previous studies by our group1,8.
The Institutional Review Boards of the participating centers approved 
the study protocol. All subjects gave informed consent. 
Laboratory Methods
The H+/K+ ATPase antibodies in serum were determined by a specific 
enzyme-linked immunosorbent assay (ELISA; QUANTA Litetm GPA ELISA, 
INOVA Diagnostics, San Diego, USA). According to the manufacturer 
recommendations, a prediluted negative, a low positive, and a high 
positive control (supplied by manufacturer) were aliquoted in duplicate 
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in the wells of a preincubated 96-well ELISA plate. Patient sera were 
diluted to a measurable solution with horseradish peroxidase sample 
diluent (1:101) and afterwards added to the plate as well. The remaining 
part of the assay was performed according to the manufacturer’s 
manual. Absorbance at 450-620 nm was measured with a microplate 
reader Multiskan RC (Thermo Life Sciences, Breda, The Netherlands). 
The H+/K+ ATPase-Abs level in the unknown samples was calculated 
according to the manual: ([Sample OD]/[OD of the H+/K+ ATPase-Abs low 
positive control]) x 25 units. Using the control values, the concentrations 
of the samples were calculated based on their optical density values. 
The inter-assay variation was less than 10%. Our internal control was 
comparable with the manufacturer’s controls and stable over all the 
plates we used.
Antibodies to gastric parietal cells were determined via indirect 
immunofluorescence (IIF) according to standard routine diagnostic 
procedures in use at the Department of Immunology at the Erasmus MC. 
Briefly, serum was incubated at 1:10 dilution on cryostat sections from 
rat stomach (IMMCO diagnostics, New York, USA) followed by incubation 
with a second antibody (i.e., fluorescein isothiocyanate-conjugated 
sheep anti-human immunoglobulin; De Beer Medicals, Diessen, The 
Netherlands). In each assay, positive and negative serum controls 
were included. These positive and negative sera in the IIF assay were 
also used in the previously described ELISA for H+/K+ ATPase-Abs. All 
sections were evaluated by at least two technicians. In case of positive 
fluorescence, serum was screened for mitochondrial antibodies using rat 
kidney sections (IMMCO diagnostics, New York, USA). When positive for 
mitochondrial antibodies, sera were considered dubious and were not 
included in the analysis.
The glutamate decarboxylase-65 antibodies (GAD65-Abs) and 
glutamate decarboxylase-67 antibodies (GAD67-Abs) were detected by 
radioimmunoassay (RIA) as described by Grubin et al25. Recombinant 
35S-GAD65 and GAD67 were made in an in vitro transcription and 
translation reaction (Promega, Madison, WI, USA) described elsewhere26,27. 
Samples were analyzed in triplicate. Antibody levels were expressed as a 
relative index to correct for inter-assay variation using the World Health 
Organization standard for GAD65-Abs and GAD67-Abs as positive control 
subjects28. To determine the relative index, positive and negative controls 
were included in all assays25. The threshold for positivity for both GAD 
antibodies was taken at the 97th percentile of the GAD index levels of the 
220 healthy control subjects.
The TPO-Abs levels had been measured previously8 with ELISA (Milenia 
assay, DPC, Breda, The Netherlands) according to the manufacturer’s 
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recommended protocol. A level of 10 units/ml or higher was considered 
as positive for the presence of TPO-Abs.
The sIL-2R levels had been measured previously1 by automatic 
Immulite chemiluminescent enzyme immunometric assay (DPC) 
according to manufacturer instructions.
Statistical Analysis
Data were analyzed using the SPSS statistical package for Windows 
(SPSS, Chicago, Illinois, USA). Logistic regression and analysis of 
covariance (ANCOVA) were used to determine differences between 
groups, corrected for age and gender.
To investigate the difference in GAD65-Abs and GAD67-Abs index 
between control subjects and bipolar patients, a log transformation was 
performed on the data to obtain Gaussian distribution. Correlations and 
associations between the various auto-antibodies were examined using 
Spearman’s rho test. All tests were tested for two-tailed significance and 
a p value below .05 was considered to be statistically significant.
Results
Antibodies to H+/K+ ATPase
The bipolar patients had a higher prevalence of antibodies to 
H+/K+ ATPase compared with the healthy control subjects (11.7% versus 
6.1%, p=.049, corrected for age and gender, Table 1). The percentage 
of rapid cyclers as well as medication use was similar in H+/K+ ATPase-
Abs positive and negative bipolar patients (Table 2). There were also 
no relationships between H+/K+ ATPase-Abs positivity and duration of 
illness, present mood, or subtype of BD (Table 2).
The schizophrenia patients, our comparison group, had a prevalence 
of H+/K+ ATPase-Abs of only 6.8%, a value that was similar to that of 
the healthy control subjects (p=.454 versus healthy control subjects, 
Table 1).
Apart from the H+/K+ ATPase-Abs measured in ELISA, we also tested 
for antibodies to gastric parietal cells using the classical and original 
IIF assay. Using this assay, differences between bipolar patients and 
healthy control subjects could not be found (we therefore did not test the 
schizophrenia patients with the IFF assay). We consider this discrepancy 
between the two assays to be the result of the poorer sensitivity and 
specificity of the IIF assay compared with the newer H+/K+ ATPase-Abs 
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ELISA. Reading of the IIF requires subjective interpretation and is subject 
to variability in the quality and reproducibility of the tissue sections used 
to manufacture the slides (indeed, the negative standard used for IIF 
gave weak positive results in the H+/K+ ATPase-Abs ELISA).
Antibodies to GAD65 and GAD67
The prevalence of GAD65-Abs positivity (defined as a level higher 
than the 97th percentile of levels found in the healthy control subjects) 
was significantly higher in the group of bipolar patients compared with 
the control subjects. A prevalence of 11.3% GAD65-Abs positivity was 
found in bipolar patients compared with the 2.6% positivity in the control 
subjects (p=.002, corrected for age and gender, Table 1). This was also 
reflected in the calculated mean GAD65-Abs index that was significantly 
higher in bipolar patients compared with the control subjects. Both the 
normal mean value and the log transformed mean value (to obtain a 
Table 1.  Prevalence of H+/K+ ATPase-, GAD65- and GAD67-antibodies in Healthy
  Control, Bipolar and Schizophrenia Subjects and the Mean GAD65-Abs
  and GAD67-Abs Index.
HC BD p value SCH p value
(n=220) (n=239) vs. HC (n=74) vs. HC
H+/K+ ATPase-Abs 
positivity1 (%)
6.10% 11.70% .049 6.80% .454
GAD65-Abs positivity1 (%) 2.60% 11.30% .002 4.10% .488
GAD65-Abs index2  .018 ± .035  .025 ± .019 .038  .014 ± .071 .702
GAD65-Abs index3  .702 ± .016  .706 ± .009 .016  .699 ± .031 .566
GAD67-Abs positivity4 (%) 3.00% 6.80% .159 9.50% .166
GAD67-Abs index5 -.032 ± .167 -.006 ± .400 .158 -.005 ± .389 .295
GAD67-Abs index6  .673 ± .078  .678 ± .137 .247  .677 ± .149 .466
1 Logistic regression, adjusted for age, gender, and GAD67-Abs index
2 Mean ± SD; ANCOVA on index value, adjusted for age, gender, and GAD67-Abs index
3 Mean log-transformed ± SD; ANCOVA on log index, adjusted for age, gender, and GAD67- 
  Abs log index
4 Logistic regression, adjusted for age, gender, and GAD65-Abs index
5 Mean ± SD; ANCOVA on index value, adjusted for age, gender, and GAD65-Abs index
6 Mean log-transformed ± SD; ANCOVA on log-index, adjusted for age, gender, and GAD65-
  Abs log-index
ANCOVA, analysis of covariance; H+/K+ ATPase-Abs, H+/K+ adenosine triphosphatase 
antibodies; GAD65-Abs, glutamic acid decarboxylase-65-antibodies; GAD67-Abs, glutamic 
acid decarboxylase-67-antibodies; vs., versus; HC, healthy control subject; BD, bipolar 
disorder; SCH, schizophrenia.
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Gaussian distribution) were significantly different, also after adjustments 
for age and gender (p=.038 and p=.016 respectively; Table 1).
In contrast to the prevalence of GAD65-Abs positivity, that of GAD67-
Abs positivity was not significantly higher in the group of bipolar patients 
and a prevalence value of 6.8% versus 3% (p=.159) was found (Table 1).
The data in Table 2 show that there was no correlation between 
GAD65-Abs positivity and rapid cycling or medication use in the bipolar 
group or between GAD65-Abs positivity and years since first symptoms 
or duration of treatment. In the GAD65-Abs positive and negative groups, 
body mass index (BMI) did also not differ. In line with this observation 
there was also no correlation between BMI and GAD65-Abs positivity 
(r=.01, p=.881). Interestingly, bipolar patients with GAD65-Abs tended 
to have more active forms of the illness (either mania/hypomania or 
depression) compared with the GAD65-Abs negative bipolar patients. 
Table 2 shows symptomatic BD in 58% of GAD65-Abs positive patients 
and 46% in GAD65-Abs negative patients, although this difference did 
not reach statistical significance (adjusted for age and gender, p=.065). 
When we compared GAD65-Abs positivity in patients with symptomatic 
BD with values found in euthymic patients, this trend was also visible: 
values of 15% versus 9.9% (data not shown) were found respectively, 
but again this difference was not statistically significant (adjusted for age 
and gender p=.085). 
With regard to our comparison group, the schizophrenia patients showed 
a normal prevalence and index value of GAD65-Abs, which was comparable 
to that of the control group (Table 1). The prevalence of GAD67-Abs positivity 
was relatively high in the schizophrenia group, that is 9.5%, yet the 
difference with the control group was not statistically significant (Table 1).
Comparisons of Antibodies to H+/K+ ATPase and 
GAD65/GAD67 to Antibodies to TPO and to Serum 
Levels of Soluble IL-2 Receptor (sIL-2R)
In a previous study, we reported on a higher prevalence of antibodies 
to TPO and autoimmune hypothyroidism in the same cohort of bipolar 
patients as studied here8. We also reported on a higher level of sIL-2R in the 
patients of this bipolar cohort and took this as a sign of T-cell activation1.
In this study, we correlated the positivity for antibodies to H+/K+ ATPase 
and to GAD65 with each other and to positivity for antibodies to TPO in 
our test groups. We were unable to find any significant correlations.
We also studied the relationship between the serum levels of sIL-2R 
and the three organ-specific auto-antibodies. Tables 2 and 3 show that the 
levels of sIL-2R did not correlate with the level of antibodies to GAD65 or 
Chapter 6.1
156
with the level of antibodies to H+/K+ ATPase. Tables 3, however, also shows 
that the levels of sIL-2R did significantly and negatively correlate to the 
titer of TPO-Abs (interestingly, for all three auto-antibodies, correlation 
coefficients were negative). Also, TPO-Abs positive patients had a lower 
sIL-2R level compared with TPO-Abs negative patients (i.e., 336 versus 
435 pg/ml [mean]), but this did not reach statistical significance.
Discussion
In this cross-sectional study, we found that bipolar patients not only 
have a higher prevalence of antibodies to TPO as reported previously8, 
but also a higher prevalence of antibodies to H+/K+ ATPase and GAD65 
compared with healthy control subjects. These higher prevalences of 
H+/K+ ATPase-Abs and GAD65-Abs were not found in our comparison group 
of schizophrenia patients (this also applied for a normal 5% prevalence 
of TPO-Abs in the schizophrenia patients; unpublished results). The 
prevalence of GAD67-Abs was not increased in bipolar patients.
The tendency to develop organ-specific autoimmunity did not correlate 
with a rapid-cycling course of BD or the use of medications. Although it 
is known that lithium in particular has immune-modulating effects29, we 
did not find a correlation between past or present lithium exposure and 
TPO- Abs8, H+/K+ ATPase-Abs, or GAD65-Abs. Likewise, Vestegaard and 
Schou30 found that lithium did not induce diabetes mellitus. To the best 
Table 3. Correlations of Auto-antibodies with sIL-2R.
sIL-2R1
H+/K+ ATPase-Abs r=-.103
(p=.130)
GAD65-Abs r=-.104
(p=.127)
GAD67-Abs r=-.087
(p=.202)
TPO-Abs r=-.286
(p<.001)
1 Spearman’s rho test
H+/K+ ATPase-Abs, H+/K+ adenosine triphosphatase antibodies; GAD65-Abs, glutamic acid
decarboxylase-65-antibodies; GAD67-Abs, glutamic acid decarboxylase-67-antibodies; 
TPO-Abs, thyroperoxidase antibodies; sIL-2R, soluble IL-2 receptor.
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of our knowledge, there are no data on the prevalence of autoimmune 
atrophic gastritis in lithium-treated subjects.
Although our sample of bipolar patients is one of the largest studied, 
the sample size still limits the power of statistical analysis. Another 
limitation of the study is that the healthy control group and the comparison 
schizophrenia group are not entirely comparable with the bipolar patient 
group because they differed slightly in the female:male ratio and in age. 
Gender and age do affect the prevalence of TPO-Abs and H+/K+ ATPase-
Abs (higher in women at older age11,31), yet it is questionable whether 
this also applies for GAD65-Abs32. To rule out a possible confounding 
effect of age and gender, we adjusted for these variables in our statistical 
models. Hence, we are confident that the higher prevalence of TPO-Abs, 
H+/K+ ATPase-Abs and GAD65-Abs in BD reported here, is not the result 
of such confounding effects. In addition, the values found in this study 
for positivity of the organ-specific auto-antibodies in the healthy control 
group and the comparison schizophrenia group are in the range of values 
found in population-based control groups in the literature (i.e., around 
4-7%)33,34.
There are, however, putative confounding factors that we could not 
correct for because exact and reliable information was not available for 
a substantial proportion of our controls. One of these is the smoking 
behavior (we assume that almost all of our control subjects did not 
smoke, whereas most of the patients did). Smoking is known to activate 
the cell-mediated immune system, yet effects on the prevalence of 
organ-specific auto-antibodies range from unknown (H+/K+ ATPase-Abs, 
GAD65-Abs) to nonexistent, to protective (TPO-Abs)31. 
It is also of interest that the GAD65-Abs index has been reported to relate 
to the BMI; both positive35 and negative correlations36-39 have been found. 
In our patients, a correlation did not exist between the BMI and GAD65-
Abs (see Table 2). A correlation of BMI to GAD65-Abs was not possible in 
our control group because we lacked reliable information on the weight 
of our healthy subjects. It must be noted in this regard that our patient 
group was slightly overweight (i.e., mean BMI of 28, normal 20-25). 
The impact of mood state on the functioning of the immune system of 
bipolar patients is controversial. Hornig et al2, Maes et al4, and Rapaport 
et al6 showed that the activation of the cell-mediated immune system and 
of the acute phase response did not normalize with patients’ remission. 
These authors concluded that the immune arousal of patients with a 
mood disorder was a trait phenomenon; however, Tsai et al7 showed 
a normalization of cell-mediated immune system activation and acute 
phase response in patients in remission and concluded that there is a 
state dependency of the immune activation.
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We previously reported on the activation of the T cell system in BD and 
used as one of the parameters the sIL-2R levels. We showed higher levels of 
sIL-2R in the sera of depressed, manic/hypomanic and euthymic patients 
compared with healthy control subjects, yet the levels of sIL-2R in manic/
hypomanic patients were the highest. We concluded that the cellular 
immune activation is both a trait and a state phenomenon of the disorder1.
We show here some influence of the illness on positivity for GAD65-
Abs, albeit a borderline statistically significant effect (p=.065). The trend 
detected was that there were more euthymic subjects among bipolar 
GAD65-Abs negative than bipolar GAD65-Abs positive patients. The 
latter had a higher prevalence of both depression and mania compared 
with euthymic patients. In our previous study on the prevalence of TPO-
Abs in BD, we found no association with current mood8.
Interestingly, we found negative correlations between the serum level 
of sIL-2R and the titer of the three organ-specific auto-antibodies, and 
this reached statistical significance for TPO-Abs. A possible explanation 
for the discrepancy might be found in the actual function of the raised 
sIL-2R in the serum of the bipolar patients. The function of this shed 
receptor, although indicating T cell activation, is to capture circulating 
IL-2. Raised levels of the shed receptor thus result in the actual down 
regulation of T cell activation, representing a negative feedback system40. 
This down regulation might also affect the activity of autoreactive B cells 
and the production of auto-antibodies.
GAD65-Abs is an important marker of type I diabetes. The risk to 
develop type I diabetes is, however, not only dependent on the positivity 
for GAD65-Abs, but is also, and in particular, influenced by the titer of the 
GAD65-Abs and the co-occurrence of other islet-related auto-antibodies 
such as antibodies to insulin, insulinoma antibody 2 (IA-2), or islet cell 
antibody (ICA)12,41. The prevalence of diabetes is elevated in bipolar 
patients42,43; however, most reports on the subject did not distinguish 
between type I and II diabetes. Regenold et al44, limiting themselves 
to type II diabetes, showed a higher prevalence of diabetes mellitus 
in bipolar patients. We are not aware of any study that systematically 
investigated the prevalence of type I diabetes in bipolar patients or the 
co-occurrence of GAD65-Abs, ICA, IA-2, or insulin auto-antibodies. In the 
entire Stanley Foundation Bipolar Network cohort, 27 out of 967 patients 
(i.e., 2.8%) self-reported that they had diabetes mellitus, and 6 of those 
27 were insulin dependent (R.W. Kupka, personal communication). Hence, 
at least 6 out 967 bipolar patients (i.e., .62%) had insulin-dependent 
diabetes, a figure that is slightly higher than the prevalence figures for 
type I diabetes in the literature for community-based population 
groups in the United Kingdom of the same age as our SFBN cohort 
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(i.e., .4%)45. Values range in such community-based population groups 
from .2% at 20 years of age to .8% at 80 years of age, however45. 
Moreover, prevalence also depends on geography (e.g., low in European 
Mediterranean countries, high in Nordic countries). We therefore cannot 
conclude that there is a putative-raised prevalence of type I diabetes in 
BD because we lack solid prevalence figures for type I diabetes in both 
the Stanley Foundation group and the matched healthy control group.
The same arguments can be used in a discussion of whether the 
raised prevalence of H+/K+ ATPase-Abs in BD is a sign of a higher risk 
for autoimmune atrophic gastritis because gastric auto-antibodies 
are characteristic of (type A) autoimmune gastritis11. Controlled 
epidemiological studies need to be performed to answer this question.
Because our findings suggest that BD is associated with organ-specific 
autoimmunity, the question of whether bipolar mood disorder is itself an 
autoimmune disease can be raised. GAD65 expression is not restricted to 
the pancreas, but is also present in nervous tissue. The specific GAD65-Abs 
in bipolar patients may thus be viewed as not directed against pancreatic 
tissue alone, but against nervous tissue as well. Would our observation of a 
raised prevalence of GAD65-Abs in bipolar patients mean that BD belongs 
to the spectrum of brain-specific autoimmune diseases, with GAD65-Abs 
in fact directed against GAD65-positive nervous tissue in the brain? It 
has been shown that the expression of GAD65 and GAD67 is reduced 
in the brains of bipolar patients46-48, whereas auto-antibodies to brain 
structures have also been detected in mood disorders and schizophrenia49-
52. GAD67-Abs were not elevated in our bipolar patients (this report), 
however, whereas GAD67 is expressed in nervous tissue. A high titer of 
GAD67-Abs (together with a high titer of GAD65-Abs) is a hallmark of 
an uncommon neurological autoimmune disease Stiff Man Syndrome, 
which is clinically associated with insulin-dependent diabetes mellitus53. 
Collectively, although the low prevalence of GAD67-Abs suggests 
that an autoimmune reaction to nervous tissue is not likely in BD, we 
cannot rule out with certainty that the disorder itself is an organ-specific 
autoimmune disease. More types of antibodies to other autoantigens of 
the brain need to be determined.
In conclusion, our data are compatible with the view that patients 
with bipolar disorder show various signs of an enhanced organ-specific 
autoimmune reaction to TPO, H+/K+ ATPase and GAD65. The positivity of 
TPO-Abs indeed led to a greater prevalence of autoimmune thyroid failure 
in our bipolar patients8. It remains unclear whether the higher prevalence 
of antibodies to H+/K+ ATPase and GAD65 are linked to a higher risk for 
developing autoimmune atrophic gastritis and type I diabetes.
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Abstract
Background
The association between mood disorders and organ specific 
autoimmune diseases has previously been studied in a large cohort of well-
characterized bipolar patients of the Stanley Foundation Bipolar Network 
(SFBN). With regard to antibodies against thyroid peroxidase, glutamic 
acid decarboxylase subtype 65, and H+/K+-adenosine triphosphatase 
prevalences were found increased. The purpose of the present study was 
to determine the seroprevalence of antinuclear antibodies (ANA) in the 
SFBN cohort of bipolar patients.
Methods
Screening for ANA positivity was performed, using indirect 
immunofluorescence (IIF) with HEp2000-cells in 290 bipolar samples. 
Data were compared to 149 healthy control subjects and 74 schizophrenic 
patients. The fine specificity of ANA was determined in ANA positive 
samples focusing on antibodies against extractable nuclear antigens (ENA; 
such as SS-A/Ro and SS-B/La) and dsDNA (using standard techniques).
Results
The prevalence ANA was significantly increased in bipolar patients 
(8.6%) compared to healthy controls (3.4%) and also increased, although 
not significantly, compared to schizophrenic patients (2.7%). Regarding 
the specificity of these ANA, 3 bipolar patients had detectable serum 
levels of SS-A/Ro and/or SS-B/La Abs and 4 patients produced dsDNA-
Abs. In the samples of the healthy control subjects and schizophrenic 
patients, ENA-Abs or dsDNA-Abs were lacking.
Conclusion
In conclusion, we found a significant (factor 2.5) increase of the 
prevalence of ANA in bipolar disorder. Together with our data on thyroid, 
pancreatic and gastric autoimmunity in bipolar disorder, it is suggestive 
that bipolar disorder is characterized by another set point of the immune 
system leading to vulnerability for autoimmune processes.
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Introduction
The association between mood disorders and autoimmune diseases has 
frequently been studied within the research field of immuno-psychiatry1-3. 
The majority of these studies have focused on autoimmune thyroiditis. 
Various groups determined the prevalence of auto-antibodies (Abs) 
directed against thyroid antigens in patients with mood disorders. The 
state of the art is that autoAbs associated with autoimmune thyroiditis 
are more prevalent in patients with both unipolar4-7 and bipolar disorder8-
12 compared with the prevalence found in the general population. It 
must be noted, however, that some consider thyroid autoimmunity to 
be caused by lithium, which is frequently used in the treatment of mood 
disorders13,14.
We studied in a large cohort of well-characterized bipolar patients 
collected within the Stanley Foundation Bipolar Network (SFBN; a multi-
center longitudinal research program), the prevalence of auto-antibodies 
against thyroid peroxidase (TPO-Abs; associated with autoimmune 
thyroiditis), glutamic acid decarboxylase subtype 65 (GAD65-Abs; 
associated with diabetes mellitus type I), and hydrogen-potassium 
adenosine triphosphatase (H+/K+ ATPase-Abs; associated with atrophic 
gastritis and pernicious anemia). TPO-Abs (28% versus 13% in a healthy 
population) and autoimmune thyroiditis (17% versus 1%) were highly 
prevalent in this cohort 12. Moreover, the prevalence figures of autoAbs 
against GAD65 and H+/K+ ATPase were increased (11% versus 3%, and 
12% versus 6%, respectively)15. 
Systemic autoimmune diseases like systemic lupus erythematosus 
(SLE)16,17, rheumatoid arthritis18, and Sjögren’s syndrome19,20, have 
been reported to possess a high comorbidity with psychiatric disorders. 
Severe mood disturbances co-occur in 40-70% of patients with these 
systemic autoimmune diseases18,21,22. Specifically for SLE, the association 
with psychiatric disorders is very tight because psychosis is one of the 
diagnostic criteria for this disease16.
Antinuclear antibodies (ANA) are commonly found in the serum of 
patients with systemic autoimmune disorders. Various authors have 
addressed the question whether ANA are also present with a higher 
frequency in serum of patients with mood disorders23-36. The results and 
prevalence figures are rather variable in these studies and conclusions 
are thus difficult to draw. The variability is probably due to various 
factors, including the fact that studies were performed with a variety of 
techniques, with different criteria for ANA positivity, and with relatively 
small or heterogeneous populations.
The purpose of the present study was to determine the seroprevalence 
ANA in Bipolar Disorder
167
of ANA in a well-characterized cohort of 290 bipolar patients collected 
within the SFBN. We compared the bipolar samples with healthy control 
subjects and schizophrenic patients. Subsequently, the fine specificity of 
ANA was determined in all the positive samples focusing on antibodies 
against extractable nuclear antigens (ENA) such as antibodies against 
SS-A/Ro and SS-B/La (Sjögren’s Syndrome antigen A and B, also called 
Ro and La; associated with Sjögren’s Syndrome) and double-stranded 
DNA (dsDNA; a hallmark of SLE), using well established and state of the 
art standard techniques.
Materials and Methods
Subjects
Bipolar Patients: Blood samples were obtained from 290 outpatients 
with bipolar I, II, or not otherwise specified (NOS) disorder participating 
in a multi-center longitudinal treatment research program, the SFBN. 
This study was performed in the United States and The Netherlands 
and is described elsewhere in detail37,38. A DSM-IV39 diagnosis of bipolar 
disorder was made by means of the Structured Clinical Interview for 
DSM-IV Axis I (SCID)40. A detailed illness history, including age of onset, 
previous illness course, medical history and medication, was assessed at 
entry into the Network. Blood for the present study was drawn during one 
of the monthly follow-up visits, when a research clinician also assessed 
the current mood state, by means of a detailed interview including the 
Young Mania Rating Scale41, the Inventory of Depressive Symptoms42, 
and the Clinical Global Impressions Scale – Bipolar Version43. 40,44
Subjects were 160 (55%) females and 130 (45%) males, mean age 
45 years (range 22-83). At the time of blood collection, 165 (57%) 
were euthymic, 74 (26%) depressed, 27 (9%) manic/hypomanic, 17 
(6%) cycling, and of 7 (2%) patients the mood state was unknown. 
Current treatment was as follows; 146 (50%) used lithium, 64 (22%) 
used carbamazepine, 118 (41%) used valproate, 111 (38%) used 
antidepressants, and 63 (22%) used antipsychotics. 236 (81%) Patients 
had used lithium in the past. The mean duration of illness was 21.8 years 
(range 1-67), however the main duration of treatment was 14.9 years 
(range 0-40).
Healthy Control Subjects: Blood was also collected from 149 healthy 
control subjects (i.e., the staff of the Altrecht Institute for Mental Health 
Care, Utrecht and of the Department of Immunology, Erasmus MC, 
Rotterdam, The Netherlands). Each one gave written information about 
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medication use and medical history and was free of any psychiatric or 
medical illness. Nobody used psychotropic medication. Control subjects 
were 99 (66%) females and 50 (34%) males, mean age 32 years (range 
19-62). The racial composition of both the patient group and the control 
group was comparable, being mainly of Caucasian origin.
Schizophrenic Patients: A second control group, used as disease 
contrast group, consisted of 74 in- and outpatients with a DSM-IV 
diagnosis of schizophrenic39, made by means of the SCID40. A research 
clinician assessed current and past medication use at the time of blood 
sampling. Subjects were 16 (22%) females and 58 (78%) males, mean 
age 41 years (range 19-61).
Blood was drawn and serum collected which was divided in aliquots 
and stored immediately at minus 20°C. All samples were sent frozen to 
the Department of Immunology of the Erasmus MC and finally stored 
there at minus 80°C, enabling us to test patient and control material 
in the same series of experiments at appropriate times. The average 
duration of storage before testing was the same for the patient and 
control groups, i.e. about 4 to 5 years. It is our experience that titers 
of auto-antibodies do not change during such storage time when sera 
are not repeatedly thawed and frozen during storage, which was not 
the case. Our group used aliquots of the blood and serum samples for 
previously published studies12,15, see also below. The Institutional Review 
Boards (IRBs) of the participating centers approved the study protocol. 
All 513 subjects gave informed consent.
Antibody Assays
Antinuclear Antibody (ANA) Screening with Indirect 
Immunofluorescence (IIF) (STEP 1): Indirect immunofluorescence 
was performed to screen for antibodies against nuclear antigens (i.e., 
antinuclear antibodies or ANA), according to standard routine diagnostic 
procedures as used at the Department of Immunology (Diagnostic unit; 
Erasmus MC, Rotterdam, The Netherlands). HEp-2000 cells were used as 
substrate for the IIF assay (Immuno Concepts, Sacramento, CA, USA). 
Briefly, serum was incubated at 1:80 dilutions on glass slides with HEp-
2000 cells and further diluted if necessary. Subsequently, incubation with 
a second antibody, i.e. fluorescein isothiocyanate-conjugated sheep anti-
human immunoglobulin G, took place. In each assay, blancs, positive 
and negative serum controls were included. All slides were evaluated 
by at least two independent and experienced technicians. In all cases, 
the technicians were blinded for the diagnosis. Sera with titer >80 were 
considered as being positive samples. In case of positive fluorescence, 
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Figure 1. Test Algorithm of the Antinuclear Antibody Screening.
Test algorithm of this study; after the first ANA screening, all positive IF samples with a 
nuclear pattern were tested for specific antibodies, either one of the extractable nuclear 
antigen antibodies (ENA-Abs) or dsDNA-Abs. These specific antibodies are associated with 
various systemic autoimmune diseases, depicted in the last column.
ANA, antinuclear antibody; IIF, indirect immune fluorescence; HEp, human epithelial cell 
line; H, homogenous; N, nucleolar; S, speckled; ND, nuclear dots; centr, centriole; Aca, 
anti-centromere pattern; MC, mitochondrium; act, actin; Ab, antibody; ENA, extractable 
nuclear antigen, ELISA, enzyme linked immunosorbent assay; FEIA, fluorescent-enzyme 
immunoassay; LIA, line-blot immunoassay; dsDNA, double stranded DNA; M2, antibodies 
against a specific target within mitochondria; SS-A/Ro, Sjögren’s Syndrome antigen A 
(also called Ro); SS-B/La, Sjögren’s Syndrome antigen B (also called La); Sm, Smith; RNP, 
ribonuclear proteins; Jo-1, Histidyl-tRNA sythetase; SCL-70, scleroderma Abs directed 
against topoisomerase-1; SLE, systemic lupus erythematosus; CREST, autoimmune disease 
with symptoms of calcinosis, Raynaud’s phenomenon, esophagus spasm, scleroderma, and 
teleangiectasy; MCTD, mixed connective tissue disease; PBC, primary billiary cirrhosis.
Chapter 6.2
170
the staining pattern was also described, distinguishing the various 
nuclear patterns and cytoplasmic patterns (Figure 1). While ANA testing 
is an excellent screening test, it is by no means a test to determine the 
specificity of the ANA. Therefore we continued with further specification 
for antibodies against extractable nuclear antigens (ENA-Abs) or double 
stranded DNA (dsDNA-Abs).
The samples with a positive cytoplasmic pattern in HEp-2000 cells 
were further tested on rat kidney and stomach slides (IIF) and with a 
specific M2-ELISA (INOVA Diagnostics, San Diego, CA, USA) to confirm 
antibody specificity against mitochondria or actin (Figure 1).
ENA-Abs and dsDNA-Abs Specification (STEP 2): According to 
the test algorithm of this study (Figure 1), all positive IF samples with a 
nuclear pattern were tested with sensitive techniques for the presence of 
specific antinuclear antibodies, either one of the ENA-Abs (i.e., SS-A/Ro, 
SS-B/La, Smith [Sm], ribonuclear protein [RNP], Histidyl-tRNA sythetase 
[Jo-1], and scleroderma Abs [SCL-70]) or dsDNA-Abs.
In order to screen for ENA-Abs, enzyme-linked immunosorbent 
assays (Quanta Litetm ENA 6) were used according to the manufacturer’s 
manual (INOVA Diagnostics, San Diego, CA, USA). If screening revealed 
positivity for one of the ENA-Abs, an Ab-specific ELISA (SCL-70 ELISA: 
Varelisa, Pharmacia Diagnostics AB, Freiburg Germany/other ENA 
ELISA’s: INOVA Diagnostics, San Diego, CA, USA), a fluorescent-enzyme 
immunoassay (FEIA; ImmunoCAP-FEIA system, Pharmacia Diagnostics 
AB, Uppsala, Sweden), a line-blot immunoassay (LIA; INNO-LIA ANA 
update, Innogenetics, Gent, Belgium), and Luminex technology (FIDISTM 
connective 10, BioMedical Diagnostics, Marne la Vallée, France), were 
performed to confirm this finding. Ultimately, a serum sample was labeled 
as positive for a specific ENA when at least two tests had a positive result.
Anti-dsDNA antibodies were determined with a FEIA (ImmunoCAP-
FEIA system [Pharmacia Diagnostics AB, Uppsala, Sweden]). All assays 
were carried out in the diagnostic unit of the Department of Immunology, 
Erasmus MC Rotterdam, The Netherlands.
Antibody Assays against TPO and GAD65: In the majority of 
subjects used for the present study, endocrine auto-antibodies were 
determined previously. The presence of antibodies against TPO had been 
measured with an enzyme linked immunosorbent assay (ELISA; Milenia 
assay, DPC, Breda, The Netherlands) according to the method indicated 
by the manufacturer12. Second, Abs against H+/K+ ATPase and GAD65 
were determined, respectively by an ELISA (QUANTA Litetm GPA ELISA, 
INOVA Diagnostics, Inc., San Diego USA) and by radioimmunoassay 
(RIA; FIRM45), as previously published15.
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Statistical Analysis
Statistical analysis was performed with the SPSS 11.0 package for 
Windows (SPSS, Chicago, Illinois, USA). All comparisons of categorized 
variables with 2x2 tables were tested for statistical significance using the 
Fisher exact test. We choose for this strict statistical approach, instead of 
Chi square tests, because figures in the 2x2 tables are often less than 5. 
Statistical significance of continuous variables between (sub-)groups was 
determined by Mann-Whitney U tests. All tests were tested for two-tailed 
significance and p values below .05 were considered to be statistically 
significant.
Results
Antibodies against Nuclear Antigens are increased in 
Bipolar Patients
As depicted in Table 1, 25 bipolar patients showed a positive nuclear IIF 
staining. The prevalence of such ANA positivity in bipolar disorder (8.6%) 
is statistically significant increased compared to the prevalence in the 
healthy control subject group (3.4%, p=.04). However, significance was 
not reached compared to the prevalence among schizophrenic patients 
(2.7%, p=.13), probably due to low numbers. The patterns of nuclear 
staining patterns were variable and not significantly different between 
patient groups and controls (Table 1).
Antibodies against Antigens in Cytoplasm in HEp2000-
Cells are not increased in Bipolar Patients
Although in the IIF assays, the majority of positive samples showed a 
nuclear staining pattern, some samples showed Ab-reactivity to antigens 
within the cytoplasm, such as to actin (5) and to mitochondria (2; Table 1).
 However, numbers of positive samples are low and differences between 
patient groups and controls were not significant.
Further Typing of Antibodies against Specific Nuclear 
Antigens
The second step of our test algorithm (Figure 1) was to further identify 
the ANA specificity. We investigated antibodies against ENA and dsDNA 
in all the samples with a positive nuclear IIF staining. Of all the positive 
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nuclear IIF serum samples tested in the bipolar group, two samples had 
Abs against SS-A/Ro, and one sample had Abs both against SS-A/Ro and 
SS-B/La (Table 2). Other ENA-Abs (i.e., Sm, RNP, Jo-1, and SCL-70) could 
not be detected. None of the healthy control samples or of the schizophrenic 
samples had Abs against one of the ENA. Regarding Abs against dsDNA, 
4 bipolar samples were positive, although one of these samples had a low 
titer (13.7 IU/ml). This finding contrasted to the absence of dsDNA-Abs in 
the two other groups tested (i.e., healthy control subjects and schizophrenic 
patients). All in all numbers of positivity are too low to evaluate statistically.
Table 1. Results of STEP 1: ANA Screening.
Bipolar 
Disorder 
(n=290)
Healthy 
Control 
Subjects
(n=149)
Stats
HC vs. 
BD1
Schizophrenic 
Patients
(n=74)
Stats
SCH vs. 
BD1
ANA screening: IIF assay
1) IIF staining
Positive 8.6% (25) 3.4% (5) p<.05 2.7% (2) ns
Negative 91.4% (265) 96.6% (144) (χ2=4.29) 97.3% (72) (χ2=3.01)
2) IIF patterns
N 1.4% (4) .7% (1) 1.4% (1)
H 4.5% (13) 0 0
Combination 
N/H
.3% (1) 0 0
S .3% (1) .7% (1) 1.4% (1)
ND .7% (2) 1.3% (2) 0
SS-A/Ro .7% (2) 0 0
centr .3% (1) .7% (1) 0
Aca .3% (1) 0 0
Cytoplasmic staining
MC .7% (2) 0 ns 0 ns
Act 1.4% (4) .7% (1) ns 0 ns
1  Statistics is performed by using Fisher exact test. The Pearson Chi-Square value (χ2) is
  depicted between brackets after the p value
ANA, antinuclear antibodies; IIF, indirect immunofluorescence; N, nucleolar; H, homogenous; 
S, speckled; ND, nuclear dots; SS-A/Ro, Sjögren’s Syndrome antigen A; centr, centriole; 
Aca, anti-centromere pattern; MC, mitochondrium; act, actin; Abs, antibodies; BD, bipolar 
disorder; HC, healthy control subjects; SCH, schizophrenic patients; ns, not statistically 
significant.
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Table 2. Results of STEP 2: Further ANA Specification.
Bipolar 
Disorder 
(n=25)
Healthy 
Control 
Subjects
(n=5)
Stats
HC vs. 
BD1
Schizophrenic 
Patients
(n=2)
Specific nuclear Abs
Total of positive samples 
after typing 7 0
p=.101
(χ2=3.66) 0
ENA-Abs 3
SS-A/Ro 2
SS-A/Ro & SS-B/La 1
Sm 0
RNP 0
Jo-1 0
SCL-70 0
dsDNA-Abs 4 0 0
1 Statistics is performed by using Fisher exact test. The Pearson Chi-Square value (χ2) is
  depicted between brackets after the p value
ENA, extractable nuclear antigen; SS-A/Ro, Sjögren’s Syndrome antigen A (also called Ro); 
SS-B/La, Sjögren’s Syndrome antigen B (also called La); Sm, Smith; RNP, ribonuclear 
proteins; Jo-1, Histidyl-tRNA sythetase; SCL-70, scleroderma Abs directed against 
topoisomerase-1; dsDNA-Abs, antibodies against double stranded DNA; BD, bipolar disorder; 
HC, healthy control subjects; SCH, schizophrenic patients; ns, not statistically significant.
Association of ANA, ENA-Abs, and dsDNA-Abs with 
Demographic or Clinical Characteristics
Age neither influenced the presence of ANA, nor the presence of ENA-
Abs or dsDNA-Abs. Yet, Abs against ENA or dsDNA are only present 
in 7 samples and these numbers are too low to draw valid statistical 
conclusions. The same applies to the cycling pattern, the duration of 
illness, and the duration of treatment (Table 3). Nevertheless, for some 
demographic and clinical features we found interesting trends, although 
none of them statistically significant. In the entire bipolar patient sample 
55% were female patients, while in the patients with detectable ANA 
or Abs against ENA or dsDNA the percentage of female patients was 
increased (respectively 68% and 86%). In the patients with detectable 
ANA, ENA-Abs, or dsDNA-Abs, slightly more patients were manic or 
depressed (60% for ANA and 71% for ENA- and dsDNA-Abs) compared 
with the bipolar cohort as a whole (41%). Separating the patients in the 
Chapter 6.2
174
Table 3. Association of some Demographic and Clinical Characteristics.
Entire Bipolar 
Cohort 
(n=290)
ANA Screening 
(STEP 1)
ENA- or dsDNA-Abs 
(STEP 2)
Positive 
(n=25) Stats
Positive 
(n=7) Stats
Age1 44.9 ± 10.9 45.2 ± 10.8 ns 50.7 ± 5.7 ns
Female2 55% (160/290) 68% (17/25) ns(χ2=1.06) 86% (6/7)
ns
(χ2=1.50)
Euthymic mood 
state2
(7 missing values)
57% (165/283) 40% (10/25) ns(χ2=2.452) 29% (2/7)
ns
(χ2=1.40)
Duration of illness 
(years)1 21.8 ± 12.2 24.7 ± 10.8 ns 24.6 ± 13.7 ns
Treatment
Duration of 
treatment 
(years)1
14.9 ± 9.6 15.8 ± 9.1 ns 16.0 ± 8.7 ns
Duration of 
lithium treatment 
(months)1
77 ± 62 98 ± 58 ns 57 ± 14 ns
Lithium (current)2 50% (146/290) 32% (8/25) ns(χ2=2.41) 71% (5/7)
ns
(χ2=.52)
Carbamazepine 
(current)2 22% (64/290) 28% (7/25)
ns
(χ2=.19) 29% (2/7)
ns
(χ2=.00)
Valproate 
(current)2 41% (118/290) 60% (15/25)
ns
(χ2=2.77) 29% (2/7)
ns
(χ2=.07)
AutoAbs status
TPO-Abs positive2
(1 missing value) 27% (77/289) 32% (8/25)
ns
(χ2=.00) 57% (4/7)
ns
(χ2=.09)
H+/K+ ATPase-Abs 
positive2
(4 missing values)
11% (31/286) 20% (5/25) ns(χ2=1.10) 14% (1/7)
ns
(χ2=.11)
GAD65-Abs 
positive2
(7 missing values)
10% (29/283) 4% (1/25) ns(χ2=.43) 14% (1/7)
ns
(χ2=.15)
Association of some demographic and clinical characteristics of the bipolar patients with:
1) Results of antinuclear antibody (ANA) screening (first step of test algorithm)
2) Results of further ANA specification (second step), either for antibodies against 
  extractable nuclear antigens (ENA-Abs) or double stranded DNA (dsDNA-Abs)
1  Statistics is performed by using Mann-Whitney U test. Data are expressed as mean ± SD
2 Statistics is performed by using Fisher exact test. The Pearson Chi-Square value (χ2) is 
 depicted between brackets after the p value. Data are expressed as percentage of the
  different subgroups followed by the exact number between brackets
IIF, indirect immunofluorescence; ns, not statistically significant; Abs, antibodies; TPO, 
thyroid peroxidase; GAD65, glutamic acid decarboxylase subtype 65; H+/K+ ATPase, 
hydrogen-potassium adenosine triphosphatase.
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four different mood states did not reveal extra information.
Because it is well known that different types of medication can 
affect the production of ANA, special attention was paid to the different 
types of treatment. Only 32% of the ANA-positive group used lithium 
compared with 50% in the entire bipolar cohort. However, in the group of 
patients with Abs against ENA or dsDNA, 5 out of 7 (71%) patients used 
lithium, which can not exclude a possible association between current 
lithium use and the production of specific ANA. The opposite is found 
with regard to valproate, which was used more frequently (60%) in the 
positive ANA group than in the total group (38%). However, few patients 
(29%) with Abs against ENA or dsDNA used valproate. No clear effects of 
carbamazepine or other treatment approaches could be found.
We also checked in our database for associations of ANA, ENA-Abs 
or dsDNA-Abs with the previous determined autoAbs against TPO, 
H+/K+ ATPase and GAD65. No associations were found (Table 3). However, 
concerning the samples positive for Abs against ENA or dsDNA, 4 out of 
7 samples had also at least one organ-specific autoAb.
Discussion
In this study we found a significantly increased prevalence of antinuclear 
antibodies (ANA) in bipolar patients (8.6%) compared to healthy 
controls (3.4%) and also, although not significantly, to schizophrenic 
patients (2.7%). Regarding the specificity of these ANA for well-known 
nuclear antigens, 3 patients had detectable serum levels of Abs against 
SS-A/Ro and/or SS-B/La and four patients produced dsDNA-Abs. Although 
it is rather remarkable that 7 bipolar patients had specific Abs against 
nuclear targets, while healthy control subjects and schizophrenic patients 
did not, group sizes were too small to reach statistical significance with 
regard to Abs against ENA or dsDNA.
It must be noted that specific ANA against SS-A/Ro, SS-B/La and 
dsDNA are associated with systemic autoimmune diseases, respectively 
Sjögren’s Syndrome and SLE. Questionnaires, obtained during inclusion of 
the study, of the 7 patients with specific ANA were viewed retrospectively, 
focusing on physical complaints. Although the information is rather 
sparse, none of them had clear indications for either SLE or Sjögren’s 
syndrome. In two other studies among psychiatric patients with various 
diagnoses a similar approach was followed, but these studies also did not 
reveal any comorbid systemic autoimmune diseases26,32.
As mentioned in the introduction, the current study is not the first 
on the seroprevalence of ANA in patients with mood disorders. An 
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overview of 14 studies investigating the prevalence of ANA in patients 
either with unipolar or bipolar disorder is summarized in Table 4. In these 
studies, different techniques for ANA detection were used. Although 9 
out of 14 used IIF techniques, the antigenic substrates vary. Our current 
investigation is the first to use the HEp2000-cell line as an antigenic 
substrate, which is presently used in many of the immunodiagnostic 
centres. Table 4 shows that prevalences range from 0%-72%. Next to 
the variability in technique or the heterogeneity of subject groups, this 
could also be caused by the different criteria used as cut off for (ANA) 
positivity, like including or excluding non-specific (borderline) findings. 
Therefore, a general conclusion cannot be drawn from these studies. 
Seven studies24,28-31,35,36 found no difference between patients and control 
groups, but 7 other studies23,25-27,32-34 found an increased seroprevalence 
of ANA. Our study seems to fit with this increased prevalence of ANA, be 
it under strict conditions by excluding non-specific findings (i.e., low titers 
and weak nucleolar stainings). Further typing of the positive ANA samples 
revealed indications that the prevalence of specific ANA, like ENA-Abs 
and dsDNA-Abs, is increased in bipolar disorder, as well. Although our 
bipolar cohort is, to the best of our knowledge, the largest ever studied 
(Table 4), statistical significance could not be reached for these low 
prevalent Abs against ENA and dsDNA. We calculated46 that with the 
differences we have found, group sizes should have been at least 450 
individuals each to accomplish this goal. This is in accordance with 
previous data both with regard to the few psychiatric studies determining 
ENA-Abs32,33 or dsDNA-Abs26,32,33,35,36.
Table 4.  Survey on Studies investigating Prevalence of Antibodies directed 
 against Nuclear Targets in Patients with Mood Disorders.
1  low titers (i.e., titer ≤ 80)/weak staining: excluded 
2  low titers (i.e., titer ≤ 80)/weak staining: included 
3  in study: nothing mentioned about borderline findings 
4  no substrate mentioned in methods section 
=  prevalence not significantly different versus HC 
*1 prevalence of patients with mood disorder significantly increased versus HC 
*2 prevalence of psychiatric patients significantly increased versus HC, but not specific for 
 mood disorders
#, number of patients in the various (sub)groups; Ab, antibody; ANA, antinuclear 
antibodies; ENA, extractable nuclear antigens; dsDNA, double stranded DNA; ss, single 
stranded; FCT test, fluorescent calf thymus test; IIF, indirect immunofluorescence 
technique (between brackets are the used substrates); HEp2, human epithelial cell line; 
granulo’s, granulocytes; ACP technique, ammonium sulphate precipitation technique; 
ELISA, enzyme linked immunoassay; Immunodiff. Test, immunodiffusion screenings test; 
nd, not described in paper; UP, unipolar depressed patients; BD, bipolar patients; PD, 
nondepressed psychiatric patients; HC, healthy control subjects; PP, psychiatric patients; 
MD, patients with a mood disorder; Co, control group; depr., depressed mood.
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The two confounding factors stated frequently in literature regarding 
the seroprevalence of ANA, are treatment and gender. Regarding 
psychotropic treatment, chlorpromazine is often mentioned as a possible 
ANA inducer25,47,48. None of our patients used this antipsychotic. Other 
studies26,49 brought up lithium as possible ANA inducer, but other studies 
did not confirm this28,30,31. Our data even tend to contradict an ANA-
inducing effect of lithium, as fewer ANA positive patients were treated 
with lithium compared with the total cohort, but the difference is not 
statistically significant. Regarding results of the second step (i.e., 
specifically determining ENA-Abs or dsDNA-Abs), 5 out of 7 patients used 
lithium, which in contrast does suggest an effect of lithium, but again 
the difference is not statistically significant. With the possible exception 
of valproate, which was (also not significantly) more prevalent in the 
group of bipolar patients positive for ANA screening, other psychotropic 
treatments were not associated with the presence of ANA. Regarding 
these associations it should be noted that our study is naturalistic, which 
could have led to bias by indication for the various treatments. Moreover, 
most patients received more than one type of medication. This problem 
was already encountered by various other groups, nevertheless the 
majority of them confirmed the lack of significant association between 
the presence of ANA and the various psychotropic treatments23,32,34,36.
Concerning gender, we found in our sample a higher prevalence of 
females in the ANA positive groups, although not statistically significant. 
Regarding previous studies, some did find a significant association between 
ANA and female gender23,25,35,36, whereas others did not27,34. Within the 
results of the ANA screening, logistic regression correcting for age and 
gender did not alter the overall conclusions (data not shown). Unfortunately, 
the number of positive samples was too small to legitimally perform 
logistic regression correcting for all the possible confounding factors.
A common topic of discussion in immunologic research in mood 
disorders is the state or trait relationships of the immune alterations. We 
found a non-significant trend towards increased ANA positivity in patients 
who were in a manic or depressive episode, as was previously found by 
Hornig et al36. With regard to the disease specificity, we did not find 
increased ANA positivity in the schizophrenic patients, which confirms 
other studies23,24. However, other studies reject that the presence of 
ANA can be disease specific, either by concluding that ANA prevalence is 
increased in psychiatric patients regardless of their diagnosis25,33, or by 
concluding that psychiatric patients in general do not have an increased 
risk on ANA24,35.
In conclusion, we found an increased prevalence of ANA in bipolar 
disorder, compared with healthy control subjects. Larger groups need 
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to be investigated to establish whether this also results in a significant 
increased prevalence of specific ANA, associated with systemic 
autoimmune diseases such as Sjögren’s Syndrome or SLE. Nevertheless, 
together with our previously published data on thyroid, pancreatic and 
gastric autoimmunity in bipolar disorder, it is suggestive that bipolar 
disorder is characterized by an altered set point of the immune system 
leading to vulnerability for autoimmune processes in general.
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7.1 Conclusions
Although the exact pathophysiology of bipolar disorder has not been 
unraveled, this thesis adds to the increasing evidence that aberrancies 
in the immune system of patients with bipolar disorder represent one of 
the jigsaw pieces in it’s complex pathophysiology1-4. The main results of 
this thesis work are summarized in Figure 1 and show:
1. that the increased sensitivity of bipolar patients for autoimmune 
phenomena is not restricted to the thyroid5 and that the prevalences 
of auto-antibodies against GAD65 (associated with diabetes mellitus 
type I), H+/K+ ATPase (associated with autoimmune gastritis), and 
ANA (associated with various systemic autoimmune diseases) in the 
serum of bipolar patients were also increasedChapter 6.1, 6.2.
2. that T cells of bipolar patients were less sensitive to the suppressive 
effect of dexamethasone (DEX), a synthetic steroidChapter 5.1.
3. that monocytes of bipolar patients were aberrant:
 a. LPS-stimulated monocytes of non-lithium treated bipolar
  patients were characterized by an abnormal IL-1β/IL-6 
  production ratio (i.e., a relatively low IL-1β in comparison to 
  a relatively high IL-6 production)Chapter 3.1.
 b. monocytes of non-lithium treated bipolar patients had a
  reduced capacity to differentiate into fully active DC compared 
  to healthy control subjects Chapter 4.1.
4. that lithium treatment restored the monocyte aberranciesChapter 3.1, 4.1.
In summary, our results show clear indications for various B cell, T cell, 
and monocyte/macrophage aberrancies in patients with bipolar disorder 
compared to healthy control subjects. Also taking the literature into 
consideration, it is for us obvious that the immune system is affected in 
bipolar disorder. Various hypotheses have been proposed regarding the 
involvement of the immune system in mood disorders. In the following 
section we will discuss briefly some of the immune hypotheses in light of 
our current findings.
Autoimmune Theory
From a clinical point of view, the link between psychiatric disorders and 
autoimmune diseases is very intriguing. In the early 1960s Burch proposed 
an autoimmune hypothesis for schizophrenia, based on the age of onset, 
the sex differences and the relapsing remitting course of this psychiatric 
disorder6. A recent review by Jones et al once again puts emphasis on this 
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hypothesis in schizophrenia by putting forth several levels of evidence7. 
Comparable models have also been formed for other psychiatric 
disorders, including mood disorders. However, from an immunological 
point of view the conclusion that some psychiatric disorders have an 
autoimmune basis is too simple based on the current state of research.
In our studies we found a strong association between bipolar disorder 
and organ specific and systemic autoimmune diseasesChapter 6.1 and 6.2 (i.e., 
we found an increased prevalence of TPO-antibodies (Abs), GAD65-Abs, 
H+/K+ ATPase-Abs, and ANA in bipolar disorder). These auto-antibodies 
are often markers of underlying more pathogenic events, such as the 
presence of auto reactive CD4+ Th1 cells and CD8+ cytotoxic T cells, 
leading to organ destruction and failure. Indeed in a previous study5 
we showed that bipolar patients have a higher risk of developing 
autoimmune thyroiditis, linked to the presence of TPO-Abs. Concerning 
the other auto-antibodies under investigation, the results are more 
difficult to interpret regarding their clinical consequences. GAD65-
Abs are a marker for Diabetes Mellitus (DM) type I. Although the rate 
of diabetes was slightly increased in our SFBN cohort, the distinction 
between autoimmune induced pancreas destruction (DM type I) and DM 
due to insulin resistance (DM type II) was difficult to make in the bipolar 
groupChapter 6.1. Also, exact clinical data on atrophic gastritis or pernicious 
anemia, regularly associated with Abs against H+/K+ ATPase, were not 
present in our cohort and are also not present in the literatureChapter 6.1. 
Furthermore, there were no clear indications that in the bipolar group 
more patients suffered from systemic autoimmune diseases, like SLE or 
Sjögrens syndromeChapter 6.2.
We also found circumstantial evidence that bipolar disorder is 
associated with autoimmunity. Namely we showed that monocytes of 
bipolar patients are mildly hampered in their differentiation into fully 
active DC, both on the level of membrane markers (phenotype) and 
on the level of their decreased potency to stimulate autologous T cells. 
DC are an important determinant in autoimmunity as similar mild 
differentiation defects have been found in DC of patients with recent 
onset type I diabetes and their first-degree relatives8. In animal models, 
such as the NOD mice9 or the BB-DP rat10 aberrancies of DC are found 
consistently, similar to our findings in bipolar disorder. Restoring the DC 
disturbances in these animal models does prevent the development of 
autoimmunity11. Moreover, the typical reduced glucocorticoid sensitivity 
found in patients with mood disorders has also been found in animal 
models for both organ specific autoimmune disorders, such as the 
Obese strain of chickens (animal model with a spontaneously occurring 
Hashimoto-like autoimmune thyroiditis) and systemic autoimmune 
Chapter 7
188
diseases, such as murine lupus erythematosus12.
Despite these findings, we do not think it is likely that bipolar disorder 
is an autoimmune disease, since specific brain antibodies have not been 
found in this disorder. We consider it more likely that the association 
between bipolar disorder and autoimmunity is caused by a common 
defect in the immune system, like in the monocyte/macrophage system 
forming the basis for, on the one hand the mood symptoms, and on the 
other hand the autoimmune phenomena.
Glucocorticoid Resistance Hypothesis
A consistent finding in mood disorders is a disturbance of the HPA 
axis13. The main feature of this disturbance can be summarized as an 
increased relative resistance of the sensing GC receptors in the body, 
such as the brain, for steroids, causing a disturbed feedback mechanism 
and increased circulating cortisol levels. The awareness of this 
aberrancy resulted in the glucocorticoid resistance hypothesis for mood 
disorders14-17. Our data, regarding the diminished suppressive effect of 
DEX on T cellsChapter 5.1, supports this hypothesis on the level of circulating 
T cells. Moreover, the resistance to GC on the T cell level could explain 
the previously found T-cell activation in bipolar patients, indicated by 
a higher serum level of sIL-2R and increased numbers of CD3+CD25+ 
T cells18.
Apart from possible intrinsic molecular defects in the downstream 
intracellular chain from the GC receptor, which causes the glucocorticoid 
resistance, there is also evidence that an increased level of products of 
activated macrophages, like the pro-inflammatory cytokine IL-1β, leads 
to a residual sensitivity to GC19-21. This finding is interesting since it links 
the glucocorticoid resistance hypothesis to the macrophage theory of 
depression.
Macrophage Theory of Depression
The basis of the macrophage theory of depression22-24 is the finding 
that pro-inflammatory cytokines, produced by monocytes/macrophages25 
like IL-1β and IL-6, are able to induce behavioral changes26 and that the 
production of these cytokines is increased in patients with major depression.
In order to expand this theory to bipolar disorder, we showed that 
monocytes of non-lithium treated bipolar patients were characterized 
by an abnormal IL-1β/IL-6 production ratio (i.e., a relatively low IL-1β 
production in comparison to a relatively high IL-6 productionChapter 3.1). 
Although we were able to confirm that the pro-inflammatory set point of 
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the monocytes of bipolar patients is altered, we were not able to confirm 
that there is simply an increased production of these pro-inflammatory 
cytokines. The implications of the disbalanced production of IL-1β and 
IL-6 can be on the level of the regulation of neurotransmitters in the 
brain, where both cytokines sort differential effects27,28.
Ongoing research on immune activation in mood disorders also made 
the link to indoleamine 2,3-dioxygenase (IDO). This enzyme is, amongst 
others, present in macrophages and DC can be activated by immune 
activation29. Indoleamine 2,3-dioxygenase catabolizes tryptophan, one 
of the building stones of serotonin, and an increased activity of IDO 
can thus lead to a deficiency of serotonergic (5HT) neurotransmission30. 
Furthermore, one of the breakdown products of tryptophan, quinolinate 
and kynurenate, are respectively neurodegenerative and neuroprotective. 
In the “neurodegeneration hypothesis of depression” it is postulated that 
IDO is activated via immune activation, which results in an alteration 
of these neurodegenerative and neuroprotective compounds. This 
dysbalance can contribute to the development of mood disorders31. In 
our studies we did not measure the IDO activity.
Modified Hypothesis
The studies performed in this thesis enable us to adjust our current 
hypotheses (Figure 2). We found in our studies indications for intrinsic 
defects (i.e., not related to the state of bipolar disorder): an alteration 
in the pro-inflammatory set point of bipolar monocytes, a defective 
generation of DC from bipolar monocytes, and a resistance of bipolar 
T cells for glucocorticoids. These aberrancies have in earlier research 
either been implicated in the induction of mood disturbances (i.e., 
aberrant pro-inflammatory set point of monocytes in the macrophage 
theory of depression) or in the induction of autoimmunity (i.e., defective 
DC generation8-11, or GC resistance12). To join these findings into one 
comprehensive model (Figure 2), the multidirectional interplay between 
the immune system, the endocrine system, and the central nervous system 
is crucial (i.e., neuro-immuno-endocrine axis). We hypothesize that the 
equilibrium of the neuro-immuno-endocrine axis is altered in patients 
with bipolar disorder. Such disequilibrium can eventually develop into a 
mood disorder, when other predisposing factors/vulnerabilities for mood 
disorders are also present, such as polymorphisms (acquired or congenital). 
On the other hand, this disequilibrium of the neuro-immuno-endocrine 
axis can also lead to clinically overt autoimmune diseases, explaining the 
high association between bipolar disorder and autoimmunity. In these 
cases other disturbances in the immune system should be additionally 
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present, such as a decreased function of regulatory T cells, tolerogenic 
DC, or a cross reaction with a similar antigen. Probably, multiple factors 
play a role in the adjustment of the neuro-immuno-endocrine axis, such 
as genetically determined polymorphisms of important molecules in this 
axis (cytokines, chemokines, cytokine-/GC-receptors) or environmental 
factors (earlier infections, stress factors during pregnancy or early life).
In conclusion, our current hypothesis is that intrinsic aberrancies of 
the immune system, particularly in the monocyte/macrophage system, 
lead to both mood disturbances as well as to autoimmunity depending 
on other elicitating and genetically determined intrinsic factors in the 
endocrine or central nervous system and/or extrinsic factors such as 
stress and infections, which we currently did not study. 
7.2 Methodological Considerations: Strengths
  and Limitations of our Studies
The Classification of Bipolar Disorder
The Diagnostic and Statistical Manual of Mental Disorders (DSM) is a 
classification method originally introduced to categorize the variety of 
Autoimmunity
“Phenotype”
“Intrinsic Defects”
“Extrinsic Factors”
Bipolar Disorder
Immune system
Monocytes (alterations in pro-infl setpoint)
DC (defective differentiation)
T cells (activation)
Endocrine system
GC resistancy
Central Nervous system
E.g., Stress, Medication, Infections
Figure 2. Modified Hypothesis on the Pathophysiology of Bipolar Disorder.
DC, dendritic cell; GC, glucocorticoids.
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psychiatric symptoms for research purposes. However, the diagnostic 
boundaries in classification methods, such as DSM-IV, remain hazy and 
the individual phenotypes within one diagnosis diverge. Bipolar disorder, 
as a diagnostic entity, is in this respect no exception, especially when you 
take the whole bipolar spectrum into account. In the present study we 
used the fourth edition32 and only included patients, who clearly fulfilled 
the diagnostic criteria for bipolar disorder I or II (narrow phenotype) 
to make the study group as uniform as possible. We therefore did not 
include patients with cyclothymic or dysthymic disorder.
A strong point in this study is the registration of a large variety of 
demographic and clinical characteristics of the bipolar patients in this 
SFBN cohort into a central database. In this way possible confounders, 
such as age, gender, or mood state33,34, could be taken into consideration 
in our statistical analyses.
Treatment
With regard to the psychotropic treatment, which is an important co-
variable in our database, the following has to be mentioned. Patients 
were treated “as usual” and on average 90% of patients used 2 or 
more different types of psychotropic medications at the time of drawing 
blood, depending on their clinical features. This “polytreatment” makes 
it hard to draw firm conclusions on the effects of a single treatment on 
the different immune parameters. Because lithium is a clear immune 
modulator35,36, as mentioned previously, we decided to focus mainly in 
our data analyses on the effects of this particular drug.
Duration of Illness
As mentioned in the introduction of this thesis, an accurate diagnosis 
during the first mood episode of patients with bipolar disorder is very 
difficult37,38. The time-gap between the disease onset and the starting 
point of treatment (on average 10 years) in our SFBN patient sample is 
in this respect very illustrative. For a biological study, as described in this 
thesis, it would be an advantage if one could catch patients early in their 
disease development, when they are still free of treatment. However, 
this is a general problem in the immunopsychiatric research field and it 
underlines the importance of finding early biological markers for bipolar 
disorder. Possibly these markers can be found in an aberrant function or 
set point of the immune system.
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Sample Size
Compared to other studies on bipolar patients, the sample sizes of 
the immune studies within the SFBN cohort are among the largest ever 
studied. In the majority of our studies, sample sizes were large enough 
to control for single confounding factors, which were included in our 
database. However, to legitimately take all the possible confounders 
within our study into account and to build one statistical model, group 
sizes need to be larger. In the auto-antibody studies, which included 
over 200 bipolar patients, we were able to perform more elaborative 
statistical analyses. In these studies we did not find clear indications for 
important confounders.
Healthy Control Subjects: Age, Gender, and Psychiatric 
Interview
A general point of concern in our studies is the age of the subject 
groups. The mean age of the included healthy control subjects was 
in general not significantly lower as compared to the bipolar patients. 
Although on a single study level the role of age introduces differences 
in outcomes33,39-41, a recent meta-analysis3 on immune assays in mood 
disorders showed that age did not demonstrate a significant moderating 
effect with any of the immune variables. Statistical analysis in our studies 
did not reveal age as a confounding factor either.
In the meta-analysis mentioned above3, female gender was associated 
with increases in B- and T-cell numbers. In particular, we paid attention to 
this possible confounding factor and matched the bipolar and the healthy 
control group as good as possible for gender. Performing statistical 
analyses in this respect, we were not able to find differences between 
the male and female group with the exception of the production of auto-
antibodies, as was expected42.
Another point of concern in the healthy control subject group is the 
fact that they did not undergo a (semi-)structured psychiatric interview. 
We did ask them in a small questionnaire if they were healthy (both 
physically and mentally) and if they took any kind of medication at the time 
of drawing blood. They were only allowed to take oral anticonceptives, 
otherwise they were excluded. We also excluded two individuals with a 
positive family history for psychiatric disorders (schizophrenia and major 
depression). Virtually all healthy volunteers were co-workers or medical 
students and with virtual certainty it can be states that our healthy 
control group was free of major psychiatric disorders. However, we could 
not control for any potential low level stress or mood symptoms.
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Smoking Behavior
Finally, smoking habits influence the immune system33,43, although 
one study disputes this39. Unfortunately we could not take smoking into 
consideration in our evaluations, because details on the smoking behavior 
of individual patients are lacking in the SFBN cohort. As a general rule, 
the majority of the bipolar and schizophrenia patients are most likely 
smokers, in contrast to our healthy controls.
Technical Flaws of the Assays
Some of the experimental designs, particularly the bio-assays such 
as the DC generation, used for the immune measurements in this thesis 
are sensitive to various external factors, such as the batch of FCS or 
the types of plastics used, stressing the importance of taking internal 
controls along in the experiments. The studies performed in this thesis 
were performed with this awareness and paired control samples were 
taken along in the same set of experiments. For future research it would 
be advantageous to develop experimental designs, which are more 
standardized and less variable. This would also be of benefit to decrease 
the variability of results between different research groups and reports 
in the literature.
Lithium
As mentioned previously, we also studied the effects of lithium in 
the immune studies reported in this thesis. The main reason being the 
previously reported immune modulating capacity of this potent mood 
stabilizing drug35,36. In general our data shows that lithium treatment 
clearly influences the immune status of our patients. Lithium treatment 
restored the aberrant IL-1β/IL-6 ratio and the aberrant capacity of 
monocytes to differentiate into potent DC. Despite that, the production 
of auto-antibodies or the relative DEX resistancy of T cells was not 
significantly affected by lithium treatment.
Besides the in vivo treatment effect of lithium, we also studied the 
in vitro acute effects of lithium by adding lithium chloride (LiCl) to our 
various immune assays. As a general rule, in vitro addition of LiCl did 
not have the same effects as in vivo lithium treatment. In the monocyte-
derived DC cultures the suppressed DC generation and activation after 
in vitro exposure to LiCl (10mM) contrasted with the restored, activated 
phenotype due to lithium treatment in vivoChapter 4.1. This phenomenon was 
also observed with regard to the capacity of monocytes to produce pro-
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inflammatory cytokines. In vitro addition of LiCl resulted in a decreased 
IL-1β production and a minimal effect on the IL-6 productionChapter 3.1, yet 
in vivo treatment restored the disturbed balance between these cytokines 
in bipolar patients. This clear difference between in vivo and ex vivo 
lithium exposure was also observed by Boufidou et al44. As argued by 
him and us in chapters 3.1 and 4.1, this discrepancy could be caused by 
factors such as differences in duration of lithium exposure, concentration 
of lithium, or factors which play a role in vivo but are excluded in an in 
vitro system, such as the interaction between different immune cells.
7.3 Possible Implications of our Findings
7.3.1 Implications for the Clinics
Because the exact role of the immune system in mood disorders has 
not yet been unraveled, the practical implications are rather limited. 
However, our data show a clear association between bipolar disorder 
and immune disorders, such as thyroid autoimmunity. As autoimmune 
thyroiditis has a high prevalence in bipolar patients and is relatively 
easy to treat, our data thus support the practice to evaluate the thyroid 
function of patients with a mood disorder. In particular when risk factors 
for thyroid pathology, such as treatment with lithium, female gender, or 
age above 44 years, are present along with the mood disorder, it is more 
than reasonable to measure the thyroid status of these patients thereby 
facilitating the early detection of thyroiditis, which means suppletion with 
thyroid hormone can start as soon as possible45,46. If somatic complaints 
or diagnostics are suggestive of an autoimmune disease a consult with a 
medical immunologist should be performed as well.
7.3.2 Implications for the Development of new 
Treatment Strategies
One of the main conclusions of this thesis is that the immune system is 
by and large activated (more activated T cells18, aberrant pro-inflammatory 
cytokine set-point of monocytes, increased prevalence of autoimmunity) 
in patients with bipolar disorder, in line with the general opinion for 
mood disorders. In this respect, it would be logical to incorporate the 
involvement of the immune system in treatment strategies. Although the 
studies described in this thesis did not study possible mechanisms for 
new treatment strategies, it is from a clinical point of view, interesting to 
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review the findings in the literature in this respect. Some experimental 
treatment strategies aiming at immune suppression are listed in the 
following section.
Omega-3 Polyunsaturated Fatty Acids
Although the exact working mechanism of omega-3 polyunsaturated 
fatty acids, mainly of fish oil, is not known, there is clear evidence that 
omega-3 fatty acids have anti-inflammatory properties as reviewed 
several times47,48. This dietary compound was shown to be associated 
with unipolar depression, both in epidemiological studies49,50 and on the 
cell membrane level51. Efforts to show therapeutic effects of suppletion 
of omega-3 fatty acids were successful in depressed patients52,53. This 
experimental treatment strategy also appeared to be effective in treating 
bipolar disorder, either for short-term effects54, improving lithium-induced 
psoriasis 55, reducing depressive symptoms56, or ameliorating signs of 
irritability57.
PDE-IV Inhibitor
Another experimental approach is the treatment with phosphodiesterases 
IV (PDE-IV) inhibitors. Phosphodiesterases are responsible for hydrolysis 
of the cyclic nucleotides cAMP and cGMP, particularly in nerve and 
immune cells. Rolipram, a selective PDE-IV inhibitor, suppresses the 
expression of pro-inflammatory cytokines and other components of 
the immune system58,59. In animal models, treatment with rolipram 
indicates antidepressive effects60,61. Although nausea is a severe side 
effect of rolipram, a positive effect on symptoms of depression is shown 
in some human trials as well58,62. However, some studies showed that 
some already existing antidepressants, like imipramine or amitriptyline, 
remain superior compared to rolipram63,64. The search is now shifted to 
PDE4-treatment regimens with fewer side effects.
Interference with HPA-axis
One of the best-known immune suppressants is the corticosteroid-
treatment approach. In patients with mood disorders, the levels of 
endogenous produced cortisol are increased. However, the simultaneous 
resistance of the glucocorticoid receptor makes this story complicated16,65. 
Treatment with cortisol ameliorates the mood state in some patients, but is 
also able to induce psychiatric symptoms66,67, including manic episodes68. 
Drugs designed specifically to restore the feedback function within the 
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HPA axis may be integral for future treatment of mood disorders16,69. In 
this respect, limited clinical trials have been designed treating patients 
with depression with CRH antagonists70, GR antagonists71, and with 
steroid-synthesis inhibitors like metyrapone 72,73. The first results are, at 
least for short-term effects, promising.
DHEA
Regarding hormones with immunomodulating capacity, 
dehydroepiandosterone (DHEA) has to be mentioned as well74. DHEA is 
an inactive androgen, transformed into active sex steroids in peripheral 
tissues. Briefly, the plasma concentrations decrease throughout adult 
life75. DHEA administration to patients with SLE76,77 or diabetes mellitus78,79 
showed beneficial effects for their mood state. Moreover, DHEA treatment 
may have significant antidepressant effects, mainly in patients with 
major depression80,81.
NSAID
Non-Steroidal Anti-Inflammatory Drugs (NSAID), such as ibuprofen 
and aspirin, act both as anti-inflammatory and analgesic agents via the 
inhibition of prostaglandin syntase. Trials in patients with mood disorders 
with these well-known NSAID have not yet been published. However, 
another prostaglandin syntase inhibitor (reboxetine), specifically targeting 
cyclooxygenase-2 (COX-2), has shown to have beneficial therapeutic 
effects in major depression82.
Monoclonal Abs
Monoclonal antibodies to pro-inflammatory cytokines, such as IL-6 or 
TNFα, are novel treatment strategies in severe inflammatory diseases like 
Crohn’s disease and rheumatoid arthritis. To the best of my knowledge, 
trials with these kinds of treatment regimens have not been performed 
in patients with severe mood disorders. This is probably due to the high 
costs, the intensive treatment protocols and the ethical considerations 
concerning serious side effects, including pneumonia, tuberculosis, 
lymphoma, and hepatotoxicity. It must be remembered here that major 
depression is the most common psychiatric diagnosis in Crohn's disease. 
Therapy with monoclonal anti-TNFα antibodies, such as infliximab, 
improved the quality of life in patients with active Crohn83 and decreased 
the frequency of major depression in these patients83,84. Recently, a 
study with another monoclonal anti-TNFα antibody, Etanercept, in 
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psoriasis patients, showed a significant relieve of fatigue and symptoms 
of depression associated with this chronic disease85.
7.3.3 Implications for Future Research
The results obtained in the studies published in this thesis open doors 
for future research regarding the role of the immune system in the 
pathophysiology of bipolar disorder. Although some of them have already 
been mentioned previously in this chapter, we want to approach these 
aspects more systematically in the following section.
1. The majority of techniques used in this study, particularly in the 
bioassays, are time consuming and sensitive to many factors, such as 
methodological approaches. New techniques have to be developed 
to solve these kinds of problems. Presently, techniques like genomics 
and proteomics are considered to have great potential for the future.
2. Although the implementation of DSM-IV criteria improved the 
uniformity of patient groups in psychiatric research, problems 
with heterogeneity within diagnostic entities remain. In the future, 
the use of potential biomarkers would be of benefit to approach 
a psychiatric diagnosis in a novel way. Ongoing research on the 
relationship between mood disorders and the immune system will 
most likely provide such potential diagnostic markers.
3. As mentioned previously it is difficult to collect bipolar patients 
with a recent onset of bipolar disorder or without therapeutic 
interventions. It is very important to perform studies in this early 
stage of disease development, to be able to investigate state or 
trait effects, the effects of being chronically ill, and/or the effects of 
treatment. For this reason one has to search for other approaches, 
e.g. by studying in follow-up studies high risk groups such as 
offspring or siblings of bipolar patients.
4. The studies presented in this thesis are restricted to aberrancies in 
single isolated components of the immune system, like monocyte/
macrophages or T cells in vitro. Clearly, there is a need to integrate 
the findings in such isolated systems to a more holistic approach, 
which include the nervous system and the endocrine system 
as well as taking into consideration genetic and environmental 
determinants. This could be achieved by using sophisticated 
animal models or developing new animal models, which show the 
behavioral or the biological aspects of mood disorders. Various 
animal models have already shown their value. However, most 
animal models, such as animal models of sleep deprivation, 
olfactory bulbectomy, or chronic stress, at best highlight only part 
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of the clinical symptoms86. It would be challenging to develop 
an animal model for all aspects of bipolar disorder, mimicking 
behavioral components of both mood poles, which can be used for 
neurobiological studies.
7.4 Final Remark
The studies in this thesis confirm that aberrancies in the immune system 
are integral parts of bipolar disorder. From a clinical point of view, the 
association of bipolar disorder with autoimmune disease is of great interest.
The links between behaviour, the brain, the immune system and the 
endocrine system are intriguing and complex. It is expected that through 
scientific research insight will grow into the interactions between these 
systems. The ultimate goal would be to integrate all the findings, as 
small pieces of the big jigsaw, into one comprehensive model. Such a 
model will lead to new diagnostic tools and therapies. The journey of 
finding the crucial steps in the pathophysiological mechanism leading to 
bipolar disorder is not finished yet. It remains an interesting yet difficult 
challenge.
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Abbreviations
Abs   antibodies
ACTH   adreno-corticotrophin hormone
APC   antigen-presenting cells
AVP   vasopressin
BB-DP   biobreeding diabetic prone rat
BD   bipolar disorder
BMI   body mass index
BSA   bovine serum albumine
CD   cluster of differentiation
cpm   counts per minute
CTLA   cytotoxic T-lymphocyte associated antigen
CRH   corticotrophin-releasing factor
DC   dendritic cells
DM   diabetes mellitus
DEX   dexamethasone
DST   dexamethasone suppression test
DEX/CRH test  combined dexamethasone/corticotrophin-
   releasing hormone test
DM   diabetes mellitus
DSM   diagnostic and statistical manual of mental   
   disorders
ESR   erythrocyte sedimentation rate
FACS   fluorescence-activated cell sorting
FCS   fetal calf serum
FITC   fluorescein
GAD65-Abs  glutamic acid decarboxylase isotype 65
GC   glucocorticoid
GM-CSF  granulocyte-macrophpage colony-stimulating   
   factor
HC   healthy control subjects
H+/K+ ATPase-Abs  H+/K+ adenosine triphosphatase antibodies
HPA axis  hypothalamus pituitary adrenal axis
ICAM   intercellular adhesion molecule
IIF   indirect immune fluorescence
Ig   immuneglobulin
IL   interleukin
LiCl   lithium chloride
mAbs   monoclonal antibodies
MD   major depression
MFI   mean fluorescence intensity
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MHC   major histocompatibility complex
MLR   mixed lymphocyte reactions
M   mol/liter
NOD   non-obese diabetic mouse
PBMC   Peripheral blood mononuclear cells
PBS   phosphate buffered saline
PHA   phytohaemagglutinin
PE   phycoerythrin
P/S   penicillin/streptomycin
SCID   structured clinical interview for DSM-IV axis I
sIL-2R   serum-interleukin-2 receptor
SLE   systemic lupus erythematodes
SFBN   Stanley Foundation Bipolar Network
Th   T helper cell
TNF   tumor necrosis factor
TPO-Abs  thyreoperoxidase-antibodies
UG   ultraglutamine
VLA   very late antigen
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Summary
The main objective of this thesis was to obtain more insight in the 
role of the immune system in the pathogenesis of bipolar disorder by 
investigating various aberrancies in the immune system of patients with 
bipolar disorder. In Chapter 1 some general concepts, important for 
the perception of this thesis, are presented. Background information on 
bipolar disorder, the immune system, and the hypothalamus pituitary 
adrenal axis is given. Bipolar disorder is a severe and chronic mood 
disorder with a prevalence ranging from .3-3.7% (generally 1.3-1.6%) 
and a complex etiology. There is increasing evidence that the immune 
system plays a significant role in the pathophysiology of mood disorders, 
but research in this field particularly focussed on major depression. 
In this chapter an overview of earlier published research on immune 
abnormalities in mood disorders, especially bipolar disorder, is given. 
It is clear that not all immune findings point in the same direction, mainly 
due to diverse methodological approaches. Consequently, much of the 
involved mechanisms need further clarification. Also the role of lithium is 
mentioned, a potent mood stabilizer with immune modulating capacity.
In Chapter 2 the Stanley Medical Research Institute, formerly known 
as Stanley Foundation Bipolar Network (SFBN), is introduced. From this 
multi-center research program, we included 81 bipolar patients from the 
SFBN site in Utrecht. Blood was drawn, demographical and clinical data 
were collected and standardised psychiatric interviews were assessed. 
Previous immune studies in this SFBN cohort revealed an increased 
prevalence of thyroid autoimmunity in bipolar disorder and a raised 
activation state of T cells and elevated numbers of B cells in peripheral 
blood. These studies contributed to our research questions, which are 
presented in this chapter. In summary, the studies described in this 
thesis were performed to gain more insight into different parts of the 
immune system of patients with bipolar disorder.
With regard to the innate immune system, represented by monocytes, 
we found indications for an altered pro-inflammatory cytokine balance, 
as described in Chapter 3. LPS-stimulated monocytes of non-lithium 
treated bipolar patients were characterized by an abnormal IL-1β/IL-6 
production ratio (i.e., a relatively low IL-1β in comparison to a relatively 
high IL-6 production). Lithium treatment restored this status. In addition 
we studied the role of these cytokines in lithium-induced psoriasis, one 
of the major side effects of this mood stabilizing drug. The production 
profile of pro-inflammatory cytokines of monocytes of patients with 
lithium-induced psoriasis is different from that of regular psoriasis, 
indicating differences in their pathogenesis. 
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In the next chapter, Chapter 4, we focussed on the interphase between 
the innate and the adaptive (T and B cells) immune system, represented 
by monocyte-derived dendritic cells (DC). Monocytes of non-lithium 
treated bipolar patients had a reduced capacity to differentiate into 
fully active DC compared to healthy control subjects. The disturbances 
in the phenotype of monocyte-derived DC, both the marker expression 
on the cell membrane (CD1a and CD14) and the capacity to stimulate 
autologous T cells, were restored after lithium treatment.
Chapter 5 focussed on a part of the adaptive immune system 
(i.e. T cells) and more specific at their responsiveness to glucocorticoids 
(GC). In earlier studies, we found T cells of bipolar patients to be activated 
and we questioned whether this could be linked to the concept of GC-
resistancy. In vitro experiments with T cells of bipolar patients showed 
evidence for a lesser responsiveness of T cells to steroids compared to 
healthy controls.
The first immune study in the SFBN cohort found a clearly increased 
prevalence of thyroperoxidase antibodies (TPO, auto-antibodies against 
the thyroid) in bipolar patients. Also the prevalence of the associated 
autoimmune thyroiditis was increased. We questioned whether this 
was also the case for other auto-antibodies, both organ-specific Abs 
(Chapter 6.1) and more generalized Abs (Chapter 6.2). Regarding 
organ-specific auto-antibodies, the prevalence of auto-antibodies 
against H+/K+ ATPase (against proton pumps in the parietal cells in the 
stomach) and glutamic acid decarboxylase-65 (against the beta cells 
in the pancreas) was also elevated. With regard to generalized Abs, 
we also provided evidence for an increased prevalence of antinuclear 
antibodies (ANA), associated with various forms of systemic autoimmune 
diseases.
In all our studies, special attention was paid on the effects of lithium, 
a potent mood stabilizer with immunomodulatory effects. In general, 
lithium treatment normalized the immune aberrancies in bipolar disorder. 
For example it restored the aberrant pro-inflammatory cytokine profile 
and recovered the potency to develop monocyte-derived DC. We also 
studied the in vitro effects of lithium chloride in various experimental 
set-ups, such as pro-inflammatory cytokine production in cell cultures 
and monocyte-derived DC cultures. As a general rule, in vitro addition 
of LiCl did not have the same effects as in vivo lithium treatment. 
This discrepancy could be caused by factors such as differences in 
duration of lithium exposure, concentration of lithium, or factors which 
play a role in vivo but are excluded in an in vitro system, such as the 
interaction between different immune cells.
Finally in Chapter 7 the main findings and conclusions of this thesis 
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are summarized and discussed. The present study shows clear indications 
for various B cell, T cell, and monocyte/macrophage aberrancies in 
patients with bipolar disorder compared to healthy control subjects. Also 
taking the literature into consideration, it seems obvious that the immune 
system is affected in bipolar disorder and plays a role in the pathogenesis. 
Various hypotheses have been proposed regarding the involvement of 
the immune system in mood disorders, such as the autoimmune theory, 
the glucocorticoid resistance hypothesis, and the macrophage theory 
of depression. In the light of the immune findings in the SFBN cohort, 
we formulated an adapted hypothesis in which the neuro-immuno-
endocrine axis plays an important role. Intrinsic aberrancies of the 
immune system, particularly in the monocyte/macrophage system, could 
lead to both mood disturbances as well as to autoimmunity. Whether it 
will lead to mood disturbances, autoimmunity, or both depends on other 
elicitating and genetically determined intrinsic factors in the endocrine 
or central nervous system and/or extrinsic factors such as stress and 
infections.
The findings in this thesis have some implications for the clinic. 
First, the association of bipolar disorder with autoimmune diseases, 
mainly autoimmune thyroiditis, is striking. Because the exact role of 
the immune system in mood disorders has not yet been unraveled, the 
practical implications are rather limited. As autoimmune thyroiditis has a 
high prevalence in bipolar patients and is relatively easy to treat, diagnostic 
tests of the thyroid function should be implicated in the good clinical 
practice of the treatment of patients with a mood disorder, in particular 
when risk factors for thyroid pathology co-exist. Second, this thesis 
confirms the involvement of the immune system in the pathophysiology 
of bipolar disorder, which can be of help in the development of future 
treatment strategies.
Finally, the pathophysiology of bipolar disorder and the links between 
behaviour, the brain, the immune system and the endocrine system are 
intriguing and complex. The ultimate goal would be to integrate all the 
findings into one comprehensive model. Such a model will lead to new 
diagnostic tools and therapies. The journey of finding the crucial steps 
in the pathophysiological mechanism leading to bipolar disorder is not 
finished yet. It remains an interesting yet difficult challenge.

Samenvatting
209
Samenvatting
Bipolaire stoornis, vroeger manisch-depressieve stoornis genoemd, 
wordt gekenmerkt door het met intervallen optreden van heftige en 
extreme stemmingsschommelingen, waarbij de stemming zeer laag 
(depressief) of juist zeer uitgelaten (manisch) kan zijn. Soms komen in 
zo’n periode zowel kenmerken van een depressie als van een manie voor 
(gemengde episode). Kenmerkend is dat in deze periodes het normale 
leven (bijvoorbeeld werken, gezinsleven of sociale relaties) van een 
patiënt ernstig wordt verstoord. De episoden komen meestal geïsoleerd 
voor en worden afgewisseld door periodes met een gezonde (euthyme) 
stemming, waarin patiënten normaal kunnen functioneren. Echter, soms 
gaan de periodes direct in elkaar over.
Bipolaire stoornis komt bij 1.3-1.6% van de algemene bevolking voor, 
evenveel bij vrouwen als bij mannen. Bipolaire patiënten worden over 
het algemeen behandeld met een stemmingsstabilisator, zoals lithium, 
carbamazepine of valproaat. Echter, in veel gevallen gebruiken patiënten 
meer dan 1 type medicijn. De behandeling kan er voor bedoeld zijn om 
een depressie te verlichten, symptomen van een manie onder controle 
te brengen, of ernstige stemmingswisselingen te voorkomen. Over het 
algemeen gebruiken bipolaire patiënten ook medicatie in de periode dat 
ze een normale stemming hebben, om terugval te voorkomen.
De oorzaak van de bipolaire stoornis is niet precies bekend, maar uit 
onderzoek blijkt dat er verschillende factoren bij betrokken zijn. Onder 
andere speelt erfelijkheid een rol. Zo is de kans voor een broer of zus van 
een bipolaire patiënt om ook deze ziekte te ontwikkelen 40-70% voor 
een eeneiige tweeling en 5-10% voor een “gewone” broer of zus (dit ten 
opzichte van 1.3-1.6% voor de algemene bevolking). Omgevingsfactoren, 
zoals ingrijpende gebeurtenissen en sociale factoren, kunnen evenzeer 
een rol spelen bij het uitlokken van een manie of een depressie. Andere 
biologische factoren, zoals hormonale veranderingen en kleine structurele 
veranderingen in het brein, spelen ook mee. Recent onderzoek heeft 
aangetoond dat bij patiënten met een depressieve stoornis, dat wil zeggen 
bij patiënten die nog nooit een manische periode hebben doorgemaakt, 
tevens het immuunsysteem (ook wel afweersysteem genoemd) een rol 
speelt. Wetenschappelijk onderzoek naar dergelijke immunologische 
veranderingen bij bipolaire patiënten is in veel mindere mate verricht.
Het onderzoek, dat in dit proefschrift beschreven staat, had als 
belangrijkste doel om meer inzicht te krijgen in het functioneren van 
het immuunsysteem bij bipolaire patiënten. Voordat de resultaten van 
dit onderzoek beschreven worden, zullen hieronder eerst kort enkele 
immunologische basisprincipes besproken worden.
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Het immuunsysteem is een verdedigingssysteem met als doel 
indringers (zoals bacteriën en virussen) of veranderde eigen cellen (zoals 
kankercellen) te bestrijden. Het immuunsysteem is een erg vernuftig 
en complex systeem, waarin verschillende stoffen en cellen met elkaar 
samenwerken en communiceren. Het is onder te verdelen in een “aspecifiek” 
en een “specifiek” deel. Met de cellen uit het aspecifieke immuunsysteem 
worden binnendringers snel maar vaak weinig effectief te lijf gegaan. 
Het in gang zetten van het specifieke deel kost meer tijd maar resulteert 
meestal in een sterke afweer, waarbij tevens langdurige bescherming 
tegen een specifieke indringer verzorgd wordt. Witte bloedcellen zijn 
cellen van het immuunsysteem, die zich in het bloed, in de huid en 
verspreid over het lichaam bevinden. Er zijn verschillende soorten witte 
bloedcellen, die afhankelijk van het type voornamelijk een rol spelen in 
het aspecifieke of specifieke immuunsysteem. Monocyten en macrofagen 
zijn bijvoorbeeld cellen uit het aspecifieke immuunsysteem en lymfocyten 
(B en T cellen) zijn cellen uit het specifieke immuunsysteem (zie ook 
figuur 1, hoofdstuk 1). Als het immuunsysteem niet goed is “afgesteld” 
kan dit tot verschillende ziektes leiden. Indien het immuunsysteem 
in ernstige mate te kort schiet, bijvoorbeeld door het wegvallen van 
bepaalde witte bloedcellen, spreken we van een immuundeficiëntie. Bij 
een overgevoelig immuunsysteem zal het lichaam overdreven reageren 
op onschuldige prikkels, zoals bij een allergie tegen huisstofmijt. Een 
overactief immuunsysteem kan een deel van het eigen lichaam gaan 
aanvallen. Dit noemen we een auto-immuunreactie, die kan leiden tot 
een auto-immuunziekte. Ziektes als diabetes mellitus type I, reumatoïde 
artritis en schildklier auto-immuniteit zijn hier voorbeelden van. Soms 
zijn verstoringen in het immuunsysteem echter subtieler.
Het immuunsysteem werkt niet volledig op zichzelf; zo kunnen stoffen 
uit het immuunsysteem in het brein effect sorteren en kunnen hormonen 
(zoals stresshormonen) het immuunsysteem beïnvloeden. Een voorbeeld 
om dit te illustreren is het bekende fenomeen, dat mensen met een 
flinke griep en koorts vaak ook een beetje somber zijn en minder eetlust 
hebben. Onder andere om deze reden zijn onderzoekers de relatie tussen 
het immuunsysteem, het hormonale systeem en het brein (waaronder 
ook gedrag en psychiatrische ziektebeelden) gaan onderzoeken.
Om het immuunsysteem van bipolaire patiënten te kunnen 
onderzoeken werd voor onze studie van 81 bipolaire patiënten bloed 
afgenomen. Met speciale technieken werden de verschillende witte 
bloedcellen uit het bloed geïsoleerd. Deze patiënten namen deel aan een 
breder onderzoek vanuit een stichting die het “Stanley Medical Research 
Institute” heet, voorheen ook het “Stanley Foundation Bipolar Network” 
(SFBN) genoemd. Naast de afname van bloed, werden over deze 
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patiënten uitgebreide, grotendeels gestandaardiseerde, vragenlijsten 
ingevuld met klinische en demografische gegevens. Tevens werd er 
een groep gezonde controles verzameld, die qua leeftijd en geslacht 
overeen kwamen met de patiëntengroep. Ook van deze groep mensen 
werd bloed afgenomen volgens dezelfde procedures. Eerder onderzoek 
in deze patiëntenpopulatie wees uit dat er voor bipolaire patiënten een 
groter risico was op het ontwikkelen van schildklierauto-immuniteit. 
Verder bleek ook dat bepaalde cellen uit het specifieke immuunsysteem 
(T cellen) meer geactiveerd waren, dan die van gezonde controles. Het 
doel van ons vervolg onderzoek, beschreven in dit proefschrift, was om 
andere facetten van het immuunsysteem in meer detail te bestuderen.
Wat betreft het aspecifieke immuunsysteem, vonden wij dat de 
monocyten van bipolaire patiënten een subtiele verandering in hun 
“status” hadden. De verhouding van bepaalde boodschapperstoffen, 
betrokken bij het aanzetten van ontstekingsreacties (pro-inflammatoire 
cytokinen; IL-1β en IL-6), was anders ingesteld bij bipolaire patiënten ten 
opzichte van gezonde controles. Lithiumbehandeling, waarvan al eerder 
bekend was dat het invloed heeft op het immuunsysteem, herstelde 
deze balans voor een groot deel. Aangezien één van de bijwerkingen 
van lithium psoriasis is (een huidziekte, waarbij het immuunsysteem 
ook verstoord is), hebben we ook naar de productie van dezelfde 
pro-inflammatoire cytokinen in de patiënten met “gewone” psoriasis 
en met lithiumgeïnduceerde psoriasis gekeken. Het productieprofiel 
verschilde tussen deze twee vormen van psoriasis, wat een verschil in 
de ontstaansmechanismen doet vermoeden.
Monocyten kunnen zich ontwikkelen tot dendritische cellen, die op 
hun beurt het specifieke immuunsysteem kunnen activeren. Wij vonden 
dat deze dendritische cellen van bipolaire patiënten minder ontwikkeld 
waren, dan die van gezonde controles. Behandeling met lithium herstelde 
deze ontwikkeling voor een deel.
In een andere studie keken we naar het effect van glucocorticoïden 
(remmers van het immuunsysteem, die ook een rol spelen in de 
stressreactie van het lichaam). Het bleek dat T cellen van bipolaire 
patiënten minder gevoelig voor deze glucocorticoïden zijn.
Zoals eerder vermeld, hebben patiënten met een bipolaire stoornis 
een groter risico op het ontwikkelen van schildklierauto-immuniteit. 
Wij wilden weten of dit ook het geval was voor andere vormen van 
auto-immuniteit. Wij deden dit door markers te meten in het bloed, 
zogenaamde autoantistoffen, die zich richten tegen een bepaald orgaan 
of andere structuur in het lichaam. In het geval van schildlierauto-
immuniteit heet deze autoantistof “TPO-antistof”. Deze bleek vaker voor 
te komen bij bipolaire patiënten (28% t.o.v. 13% in gezonde controles). 
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De markers, geassocieerd met auto-immuniteit tegen de maag 
(H+/K+ ATPase antistoffen) en tegen eilandjes van Langerhans in de 
alvleesklier (GAD-65 antistoffen), kwamen ook meer frequent voor bij 
bipolaire patiënten (resp. 11.7% t.o.v. 6.1% en 11.3% t.o.v. 2.6%). 
Ook autoantistoffen geassocieerd met een breder pallet van auto-
immuunziekten, zoals het Syndroom van Sjögren en SLE, kwamen 
vaker voor bij bipolaire patiënten (antinucleaire antistoffen; 8.6% t.o.v. 
3.4%). Echter, statistisch konden we in onze bipolaire patiëntengroep 
niet bewijzen dat ook de geassocieerde auto-immuunziekten vaker 
voorkwamen. Een te traag werkende schildklier ten gevolge van auto-
immuniteit vormt hier een uitzondering op. Deze ziekte komt duidelijk 
meer voor bij bipolaire patiënten.
Een algemene conclusie, die uit dit proefschrift getrokken kan worden, is 
dat er op diverse niveaus van het immuunsysteem van bipolaire patiënten 
verschillen worden gevonden vergeleken met gezonde controles. Het 
immuunsysteem lijkt dan ook een rol te spelen bij het ontstaan van een 
bipolaire stoornis. Echter, het immuunsysteem is slechts een puzzelstuk 
in de complete verklaring van de oorsprong van de bipolaire stoornis. 
Verschillende theorieën zijn hier al over geformuleerd, maar geen enkele 
beslaat alles. Het zal nog een lange, maar uitdagende weg zijn om alle 
puzzelstukken te vinden die de complete ontstaanswijze van de bipolaire 
stoornis verklaren.
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Dankwoord
Op de voorkant van dit boekje staat maar één naam, toch hebben er veel 
meer mensen bijgedragen aan het slagen van deze promotieperiode. Het 
is algemeen bekend dat dit hoofdstuk het meest gelezen hoofdstuk is van 
een proefschrift. Hoewel de rest van dit boekje hopelijk ook de moeite 
waard is, ben ik wel blij dat hierdoor een aantal mensen de “credits” 
krijgen die ze naar mijn mening verdienen.
Allereerst wil ik de patiënten bedanken, die bereid waren deel te nemen 
aan dit onderzoek. In Rotterdam zagen wij alleen de buisjes bloed die 
binnenkwamen zonder het verhaal van de personen erachter. Ik heb dat 
wel eens gemist en tijdens mijn bezoekjes aan Utrecht besefte ik des te 
meer wat een inzet het moest vergen om al die vragenlijsten in te vullen 
en met regelmaat langs te komen.
Prof. dr. H.A. Drexhage, mijn eerste promotor en de drijvende motor van 
de “psychiatrische tak” binnen de afdeling Immunologie; beste Hemmo, 
al vanaf mijn eerste voorzichtige stapjes op het onderzoekspad tijdens 
mijn studie was jij mijn begeleider. Heel geleidelijk werd alles uitgebreid 
tot dit boekje waarachter jij de stuwende kracht bent geweest. Dank 
voor je enthousiasme, je steun, je vertrouwen, je kritische kijk op mijn 
manuscripten en eigenzinnige ideeën. Ik kon altijd bij je terecht, ook als 
jij meer aan je hoofd had dan alleen het afdelingswerk. Dat heb ik erg in 
je gewaardeerd. Ik heb veel van je geleerd en hoop dat alle inspanningen 
met het vervolg van het onderzoek hun vruchten af gaan werpen. Het 
was het zeker waard!
Prof. dr. M.W. Hengeveld, mijn tweede promotor en huidige opleider; 
beste Michiel, hoewel de immuno-psychiatrie ver van je bed af stond en 
wij elkaar nog nauwelijks kenden, gaf jij mij meteen je vertrouwen. Een 
lange-termijn-planning werd door jou ondersteund en na mijn onderzoek 
mocht ik in Rotterdam mijn opleiding tot psychiater beginnen. Inmiddels 
ben ik al weer een paar maanden bezig en ik heb geen spijt van mijn keuze. 
Bedankt voor de mogelijkheden en voor de “haardvuurtjes”. Ik hoop dat 
ik de rest van mijn opleiding met evenveel plezier kan afronden.
Prof. dr. W.A. Nolen, een van de drijvende krachten achter de Nederlandse 
tak van het Stanley Foundation Bipolar Network, later Stanley Medical 
Research Institute genoemd; beste Willem, in het begin van het onderzoek 
had ik niet kunnen denken dat het allemaal hiertoe zou leiden. Van een 
bekende naam binnen het onderzoekveld naar stemmingsstoornissen, 
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werd jij al snel iemand die meedacht vanuit de klinische praktijk en 
mijn manuscripten van bruikbaar commentaar voorzag. Dank voor je 
enthousiasme en leermomenten.
Dr. R.W. Kupka, onderzoeker binnen het Stanley Medical Research 
Institute, tevens binnen de immuno-psychiatrische tak; beste Ralph, ik 
vergeet nooit dat ik tijdens mijn afstudeeronderzoek een keer met je 
mee mocht lopen in de kliniek. Voor het eerst zag ik de gezichten van 
sommige patiënten die achter de “500”-nummers zaten en ik was onder 
de indruk. Niet alleen van hun verhalen, maar ook van het werk als 
psychiater. Ik wil je bedanken voor jouw bijdrage aan dit proefschrift. 
Naast alle bruikbare tips, feedback en aardige mailtjes, was het prettig 
om met je samen te mogen werken en ik hoop dat ik mijn verdediging 
met evenveel plezier mag doen als jij de jouwe deed.
Prof. dr. H. Hooijkaas en prof. dr. E.P. Prens; beste Herbert en Errol, beide 
waren jullie vanuit je eigen terrein betrokken bij mijn onderzoek en altijd 
erg geïnteresseerd in de vorderingen. Dank voor de belangstelling en 
voor het gevoel dat ik altijd even kon langslopen met een vraag.
Prof. dr. R. Benner; beste Rob, “immuno-psychiatrie” als klein eilandje 
binnen de goedlopende afdeling die onder jouw leiding staat. Ondanks 
de “vreemde eend” heb je me nooit het gevoel gegeven dat we bezig 
waren met een “lelijk eendje”. Dank voor je steun en interesse.
Prof. dr. B.E. Leonard; dear Brian, thanks for reading and judging my 
manuscript. I enjoyed our scientific discussions and your passion for 
the immuno-psychiatry. I am glad that you want to be part of my 
committee.
Prof. dr. F.C. Verhulst; beste Frank, eigenlijk was jij het, samen met 
Catrien Reichart, die de aanzet gaf om in Rotterdam met mijn opleiding 
verder te gaan. Hoewel we elkaar maar zelden zagen, ben ik blij dat 
je nu in mijn commissie wilt plaatsnemen. Wie weet wat de toekomst 
verder brengt.
Zowel de voormalige als de huidige collega’s van lab 876 en 987 wil ik 
bedanken voor de goede tijd. Beste Harm, van medisch student met 
twee linker pipethanden, tot promovendus met eigen ideeën. Jij hebt het 
allemaal meegemaakt. Dank voor je hulp en alle praktische kennis. Beste 
Nadine, mede dankzij jouw werk in de beginjaren, kon ik het onderzoek 
uitwerken tot het boekje wat jou nu in het oosten van het land heeft 
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bereikt. Beste Cindy, in korte tijd van cardio, via mono, naar psycho. 
Ik vond het jammer dat ik niet tot het eind met je kon samenwerken, 
maar dank voor de postdoc die je voor me was. Beste Roos, allebei zo’n 
beetje hetzelfde traject met wel een ander einddoel in het vizier. Echt 
tegelijk hebben we zelden gewerkt, maar toch was het een gezellige 
samenwerking en goede opvolging. Succes met het vervolg! De studenten 
die binnen het project hun steentje hebben bijgedragen; beste Christa, 
Egon, Mariëlle, Linda, Javi en Abdirizak, bedankt voor jullie inzet. Tot slot 
alle andere collega’s van de “groep Drexhage”; beste Berlinda, Lonneke, 
Rebecca, Gerben, Manon, Tanja, Sacha, Marcel, Vinod, Hui, Wai-Kwan, 
Martha, Kristel, Zenovia, Corine, Sabine, Diana, Marijn, Adri, Anne, 
Leendert, Pieter en Marjan, mijn promotietijd is deels geslaagd door een 
gezellige groep collega’s om me heen. Bedankt dat jullie me namen zoals 
ik ben, inclusief de “immer korte” momenten van stress, slappe lach en 
onhandigheid. De items uit de fantastische grabbeldoos zijn overigens 
nog steeds in gebruik!
Alle andere collega’s op de afdeling Immunologie. Het was een komen 
en gaan van mijn kant (dan weer een paar maanden bij jullie, dan weer 
in de kliniek). Ondanks deze constructie voelde het altijd vertrouwd op 
de 8e. Ik heb bij jullie een gezellige tijd gehad. Mede ook dankzij mijn 
collega-promovendi, roepen de labdagen en AIO-weekenden (Marloes, 
Els en Fleur!) nog steeds goede herinneringen op.
Specifiek wil ik het secretariaat en de “ondersteunende diensten” in 
het zonnetje zetten. Beste Wendy en Tar, zonder jullie goede, geduldige 
en gezellige hulp had het boekje er niet zo mooi uitgezien. Nooit kreeg 
ik het gevoel dat ik teveel was als ik weer eens met een mail of een 
telefoontje jullie lastig viel vanuit het Dp-gebouw. Dank voor alles!
De “Stanley” collega’s uit Utrecht en in het bijzonder Ronald Vonk, Manon 
Hillegers en Grard Akkerhuis. Dank voor de samenwerking, voor de hulp 
bij het uitzoeken van extra gegevens en voor jullie goede gezelschap 
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oorsprong; Coornhert, Leuven, Rotterdam, maar ze zijn me allemaal 
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in het bijzonder noemen. Lieve Iris, “jut en jul in goede en in minder 
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Lieve Patricia, hetzelfde groepje in de Eurekaweek, naast elkaar in de 
collegebank, samen onderzoek doen op de 8e. Ik ben blij dat dit tot een 
mooie hechte vriendschap heeft geleid en dat je mijn paranimf wilt zijn.
Mijn (schoon-)familie wil ik bedanken voor de interesse en luisterende 
oren. Lieve pa en ma, jullie oprechte betrokkenheid was altijd op de 
achtergrond aanwezig; dank daarvoor. Ook de belangstelling op feestjes 
in Waddinxveen is me dierbaar. Eindelijk zal ik “afgestudeerd” zijn!
In het bijzonder wil ik ook de interesse van “oversea” noemen. Lieve 
Nienke, bedankt voor je hulp, je gezelligheid en je goede tips wat betreft 
mijn Engels. Het was me veel waard. Lieve Els, of het nu een trouwkaart 
of een proefschrift is, altijd kom je met spannende ideeën. Misschien dat 
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Het eindresultaat is er naar!
Lieve Marije, ik ben trots dat jij straks naast me wil staan, want behalve 
mijn zusje ben je veel meer voor me. Ik hoop dat je op alle fronten 
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te volgen. Dank voor alle liefde, nimmer aflatende interesse en al het 
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Hoewel mijn leerdoel was bondiger te worden, heb ik dat bij het schrijven 
van dit dankwoord maar losgelaten. Hoewel, aan sommige dingen moet 
je niet te veel woorden besteden, dat is gewoon goed. Lieve Ab, dank 
voor jouw portie humor en geduld. Laat ik maar zeggen: “Zoveel als 
alle seconden die ik aan dit boekje heb besteed, maar dan tot de macht 
oneindig”. Op naar ons volgende hoofdstuk!
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